OA19539A - Epoxyeicosatrienoic acid analogs and methods of making and using the same. - Google Patents
Epoxyeicosatrienoic acid analogs and methods of making and using the same. Download PDFInfo
- Publication number
- OA19539A OA19539A OA1201300428 OA19539A OA 19539 A OA19539 A OA 19539A OA 1201300428 OA1201300428 OA 1201300428 OA 19539 A OA19539 A OA 19539A
- Authority
- OA
- OAPI
- Prior art keywords
- mhz
- nmr
- mmol
- eet
- etoac
- Prior art date
Links
- 150000002121 epoxyeicosatrienoic acids Chemical class 0.000 title abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 138
- 239000000203 mixture Substances 0.000 claims abstract description 134
- 206010020772 Hypertension Diseases 0.000 claims abstract description 53
- 231100000268 induced nephrotoxicity Toxicity 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229940079593 drugs Drugs 0.000 claims abstract description 18
- 229960004316 cisplatin Drugs 0.000 claims description 119
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 119
- 230000002829 reduced Effects 0.000 claims description 39
- 206010029155 Nephropathy toxic Diseases 0.000 claims description 18
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000556 agonist Substances 0.000 abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 372
- 235000019439 ethyl acetate Nutrition 0.000 description 176
- 238000004809 thin layer chromatography Methods 0.000 description 123
- 239000008079 hexane Substances 0.000 description 122
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 104
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 97
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 91
- 241000700159 Rattus Species 0.000 description 81
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 80
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 72
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 230000015572 biosynthetic process Effects 0.000 description 61
- 239000003981 vehicle Substances 0.000 description 59
- 239000007787 solid Substances 0.000 description 58
- 230000002194 synthesizing Effects 0.000 description 55
- 230000000694 effects Effects 0.000 description 54
- 238000003786 synthesis reaction Methods 0.000 description 54
- 210000003734 Kidney Anatomy 0.000 description 53
- 239000011541 reaction mixture Substances 0.000 description 53
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 42
- 239000000284 extract Substances 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 41
- 229910052681 coesite Inorganic materials 0.000 description 40
- 229910052906 cristobalite Inorganic materials 0.000 description 40
- 229910052904 quartz Inorganic materials 0.000 description 40
- 229910052682 stishovite Inorganic materials 0.000 description 40
- 229910052905 tridymite Inorganic materials 0.000 description 40
- 239000012267 brine Substances 0.000 description 38
- 238000004440 column chromatography Methods 0.000 description 38
- 239000000377 silicon dioxide Substances 0.000 description 37
- 239000012230 colorless oil Substances 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- 229910052938 sodium sulfate Inorganic materials 0.000 description 35
- 230000036772 blood pressure Effects 0.000 description 33
- 238000003756 stirring Methods 0.000 description 33
- 239000007832 Na2SO4 Substances 0.000 description 32
- -1 lipid compounds Chemical class 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 238000000034 method Methods 0.000 description 24
- 230000035882 stress Effects 0.000 description 24
- 210000004027 cells Anatomy 0.000 description 23
- 108030006933 EC 3.3.2.10 Proteins 0.000 description 22
- 102100017900 EPHX2 Human genes 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 229910052786 argon Inorganic materials 0.000 description 21
- 239000003480 eluent Substances 0.000 description 21
- 239000008194 pharmaceutical composition Substances 0.000 description 21
- 102100013894 BCL2 Human genes 0.000 description 20
- 108060000885 BCL2 Proteins 0.000 description 20
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 20
- 239000007788 liquid Substances 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 17
- 230000001631 hypertensive Effects 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 102100003814 CASP3 Human genes 0.000 description 15
- 108090000397 Caspase 3 Proteins 0.000 description 15
- 108020004999 Messenger RNA Proteins 0.000 description 15
- 108009000578 Oxidative Stress Proteins 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 229920002106 messenger RNA Polymers 0.000 description 15
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 15
- 230000036542 oxidative stress Effects 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 206010022114 Injury Diseases 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 230000001965 increased Effects 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000006188 syrup Substances 0.000 description 13
- 235000020357 syrup Nutrition 0.000 description 13
- 230000002424 anti-apoptotic Effects 0.000 description 12
- 230000003110 anti-inflammatory Effects 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- YIKSCQDJHCMVMK-UHFFFAOYSA-N oxalic acid diamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000002485 urinary Effects 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
- 238000004166 bioassay Methods 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 108010048571 bcl-2-Associated X Protein Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000002633 protecting Effects 0.000 description 9
- 102000004066 Caspase-12 Human genes 0.000 description 8
- 108090000570 Caspase-12 Proteins 0.000 description 8
- 102100016385 HAVCR1 Human genes 0.000 description 8
- 101710004394 HAVCR1 Proteins 0.000 description 8
- 229940090044 Injection Drugs 0.000 description 8
- 229940118019 Malondialdehyde Drugs 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 230000003078 antioxidant Effects 0.000 description 8
- 230000001640 apoptogenic Effects 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 102000009178 bcl-2-Associated X Protein Human genes 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000973 chemotherapeutic Effects 0.000 description 8
- 230000002757 inflammatory Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- WSMYVTOQOOLQHP-UHFFFAOYSA-N malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 210000000056 organs Anatomy 0.000 description 8
- 230000002335 preservative Effects 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000001681 protective Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 230000003595 spectral Effects 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 239000003039 volatile agent Substances 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 206010059512 Apoptosis Diseases 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 6
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 6
- GNOIPBMMFNIUFM-UHFFFAOYSA-N Hexamethylphosphoramide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 6
- 101710040065 THPO Proteins 0.000 description 6
- 210000002700 Urine Anatomy 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 230000031018 biological processes and functions Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000002354 daily Effects 0.000 description 6
- 230000002939 deleterious Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000002270 dispersing agent Substances 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 230000003589 nefrotoxic Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 description 5
- MMXRRNUXCHUHOE-UHFFFAOYSA-N 7-bromoheptan-1-ol Chemical compound OCCCCCCCBr MMXRRNUXCHUHOE-UHFFFAOYSA-N 0.000 description 5
- 230000036912 Bioavailability Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 208000008787 Cardiovascular Disease Diseases 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 229940100601 Interleukin-6 Drugs 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 101700011747 MSD1 Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- FJMRFTZVYPKYRO-UHFFFAOYSA-N N-(4-hydroxy-1,3-benzothiazol-2-yl)-2,2-dimethylpropanamide Chemical compound C1=CC=C2SC(NC(=O)C(C)(C)C)=NC2=C1O FJMRFTZVYPKYRO-UHFFFAOYSA-N 0.000 description 5
- 229910004759 OSi Inorganic materials 0.000 description 5
- 101710002423 SOD1 Proteins 0.000 description 5
- 102100008800 SOD1 Human genes 0.000 description 5
- 101710002416 SOD3 Proteins 0.000 description 5
- 102100005370 SOD3 Human genes 0.000 description 5
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 5
- 102100016214 THPO Human genes 0.000 description 5
- 230000002238 attenuated Effects 0.000 description 5
- 230000035514 bioavailability Effects 0.000 description 5
- 230000004531 blood pressure lowering effect Effects 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 230000001684 chronic Effects 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 230000001054 cortical Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated Effects 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 235000006408 oxalic acid Nutrition 0.000 description 5
- 230000001590 oxidative Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 229940086735 succinate Drugs 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 230000002459 sustained Effects 0.000 description 5
- 230000001702 transmitter Effects 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- JBSCUHKPLGKXKH-ILYOTBPNSA-N 14,15-EET Chemical compound CCCCCC1OC1C\C=C/C\C=C/C\C=C/CCCC(O)=O JBSCUHKPLGKXKH-ILYOTBPNSA-N 0.000 description 4
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 102000005862 Angiotensin II Human genes 0.000 description 4
- 229950006323 Angiotensin ii Drugs 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- 229940095399 Enema Drugs 0.000 description 4
- 241000792859 Enema Species 0.000 description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II dizwitterion Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
- FRNUHRWNKHIDBJ-UHFFFAOYSA-N N-(5-hydroxypentyl)-N-propan-2-ylheptanamide Chemical compound CCCCCCC(=O)N(C(C)C)CCCCCO FRNUHRWNKHIDBJ-UHFFFAOYSA-N 0.000 description 4
- 108010002998 NADPH Oxidases Proteins 0.000 description 4
- 102000004722 NADPH Oxidases Human genes 0.000 description 4
- 102000004019 NADPH oxidase 1 Human genes 0.000 description 4
- 108090000424 NADPH oxidase 1 Proteins 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 102100009534 TNF Human genes 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000003111 delayed Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 4
- 239000007920 enema Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000000861 pro-apoptotic Effects 0.000 description 4
- 201000001195 sepiapterin reductase deficiency Diseases 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002883 vasorelaxant Effects 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- VRVUKQWNRPNACD-UHFFFAOYSA-N 1-isocyanatopentane Chemical compound CCCCCN=C=O VRVUKQWNRPNACD-UHFFFAOYSA-N 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 3
- 108010064733 Angiotensins Proteins 0.000 description 3
- 101700067048 CDC13 Proteins 0.000 description 3
- 101710024147 CYP716A53v2 Proteins 0.000 description 3
- 229960003563 Calcium Carbonate Drugs 0.000 description 3
- 210000001072 Colon Anatomy 0.000 description 3
- 210000004351 Coronary Vessels Anatomy 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 229960001375 Lactose Drugs 0.000 description 3
- 229940067606 Lecithin Drugs 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 230000036740 Metabolism Effects 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- NNFCIKHAZHQZJG-UHFFFAOYSA-N Potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 3
- 229960004063 Propylene glycol Drugs 0.000 description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N Pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
- 102100004239 SOD2 Human genes 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 108010012715 Superoxide Dismutase Proteins 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 101710040537 TNF Proteins 0.000 description 3
- HJUGFYREWKUQJT-UHFFFAOYSA-N Tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N Triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 3
- VNDYJBBGRKZCSX-UHFFFAOYSA-L Zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 3
- YIYZHARUXWKUEN-UHFFFAOYSA-N benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 YIYZHARUXWKUEN-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 230000003197 catalytic Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035786 metabolism Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000003204 osmotic Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 3
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- 229940102001 zinc bromide Drugs 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- QGAVSDVURUSLQK-UHFFFAOYSA-N Ammonium heptamolybdate Chemical compound N.N.N.N.N.N.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Mo].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo] QGAVSDVURUSLQK-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 240000005781 Arachis hypogaea Species 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N Boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N Diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 101700057458 Drice Proteins 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- AEDIXYWIVPYNBI-UHFFFAOYSA-N Heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N Heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940075582 Sorbic Acid Drugs 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- 235000018660 ammonium molybdate Nutrition 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003276 anti-hypertensive Effects 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000020127 ayran Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000004093 hydrolase inhibitor Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 200000000010 kidney injury Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- VKIAHEHMGVSTAD-UHFFFAOYSA-N oct-3-yne Chemical compound [CH2]CC#CCCCC VKIAHEHMGVSTAD-UHFFFAOYSA-N 0.000 description 2
- 230000002669 organ and tissue protective Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 150000004763 sulfides Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 2
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000000261 vasodilator Effects 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- FIWSRSRCWYARAJ-SQOFCNSWSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FIWSRSRCWYARAJ-SQOFCNSWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DXOYQVHGIODESM-KROJNAHFSA-N 11,12-EET Chemical compound CCCCC\C=C/CC1OC1C\C=C/C\C=C/CCCC(O)=O DXOYQVHGIODESM-KROJNAHFSA-N 0.000 description 1
- 150000000234 11,12-EET derivatives Chemical class 0.000 description 1
- 150000000266 14,15-EET derivatives Chemical class 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-Dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- PFQJPSASUCHKRO-UHFFFAOYSA-N 2-amino-1,3-benzothiazol-4-ol Chemical compound C1=CC=C2SC(N)=NC2=C1O PFQJPSASUCHKRO-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- VMKYTRPNOVFCGZ-UHFFFAOYSA-N 2-sulfanylphenol Chemical compound OC1=CC=CC=C1S VMKYTRPNOVFCGZ-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N 3,4-dihydro-2H-pyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- YSYGVGYIXAHIDM-UHFFFAOYSA-N 5-[tert-butyl(diphenyl)silyl]oxypentan-1-amine Chemical compound C=1C=CC=CC=1[Si](OCCCCCN)(C(C)(C)C)C1=CC=CC=C1 YSYGVGYIXAHIDM-UHFFFAOYSA-N 0.000 description 1
- VZBLASFLFFMMCM-UHFFFAOYSA-N 6-methoxynaphthalene-2-carbaldehyde Chemical compound C1=C(C=O)C=CC2=CC(OC)=CC=C21 VZBLASFLFFMMCM-UHFFFAOYSA-N 0.000 description 1
- DBWQSCSXHFNTMO-TYAUOURKSA-N 8,9-EET Chemical compound CCCCC\C=C/C\C=C/CC1OC1C\C=C/CCCC(O)=O DBWQSCSXHFNTMO-TYAUOURKSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100019683 BAX Human genes 0.000 description 1
- 102000024678 Bcl-2 family Human genes 0.000 description 1
- 108091011726 Bcl-2 family Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 101700041765 CUX1 Proteins 0.000 description 1
- 102100017370 CYP2C18 Human genes 0.000 description 1
- 102100018445 CYP2J2 Human genes 0.000 description 1
- 101710007736 CYP2J2 Proteins 0.000 description 1
- UUGAXJGDKREHIO-UHFFFAOYSA-N Calcium hydride Chemical compound [H-].[H-].[Ca+2] UUGAXJGDKREHIO-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 240000000218 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 229940105442 Cisplatin Injection Drugs 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N Dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000005763 Disodium phosphonate Substances 0.000 description 1
- 229940059082 Douche Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 210000003038 Endothelium Anatomy 0.000 description 1
- 102000005486 Epoxide hydrolase family Human genes 0.000 description 1
- 108020002908 Epoxide hydrolase family Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 229960001269 Glycine Hydrochloride Drugs 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100004058 HMOX2 Human genes 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M Monopotassium phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HUTRTAUAQNIHBN-UHFFFAOYSA-N N-(4-hydroxy-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=CC=C2SC(NC(=O)C)=NC2=C1O HUTRTAUAQNIHBN-UHFFFAOYSA-N 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 206010029149 Nephropathy Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N Picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- XIPFMBOWZXULIA-UHFFFAOYSA-N Pivalamide Chemical compound CC(C)(C)C(N)=O XIPFMBOWZXULIA-UHFFFAOYSA-N 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M Potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038436 Renal failure acute Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101700040095 SRD2 Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 229940085605 Saccharin Sodium Drugs 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N Tetrahydro-2-furanmethanol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N Thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N Trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- IGWHDMPTQKSDTL-JXOAFFINSA-N [(2R,3S,4R,5R)-3,4-dihydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 230000019711 apoptosis in response to endoplasmic reticulum stress Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 102000010470 bcl-2 Homologous Antagonist-Killer Protein Human genes 0.000 description 1
- 108010038074 bcl-2 Homologous Antagonist-Killer Protein Proteins 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 102000009410 chemokine receptors Human genes 0.000 description 1
- 108050000299 chemokine receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 description 1
- 230000001120 cytoprotect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- AZKPSTWZRWAWBY-UHFFFAOYSA-N dec-5-yne Chemical compound [CH2]CCCC#CCCCC AZKPSTWZRWAWBY-UHFFFAOYSA-N 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- PNLXWGDXZOYUKB-WCCKRBBISA-N dimethyl (2S)-2-aminobutanedioate;hydrochloride Chemical compound Cl.COC(=O)C[C@H](N)C(=O)OC PNLXWGDXZOYUKB-WCCKRBBISA-N 0.000 description 1
- BMMOKCXZISDJCQ-UHFFFAOYSA-N dimethyl 2-[(2,2,2-trifluoroacetyl)amino]butanedioate Chemical compound COC(=O)CC(C(=O)OC)NC(=O)C(F)(F)F BMMOKCXZISDJCQ-UHFFFAOYSA-N 0.000 description 1
- AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- IIRVGTWONXBBAW-UHFFFAOYSA-M disodium;dioxido(oxo)phosphanium Chemical compound [Na+].[Na+].[O-][P+]([O-])=O IIRVGTWONXBBAW-UHFFFAOYSA-M 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 108010031102 heme oxygenase-2 Proteins 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GOQJMMHTSOQIEI-UHFFFAOYSA-N hex-5-yn-1-ol Chemical compound OCCCCC#C GOQJMMHTSOQIEI-UHFFFAOYSA-N 0.000 description 1
- 101700058959 higB Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- MONRWRVYLOHUFA-UHFFFAOYSA-N pentylurea Chemical compound CCCCCNC(N)=O MONRWRVYLOHUFA-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940114148 picric acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000000019 pro-fibrinolytic Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 101700027724 pys1 Proteins 0.000 description 1
- 101700073068 pys2 Proteins 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000002000 scavenging Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- KVUMNOYKAMFTTN-UHFFFAOYSA-N tert-butyl-but-3-ynoxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](OCCC#C)(C(C)(C)C)C1=CC=CC=C1 KVUMNOYKAMFTTN-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003767 thromboxane receptor stimulating agent Substances 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002477 vacuolizing Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000002034 xenobiotic Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Abstract
Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of making and using the compounds and compositions are further described.
Description
EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application daims the benefit of U.S. Provisional Appn. No. 61/472,410, filed 10 April 6, 2011, and U.S. Provisional Appn. No. 61/608,361 filed March 8, 2012, both of which are hereby incorporated by reference herein for ail purposes
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under DK38226, HL59699, 15 GM31278, and HL51055 awarded by the National Institutes of Health. The government has certain rights in the invention.
FIELD OF THE INVENTION
[0003] This invention relates generally to analogs of epoxyeicososatrienoic acid (EET).
More particularly, the présent invention is directed to EET analogs that act as EET agonists and 20 are useful as médications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions.
BACKGROUND OF THE INVENTION
[0004] Epoxyeicosatrienoic acids (EETs) are signaling molécules that can act as short-range 25 hormones, (i.e. they are autocrine and paracrine mediators) of the cardiovascular system and kidney. They produce vasorelaxation as well as anti-inflammatory and pro-fibrinolytic effects.
[0005] Hypertension and Related Conditions. Cardiovascular disease afflicts 81 million of the 300 million people in the United States, and 75 million of these people hâve hypertension.
CYP epoxygenase métabolites hâve biological actions that implicate them as important 30 contributors to cardiovascular function and blood pressure control.
[0006] One of the first biological activities described for epoxyeicosatrienoic acids (EETs) was inhibition of rénal tubular sodium reabsorption. Subsequently, EETs were determined to dilate blood vessels and were identified as endothelium-derived hyperpolarizing factors (EDHF). These biological actions are consistent with the idea that EETs would be eicosanoids that 35 contribute to lowering of blood pressure and prevent salt-sensitive hypertension.
[0007] Altered levels of EETs may contribute to hypertension in humans. A single nucléotide polymorphism in a CYP epoxygenase gene is associated with hypertension. Experimental studies in xodents hâve also demonstrated hypertension in conditions where kidney
CYP epoxygenase enzyme and/or EET levels were decreased. Increasing EET levels with 11,12-EET-SI, a 11,12-EET analog, improved rénal afferent arteriolar function in vitro.
[0008] Currently, soluble epoxide hydrolase inhibitors (sEHI) are used in vivo to increase EET levels and this results in a generalized increase in 11,12-EET and 14,15-EET and to a lesser extent 8,9-EET. Recent in vivo studies hâve demonstrated that EET analogs lower blood pressure in hypertensive rats, and also ameliorate the metabolic syndrome phenotype in hemeoxygenase 2 déficient mice and prevent the adiposity-related vascular and rénal damage. It does appear as if some of the EET agonists like NUDSA may also inhibit sEH and increase CYP2C epoxygenase expression. This type of combinational activity described for NUDSA could provide added bénéficiai effects. As a whole, these findings hâve generated interest in targeting the CYP epoxygenase pathway and EETs for the treatment of hypertension.
[0009] Even though EETs hâve actions on rénal tubular transport and vascular function that are essential for blood pressure régulation it has become apparent that additional biological actions ascribed to EETs made them an excellent therapeutic target for other cardiovascular diseases. These additional activities demonstrated for EETs include inhibition of platelet aggregation and anti-inflammation. EETs also hâve been found to hâve effects on vascular migration and prolifération, including promoting angiogenesis. Thus, EETs hâve become a therapeutic target for end organ damage associated with cardiovascular diseases, cardiac ischémie injury, atherosclerosis, and stroke.
[0010] The therapeutic potential for EET agonists and sEHIs could extend beyond hypertension and cardiovascular diseases. Neural protection from ischémie injury has been attributed to sEHI actions on blood vessels and neurons. There is growing evidence that sEHIs provide protection from ischémie damage in the brain and heart through effects on apoptotic signaling cascades. EET agonists and sEHIs hâve also been demonstrated to modulate pain in various experimental animal models. Other possible therapeutic applications for EET agonists are sure to be discovered when these agents are tested in other disease models.
[0011] Accordingly, there is a need in the art for novel EET agonists that are active as therapeutic agents against hypertension and related cardiovascular and neural disease.
[0012] Drug-Induced Nephrotoxicity. A common side-effect of many drugs used in the treatment of various conditions is nephrotoxicity. For instance, cisplatin, a platinum-based inorganic compound, is one of the most potent and widely used chemotherapy agents available to treat a variety of malignancies, including ovarian, lung, testicular and bladder cancers. Although, cisplatin is used as an important chemotherapy drug in the clinic, it has potentially léthal adverse effects. The most common of this adverse effect is nephrotoxicity (25-40% of cisplatin treated patients develop acute rénal failure), which limits the safe and effective use of this widely used chemotherapeutic agent. The pathophysiology of cisplatin-induced nephrotoxicity involves enhanced oxidative stress, inflammation, increased endoplasmic réticulum (ER) stress and rénal cell apoptosis.
[0013] EET is an important lipid mediator that exerts a number of biological actions including anti-inflammatory, anti-oxidative and anti-apoptotic activities. A numbers of studies demonstrated that with anti-inflammatory, anti-apoptotic and anti-oxidative activities, EET possess strong organ protective potential. For instance, increased EET bioavailability resulted from reduced conversion of EET to its less active form by soluble epoxide hydrolase (sEH) inhibitor provides kidney protection in a number of preclinical models of human diseases. These studies demonstrated that the kidney protective effect of EET was related to anti-inflammatory and anti-oxidative effects of EET. Indeed, there is strong evidence that EET hâve antiinflammatory effects against acute and chronic inflammation. Apart from inflammation, EET also protect cells from apoptosis. Thus, there are strong évidences of EET’s ability to protect organ by mechanisms involve its anti-inflammatory, anti-apoptotic and anti-oxidative activities.
[0014] However, it is known that endogenously produced EETs are chemically and metabolically labile. Also, rapid metabolism, low solubility and storage issue limit the therapeutic prospect of EET. As such considérable interest has arisen in developing strategies to enhance the bioavailability of EET. In this effort, attempts hâve been made to develop EET analogs that possess EET-mimetic activity along with several key features important for stability and bio-availability. Several of such EET analogs hâve demonstrated a number of biological activities including organ protection.
[0015] In the présent study we hâve investigated the kidney protective effect of two newly developed orally active EET analogs in cisplatin-induced nephrotoxicity. We hâve demonstrated that EET analogs offered marked reno-protection during cisplatin administration and this effect was related to their anti-oxidative, anti-inflammatory, anti-ER stress and anti-apoptotic activities. We hâve further demonstrated that while protecting the kidney from the deleterious nephrotoxic effects of cisplatin, these EET analogs did not compromise cisplatin’s chemotherapeutic effect.
[0016] Acordingly, there is a need in the art for novel EET analogs that are active as therapeutic agents against the deleterious nephrotoxic effects of cisplatin.
SUMMARY OF THE INVENTION
[0017] Here, the inventors demonstrate novel compositions of epoxyeicosatrienoic acids (EET) analogs and methods of use thereof for the treatment of cardiovascular disease, particularîy the use of such compositions as as anti-hypertensive agents.
[0018] Accordingly, the invention encompasses in a first aspect certain compounds that are 14,15-EET analogs. In certain embodiments, the compound has the structure of any one of the following compounds.
H H
[0019] In one embodiment, the invention comprises compounds 7 and 30.
[0020] In another aspect, the invention provides a method of making any of compounds 1-33 as described and claimed herein.
[0021] Compounds according to the invention are, in certain embodiments, provided in the form of a composition comprising a compound as described and claimed herein in combination with a pharmaceutically acceptable carrier.
[0022] The présent invention further encompasses methods of providing treatment of hypertension in a subject, resulting in a réduction of blood pressure in a subject. Such methods include steps of administering to a subject a therapeutically effective amount of any of compounds 1-33, alone or in combination, as described and claimed herein, whereby blood pressure in the subject is reduced. In one embodiment, the method comprises administering compound 7. In an alternate embodiment the method comprises administering compound 30.
[0023] In another embodiment, the présent invention provides EET analogs having the structures selected from the group consisting of
[0024] In yet another embodiment, the invention encompasses the use of any of the 14,15EET analogs described above for the manufacture of a médicament for treating hypertension in a subject. As well, the présent invention further contemplâtes compounds according to the invention for use in treating hypertension in a subject.
[0025] The présent invention further encompasses methods of treating drug-induced nephrotoxicity in a subject. In one embodiment, the invention comprises providing treatment for the deleterious nephrotoxic effects of cisplatin in a subject. Such methods include steps of administering to a subject a therapeutically effective amount of a compound as described and claimed herein, whereby the deleterious nephrotoxic effects of the drug in the subject are reduced.
[0026] Other objects, features and advantages of the présent invention will become apparent after review of the spécification, daims and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure IA depicts the Chemical structure SRD-I-71-9, which corresponds to EET analog compound 26 of Table 1. Figure IB shows mean measured blood pressure as a function of days of treatment in spontaneously hypertensive rats administered a composition containing vehicle or compound 26. Figure IC shows mean measured blood pressure at day 0, day 7, and day 14 in spontaneously hypertensive rats administered a composition containing vehicle or compound 26.
[0028] Figure 2A depicts the Chemical structure LGK-I-119-15, which corresponds to EET analog compound 20 of Table 1. Figure 2B shows mean measured blood pressure as a function of days of treatment in spontaneously hypertensive rats administered a composition containing vehicle or compound 20. Figure 2C shows mean measured blood pressure at day 0, day 7, and day 14 in spontaneously hypertensive rats administered a composition containing vehicle or compound 20.
[0029] Figure 3A depicts the Chemical structure JLJ-I-94-6, which corresponds to EET analog compound 7 of Table 1. Figure 3B shows mean measured blood pressure as a function of days of treatment in spontaneously hypertensive rats administered a composition containing vehicle or compound 7. The data is graphed as 12 hour averages. Compounds were delivered i.p. for 14 days. Figure 3C shows mean measured blood pressure at day 0, day 7, and day 14 relative to initial treatment in spontaneously hypertensive rats administered a composition containing vehicle or compound 7.
[0030] Figure 4A depicts the Chemical structure MV-IV-110-20, which corresponds to EET analog compound 30 of Table 1. Figure 4B shows mean measured blood pressure as a function of days of treatment in spontaneously hypertensive rats administered a composition containing vehicle or compound 30. The data is graphed as 12 hour averages. Figure 3C shows mean measured blood pressure at day 0, day 7, and day 14 in spontaneously hypertensive rats administered a composition containing vehicle or compound 30.
[0031] Figure 5A shows mean measured blood pressure as a function of days of treatment inangiotensin II induced hypertensive rats administered a composition containing vehicle or compound 7. The data is graphed as 12 hour averages. Figure 5B shows mean measured blood pressure at day 0, day 7, and day 14 in angiotensin II induced hypertensive rats administered a composition containing vehicle or compound 7.
[0032] Figure 6A shows mean measured blood pressure as a function of days of treatment in angiotensin II induced hypertensive rats administered a composition containing vehicle or compound 30. The data is graphed as 12 hour averages. Figure 6B shows mean measured blood pressure at day 0, day 7, and day 14 in angiotensin II induced hypertensive rats administered a composition containing vehicle or compound 30.
[0033] Figure 7: (a) Plasma créatinine, (b) Blood urea nitrogen (BUN), (c) kidney injury molécule-1, and (d) urinary NA Gin cisplatin administered rats pretreated with either EET analogs, EET-A andEET-B or vehicle. *p<0.05 vs. normal Wistar Kyotorat; #p<0.05 vs. vehicle treated rat administered cisplatin. Data expressed as mean ±SEM,n=5-7.
[0034] Figure 8A: Représentative photomicrographs of Periodicacid-Schiff(PAS) Staining (200x) depicting tubular cast formation along with the calculated cast are a fraction (%) in the rénal cortical sections of different experimental groups. *p<0.05 vs. normal Wistar Kyotorat; #p<0.05 vs. vehicle treated rat. Data expressed as mean ±SEM, n=5-7.
[0035] Figure 8B: Représentative photomicrographs of Periodicacid-Schiff(PAS) Staining 200x) depicting tubular cast formation along with the calculated cast area fraction (%) in the rénal medullary sections of different experimental groups. *p<0.05 vs. normal Wistar Kyoto rat; #p<0.05 vs. vehicle treated rat. Data expressed as mean ±SEM,n=5-7.
[0036] Figure 9: RT-PCR analysis form RNA expressions of (a) NOX1, (b) gp91Phox, (d) SOD1, (e) SOD2, (f) SOD3 and (c) measurements of kidney thiobarbituric acid-reactive substances(TBARS) in cisplatin administered rats treated with either EET analogs A, B or vehicle. *p<0.05vs. normal Wistar Kyoto rat;# p<0.05 vs. vehicle pretreated rat administered cisplatin. Data expressed as mean ±SEM,n=5-7.
[0037] Figure 10: Rénal expression of inflammatory marker genes TNF-a(a), IL-6 (b) and IL-1 β (c) in cisplatinadministered rats pretreated with either EET analogs EET-A and EET-B or vehicle. *p<0.05 vs. normal Wistar Kyoto rat; #p<0.05 vs. vehicle pretreated rat administered cisplatin. Data expressed as mean ±SEM, n=5-7.
[0038] Figure 11: Rénal expression of endoplasmic réticulum stress marker genes GRP78/BiPpà) and caspase!2 (b) in cisplatin administered rats treated with either EET analogs EET-A and EET-B or vehicle. *p<0.05 vs. normal WistarKyoto rat; #p<0.05 vs. vehicle treated rat administered. Data expressed as mean ±SEM, n=5-7.
[0039] Figure 12: Rénal cortical caspase 3 activity (a) andrenal expression of anti-apoptotic gene Bcl2 (b) in different experimental groups. The ratios between the rénal expression of antiapoptotic gene Bcl2 and the apoptotic genes Bak (c) and Bax (d) in different experimental groups. *p<0.05 vs. normal Wistar Kyoto rat; #p<0.05 vs. vehicle treated rat administered cisplatin. Data expressed as mean ±SEM, n=5-7.
[0040] Figure 13 A: Cytotoxic effect of cisplatin in normal kidney cell (HEK293) and cancer cells (Hela, U87, NCCIT).
[0041] Figure 13B: Effect of EET analog EET-A on the cell growth of HEK293, Hela, U87, NCCIT. EET-A does not effect the chemotherapeutic effect of cisplatin in NCCIT cancer cells. Data expressed as mean±SEM, n=5-7.
[0042] Figure 14: Structure of EET analogs EET-A and EET-B.
[0043] Figure 15: Synthesis of EET-B.
[0044] Figure 16A: Synthesis of EET-A.
[0045] Figure 16B: Alternate synthesis of EET-A.
DETAILED DESCRIPTION OF THE INVENTION
I. IN GENERAL
[0046] Before the présent materials and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, materials, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the présent invention which will be limited only by any later-filed nonprovisional applications.
[0047] It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictâtes otherwise. As well, the ternis “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the tenus “comprising”, “including”, and “having” can be used interchangeably.
[0048] Unless defined otherwise, ail technical and scientific terms used herein hâve the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or équivalent to those described herein can be used in the practice or testing of the présent invention, the preferred methods and materials are now described. Ail publications and patents specifically mentioned herein are incorporated by reference for ail purposes including describing and disclosing the Chemicals, instruments, statistical analysis and méthodologies which are reported in the publications which might be used in connection with the invention. Ail references cited in this spécification are to be taken as indicative of the level of skill in the art. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
IL THE INVENTION
[0049] The inventors here disclose novel EET analogs, EET agonists, and other related lipid compounds, and compositions comprising such compounds, as well as methods of synthesizing such compounds and the use of such compositions in treating hypertension and related conditions in treating the deleterious effects of cisplatin nephrotoxicity and related conditions. The inventors’ hâve shown that several of the compounds exhibit anti-hypertensive effects and are well-tolerated in relevant rat models. A number of different delivery options are possible, including intraperitoneal injections, blood injections, or oral delivery. Liposomes, mycelles, and emulsifiers can be used in to make these préparations more soluble.
[0050] As used herein, subject means mammals and non-mammals. “Mammals” means any member of the class Mammalia including, but not limited to, humans, non-human primates such as chimpanzees and other apes and monkey species; farm animais such as cattle, horses, sheep, goats, and swine; domestic animais such as rabbits, dogs, and cats; laboratory animais including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like. The term subject does not dénoté a particular âge or sex.
[0051] As used herein, “administering” or “administration” includes any means for introducing a compound of the présent invention into the body, preferably into the systemic circulation. Examples include but are not limited to oral, buccal, sublingual, pulmonary, transdermal, transmucosal, as well as subcutaneous, intraperitoneal, intravenous, and intramuscular injection.
[0052] A therapeutically effective amount means an amount of a compound that, when administered to a subject for treating a disease or condition, is sufficient to effect such treatment for the disease. The therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity or the disease treated, the âge and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
[0053] For purposes of the présent invention, “treating” or “treatment” describes the management and care of a patient for the purpose of combating the disease, condition, or disorder. The terms embrace both preventative, i.e., prophylactic, and palliative treatments. Treating includes the administration of a compound of présent invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
[0054] A compound is administered to a patient in a therapeutically effective amount. A compound can be administered alone or as part of a pharmaceutically acceptable composition. In addition, a compound or composition can be administered ail at once, as for example, by a bolus injection, multiple times, such as by a sériés of tablets, or delivered substantially uniformly over a period of time, as for example, using transdermal delivery. Further, the dose of the compound can be varied over time. A compound can be administered using an immédiate release formulation, a controlled release formulation, or combinations thereof. The term controlled release includes sustained release, delayed release, and combinations thereof.
[0055] A pharmaceutical composition of the invention can be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a unit dose is discrète amount of the pharmaceutical composition comprising a predetermined amount of the active ingrédient. The amount of the active ingrédient is generally equal to the dosage of the active ingrédient that would be administered to a patient or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
[0056] The relative amounts of the active ingrédient, the pharmaceutically acceptable carrier, and any additional ingrédients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and condition of the human treated and further depending upon the route by which the composition is to be administered. By way of example, the composition can comprise between 0.1% and 100% (w/w) active ingrédient. A unit dose of a pharmaceutical composition of the invention will generally comprise from about 100 milligrams to about two grams of the active ingrédient, and preferably comprises from about 200 milligrams to about 1.0 gram of the active ingrédient.
[0057] A preferred dosage for humans would be in the low mg/kg range administered orally once daily. Twice daily would also be acceptable.
[0058] To improve water solubility, the preferred compounds can be formulated with cyclodextrins or cyclodextrin-derived products, derivatized with substituents such as polyethylene glycols or other polar functionality, or included in liposomes. For oral delivery, the compounds may be modified with lipophilie functionality or conjugated to actively absorbed molécules. Other approaches are discussed in Strategies to improve oral drug bioavailability, Isabel Gomez-Orellana,Expert Opinion on Drug Delivery, May 2005, Vol. 2, No. 3 : Pages 419433, which is incorporated by reference herein.
[0059] Another aspect of the invention relates to a kit comprising a pharmaceutical composition of the invention and instructional material. Instructional material includes a publication, a recording, a diagram, or any other medium of expression which is used to communicate the usefulness of the pharmaceutical composition of the invention for one of the purposes set forth herein in a human. The instructional material can also, for example, describe an appropriate dose of the pharmaceutical composition of the invention. The instructional material of the kit of the invention can, for example, be affixed to a container which contains a pharmaceutical composition of the invention or be shipped together with a container which contains the pharmaceutical composition. Alternatively, the instructional material can be shipped separately from the container with the intention that the instructional material and the pharmaceutical composition be used cooperatively by the récipient.
[0060] The invention also includes a kit comprising a pharmaceutical composition of the invention and a delivery device for delivering the composition to a human. By way of example, the delivery device can be a squeezable spray bottle, a metered-dose spray bottle, an aérosol 10 spray device, an atomizer, a dry powder delivery device, a self-propelling solvent/powder- dispensing device, a syringe, a needle, a tampon, or a dosage- measuring container. The kit can further comprise an instructional material as described herein. The kit also comprises a container for the separate compositions, such as a divided bottle or a divided foil packet. Additional examples of containers include syringes, boxes, bags, and the like. Typically, a kit comprises 15 directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parentéral), are administered at different dosage intervals, or when titration ofthe individual components ofthe combination is desired by the prescribing physician.
[0061] It may be désirable to provide a memory aid on the kit, e.g., in the form of numbers 20 next to the tablets or capsules whereby the numbers correspond with the days of the regimen that the tablets or capsules so specified should be ingested. Another example of such a memory aid is a calendar printed on the card, e.g., as follows First Week, Monday, Tuesday, . . . etc. . . . Second Week, Monday, Tuesday, etc, Other variations of memory aids will be readily apparent. A daily dose can be a single tablet or capsule or several pills or capsules to be taken on a given 25 day.
[0062] In another embodiment of the présent invention, a dispenser designed to dispense the daily doses one at a time in the order of their intended use is provided. Preferably, the dispenser is equipped with a memory aid, so as to further facilitate compliance with the dosage regimen. An example of such a memory aid is a mechanical counter, which indicates the number of daily 30 doses that hâve been dispensed. Another example of such a memory aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads ont the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
[0063] The compounds of the présent invention, optionally comprising other 35 pharmaceutically active compounds, can be administered to a patient either orally, rectally, parenterally, (for example, intravenously, intramuscularly, or subcutaneously) intracisternally, intravaginally, intraperitoneally, intravesically, locally (for example, powders, ointments or drops), or as a buccal or nasal spray. Other contemplated formulations include projected nanoparticles, liposomal préparations, resealed érythrocytes containing the active ingrédient, and immunologically-based formulations.
[0064] Parentéral administration of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a human and administration of the pharmaceutical composition through the breach in the tissue. Parentéral administration thus includes administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parentéral administration includes subcutaneous, intraperitoneal, intravenous, intraarterial, intramuscular, or intrasternal injection and intravenous, intraarterial, or kidney dialytic infusion techniques. For example, the compositions of the présent invention can be administered to a subject by brain (via vPAG) injections, intrathecal injections, intraperitoneal injections, or blood injections.
[0065] Compositions suitable for parentéral injection comprise the active ingrédient combined with a pharmaceutically acceptable carrier such as physiologically acceptable stérile aqueous or nonaqueous solutions, dispersions, suspensions, or émulsions, or may comprise stérile powders for reconstitution into stérile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, isotonie saline, éthanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, triglycérides, including vegetable oils such as olive oil, or injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for exampie, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and/or by the use of surfactants. Such formulations can be prepared, packaged, or sold in a form suitable for bolus administration or for continuons administration. Injectable formulations can be prepared, packaged, or sold in unit dosage form, such as in ampules, in multi-dose containers containing a preservative, or in single-use devices for auto-injection or injection by a medical practitioner.
[0066] Formulations for parentéral administration include suspensions, solutions, émulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodégradable formulations. Such formulations can further comprise one or more additional ingrédients including suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parentéral administration, the active ingrédient is provided in dry (i.e. powder or granular) form for reconstitution with a suitable vehicle (e.g. stérile pyrogen-free water) prior to parentéral administration of the reconstituted composition.
[0067] The pharmaceutical compositions can be prepared, packaged, or sold in the form of a stérile injectable aqueous or oily suspension or solution. This suspension or solution can be formulated according to the known art, and can comprise, in addition to the active ingrédient, additional ingrédients such as the dispersing agents, wetting agents, or suspending agents described herein. Such stérile injectable formulations can be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butanediol, for example. Other acceptable diluents and solvents include Ringer's solution, isotonie sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations which are useful include those which comprise the active ingrédient in microcrystalline form, in a liposomal préparation, or as a component of a biodégradable polymer Systems. Compositions for sustained release or implantation can comprise pharmaceutically acceptable polymeric or hydrophobie materials such as an émulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble sait.
[0068] The compounds according to the présent invention may also contain adjuvants such as preserving, wetting, emulsifying, and/or dispersing agents, including, for example, parabens, chlorobutanol, phénol, sorbic acid, and the like. It may also be désirable to include isotonie agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of injectable pharmaceutical compositions can be brought about by the use of agents capable of delaying absorption, for example, aluminum monostearate and/or gelatin. In particular, liposomes, mysomes and emulsifiers can be used in to make the présent compounds more soluble for delivery.
[0069] Dosage forms can include solid or injectable implants or depots. In preferred embodiments, the implant comprises an effective amount of an active agent and a biodégradable polymer. In preferred embodiments, a suitable biodégradable polymer can be selected from the group consisting of a polyaspartate, polyglutamate, poly(L-lactide), a poly(D,L-lactide), a poly(lactide-co-glycolide), a poly(s-caprolactone), a polyanhydride, a poly(beta-hydroxy butyrate), a poly(ortho ester) and a polyphosphazene. In other embodiments, the implant comprises an effective amount of active agent and a silastic polymer. The implant provides the release of an effective amount of active agent for an extended period of about one week to several years.
[0070] Solid dosage forms for oral administration include capsules, tablets, powders, and granules. In such solid dosage form, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, mannitol, or silicic acid; (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrroiidone, sucrose, or acacia; (c) humectants, as for example, glycerol; (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, or sodium carbonate; (e) solution retarders, as for example, paraffm; (f) absorption accelerators, as for example, quaternary ammonium compounds; (g) wetting agents, as for example, cetyl alcohol or glycerol monostearate; (h) adsorbents, as for example, kaolin or bentonite; and/or (i) lubricants, as for example, talc, calcium stéarate, magnésium stéarate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules and tablets, the dosage forms may also comprise buffering agents.
[0071] A tablet comprising the active ingrédient can, for example, be made by compressing or molding the active ingrédient, optionally with one or more additional ingrédients. Compressed tablets can be prepared by compressing, in a suitable device, the active ingrédient in a free-flowing form such as a powder or granular préparation, optionally mixed with one or more of a binder, a lubricant, an excipient, a surface active agent, and a dispersing agent. Molded tablets can be made by molding, in a suitable device, a mixture of the active ingrédient, a pharmaceutically acceptable carrier, and at least sufficient liquid to moisten the mixture.
[0072] Pharmaceutically acceptable excipients used in the manufacture of tablets include inert diluents, granulating and disintegrating agents, binding agents, and lubricating agents. Known dispersing agents include potato starch and sodium starch glycolate. Known surface active agents include sodium lauryl sulfate. Known diluents include calcium carbonate, sodium carbonate, lactose, micro crystalline cellulose, calcium phosphate, calcium hydrogen phosphate, and sodium phosphate. Known granulating and disintegrating agents include corn starch and alginic acid. Known binding agents include gelatin, acacia, pre-gelatinized maize starch, polyvinylpyrroiidone, and hydroxypropyl methylcellulose. Known lubricating agents include magnésium stéarate, stearic acid, silica, and talc.
[0073] Tablets can be non-coated or they can be coated using known methods to achieve delayed disintegration in the gastrointestinal tract of a human, thereby providing sustained release and absorption of the active ingrédient. By way of example, a material such as glyceryl monostearate or glyceryl distearate can be used to coat tablets. Further by way of example, tablets can be coated using methods described in U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874 to form osmotically-controlled release tablets. Tablets can further comprise a sweetening agent, a flavoring agent, a coloring agent, a preservative, or some combination of these in order to provide pharmaceutically élégant and palatable préparation.
[0074] Solid dosage forms such as tablets, dragees, capsules, and granules can be prepared with coatings or shells, such as enteric coatings and others well known in the art. They may also contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
[0075] Solid compositions of a similar type may also be used as fillers in soft or hard filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like. Hard capsules comprising the active ingrédient can be made using a physiologically degradable composition, such as gelatin. Such hard capsules comprise the active ingrédient, and can further comprise additional ingrédients including, for example, an inert solid diluent such as calcium carbonate, calcium phosphate, or kaolin. Soft gelatin capsules comprising the active ingrédient can be made using a physiologically degradable composition, such as gelatin. Such soft capsules comprise the active ingrédient, which can be mixed with water or an oil medium such as peanut oil, liquid paraffin, or olive oil.
[0076] Oral compositions can be made, using known technology, which specifically release orally-administered agents in the small or large intestines of a human patient. For example, formulations for delivery to the gastrointestinal System, including the colon, include enteric coated Systems, based, e.g., on méthacrylate copolymers such as poly(methacrylic acid, methyl méthacrylate), which are only soluble at pH 6 and above, so that the polymer only begins to dissolve on entry into the small intestine. The site where such polymer formulations disintegrate is dépendent on the rate of intestinal transit and the amount of polymer présent. For example, a relatively thick polymer coating is used for delivery to the proximal colon (Hardy et al., Aliment. Pharmacol. Therap. (1987) 1:273-280). Polymers capable of providing site-specific colonie delivery can also be used, wherein the polymer relies on the bacterial flora of the large bowel to provide enzymatic dégradation of the polymer coat and hence release of the drug. For example, azopolymers (U.S. Pat. No. 4,663,308), glycosides (Friend et al., J. Med. Chem. (1984) 27:261268) and a variety of naturally available and modified polysaccharides (see PCT application PCT/GB89/00581) can be used in such formulations.
[0077] Pulsed release technology such as that described in U.S. Pat. No. 4,777,049 can also be used to administer the active agent to a spécifie location within the gastrointestinal tract. Such Systems permit drug delivery at a predetermined time and can be used to deliver the active agent, optionally together with other additives that my alter the local microenvironment to promote agent stability and uptake, directly to the colon, without relying on external conditions other than the presence of water to provide in vivo release.
[0078] Liquid dosage forms for oral administration include pharmaceutically acceptable émulsions, solutions, suspensions, syrups, and élixirs. In addition to the active compounds, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, isotonie saline, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, almond oil, arachis oil, coconut oil, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame seed oil, MIGLYOL™, glycerol, fractionated vegetable oils, minerai oils such as liquid paraffin, tetrahydrofurfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
[0079] Besides such inert diluents, the compounds of the présent invention can also include adjuvants, such as wetting agents, emulsifying and suspending agents, demulcents, preservatives, buffers, salts, sweetening, flavoring, coloring and perfuming agents. Suspensions, in addition to the active compound, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol or sorbitan esters, microcrystalline cellulose, hydrogenated edible fats, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, agar-agar, and cellulose dérivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, aluminum metahydroxide, bentonite, or mixtures of these substances, and the like. Liquid formulations of a pharmaceutical composition of the invention that are suitable for oral administration can be prepared, packaged, and sold either in liquid form or in the form of a dry product intended for reconstitution with water or another suitable vehicle prior to use.
[0080] Known dispersing or wetting agents include naturally-occurring phosphatides such as lecithin, condensation products of an alkylene oxide with a fatty acid, with a long chain aliphatic alcohol, with a partial ester derived from a fatty acid and a hexitol, or with a partial ester derived from a fatty acid and a hexitol anhydride (e.g. polyoxyethylene stéarate, heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and polyoxyethylene sorbitan monooleate, respectively). Known emulsifying agents include lecithin and acacia. Known preservatives include methyl, ethyl. or n-propyl-para-hydroxybenzoates, ascorbic acid, and sorbic acid. Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin. Known thickening agents for oily suspensions include, for example, beeswax, hard paraffin, and cetyl alcohol.
[0081] Liquid solutions of the active ingrédient in aqueous or oily solvents can be prepared in substantially the same manner as liquid suspensions, the primary différence being that the active ingrédient is dissolved, rather than suspended in the solvent. Liquid solutions of the pharmaceutical composition of the invention can comprise each of the components described with regard to liquid suspensions, it being understood that suspending agents will not necessarily 10 aid dissolution of the active ingrédient in the solvent. Aqueous solvents include, for example, water and isotonie saline. Oily solvents include, for example, almond oil, oily esteis, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and minerai oils such as liquid paraffm.
[0082] Compositions for rectal or vaginal administration can be prepared by mixing a 15 compound of the présent invention and any additional compounds with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary room température, but liquid at body température, and therefore, melt in the rectum or vaginal cavity and release the active ingrédient. Such a composition can be in the form of, for example, a suppository, a rétention enema préparation, and a solution for rectal or 20 colonie irrigation. Suppository formulations can further comprise various additional ingrédients including antioxidants and preservatives. Rétention enema préparations or solutions for rectal or colonie irrigation can be made by combining the active ingrédient with a pharmaceutically acceptable liquid carrier. As is known in the art, enema préparations can be administered using, and can be packaged within, a delivery device adapted to the rectal anatomy of a human. Enema 25 préparations can further comprise various additional ingrédients including antioxidants and preservatives.
[0083] A pharmaceutical composition of the invention can be prepared, packaged, or sold in a formulation suitable for vaginal administration. Such a composition can be in the form of, for example, a suppository, an impregnated or coated vaginally-insertable material such as a tampon, 30 a douche préparation, or a solution for vaginal irrigation.
[0084] Dosage forms for topical administration of a compound according to the présent invention include ointments, powders, sprays and inhalants. The compounds are admixed under stérile conditions with a physiologically acceptable carrier, and any preservatives, buffers, and/or propellants that may be required. Formulations suitable for topical administration include liquid 35 or semi-liquid préparations such as liniments, lotions, oil-in-water or water-in-oil émulsions such as creams, ointments or pastes, and solutions or suspensions. Topically-administrable formulations can, for example, comprise from about 0.1% to about 10% (w/w) active ingrédient, although the concentration of the active ingrédient can be as high as the solubility limit of the active ingrédient in the solvent. Formulations for topical administration can further comprise one or more of the additional ingrédients described herein.
[0085] Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention. Such formulations can, for example, be in the form of eye drops including, for example, a 0.1-1.0% (w/w) solution or suspension of the active ingrédient in an aqueous or oily liquid carrier. Such drops can further comprise buffering agents, salts, or one or more other of the additional ingrédients described herein. In other embodiments, ophthalmalmically administrable formulations comprise the active ingrédient in microcrystalline form or in a liposomal préparation.
[0086] Pharmaceutical compositions of the invention formulated for pulmonary delivery can provide the active ingrédient in the form of droplets of a solution or suspension. Such formulations can be prepared, packaged, or sold as aqueous or dilute alcoholic solutions or suspensions, optionally stérile, comprising the active ingrédient, and can conveniently be administered using any nebulization or atomization device. Such formulations can further comprise one or more additional ingrédients including a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration preferably hâve an average diameter in the range from about 0.1 to about 200 nanometers.
[0087] A pharmaceutical composition of the invention can be prepared, packaged, or sold in a formulation suitable for buccal administration. Such formulations can, for example, be in the form of tablets or lozenges made using conventional methods, and can, for example, comprise 0.1 to 20% (w/w) active ingrédient, the balance comprising an orally dissolvable or degradable composition and, optionally, one or more of the additional ingrédients described herein. Alternately, formulations suitable for buccal administration can comprise a powder or an aerosolized or atomized solution or suspension comprising the active ingrédient. Such powdered, aerosolized, or atomized formulations, when dispersed, preferably hâve an average particle or droplet size in the range from about 0.1 to about 200 nanometers, and can further comprise one or more of the additional ingrédients described herein.
[0088] For parentéral administration in non-human animais, the compounds of the présent invention may be prepared in the form of a paste or a pellet and administered as an implant, usually under the skin of the head or ear of the animal. Paste formulations can be prepared by dispersing a compound or compounds in pharmaceutically acceptable oil such as peanut oil, sesame oil, corn oil or the like. Pellets containing a therapeutically effective amount of a compound or compounds can be prepared by admixing the compound with a diluent such as a carbowax, carnauba wax, and the like, and a lubricant, such as magnésium or calcium stéarate, can be added to improve the pelleting process. It is, of course, recognized that more than one pellet may be administered to an animal to achieve the desired dose level. Moreover, it has been found that such implants may also be administered periodically during the animal treatment period in order to maintain the proper active agent level in the animal's body.
[0089] The compounds of the présent invention and the pharmaceutically acceptable salts of the same, can be administered to a patient at dosage levels in the range of from about 0.01 to about 1,000 mg per day. For a normal adult human having a body weight of about 70 kg, a dosage in the range of from about 0.01 to about 300 mg is typically sufficient, with 1-10 mg/kg a preferred dosage. However, some variability in the general dosage range may be required depending upon the âge and weight of the subject being treated, the intended route of administration, the particular compound being administered and the like. The détermination of dosage ranges and optimal dosages for a particular patient is well within the ability of one of ordinary skill in the art having the benefit of the instant disclosure. It is also noted that the compounds of the présent invention can be used in sustained release, controlled release, and delayed release formulations, which forms are also well known to one of ordinary skill in the art.
[0090] It is not critical whether the compounds of the présent invention are administered directly to the cell, to a tissue comprising the cell, a body fluid that contacts the cell, or a body location from which the compound can diffuse or be transported to the cell. It is sufficient that the compound is administered to the patient in an amount and by a route whereby an amount of the compound sufficient to mobilize lipids in the cell arrives, directly or indirectly at the cell. The minimum amount varies with the identity of the compounds.
[0091] The spécifie dosage and dosage range that can be used dépends on a number of factors, including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being administered. The détermination of dosage ranges and optimal dosages for a particular patient is well within the ordinary skill of one in the art in view of this disclosure. It is understood that the ordinarily skilled physician or veterinarian will readily détermine and prescribe an effective amount of the compound to mobilize lipid stores, induce weight loss, or inhibit appetite in the patient. In so proceeding, the physician or veterinarian can, for example, prescribe a relatively low dose ai first, subsequently increasing the dose until an appropriate response is obtained. It is further understood, however, that the spécifie dose level for any particular human will dépend upon a variety of factors including the activity of the spécifie compound employed, the âge, body weight, general health, gender, and diet of the human, the time of administration, the route of administration, the rate of excrétion, any drug combination, and the severity of any disorder being treated.
[0092] Various exemplary embodiments of compositions and methods according to this invention are now described in the following examples. In these embodiments, spécifie products identified by Arabie mimerais (e.g., 1, 2, 3, etc.) refer to the spécifie structures so identified in the following description, particularly in Table 1 below and the appended daims
III. EXAMPLES
[0093] The following examples are offered for illustrative purposes only and are not intended to limit the scope of the présent invention in any way. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and the following examples and fall within the scope of the appended daims.
Example 1: Synthesis of 33 EET Analogs
[0094] In this Example, the inventors report the synthesis of a library of EET analogs. The Chemical structures of these compounds, designated as compounds 1-33, are shown in Table 1 below.
[0095] General Procedures. Unless stated otherwise, yields refer to purified products and are not optimized. Final compounds were judged >95% pure by HPLC using a Zorbax Eclipse Cl8 (250 x 4.6 mm; Agilent) connected to an Agilent 1200 API/LC-MS with acetonitr île/water combinations as solvent. Ail oxygen and/or moisture sensitive reactions were performed under an argon atmosphère using oven-dried glassware and anhydrous solvents. Anhydrous solvents were freshly distilled from sodium benzophenone ketyl, except for CH2CI2, which was distilled from CaH2. Extracts were dried over anhydrous Na2SO4 and filtered prior to removal of ail volatiles under reduced pressure. Unless otherwise noted, commercially available materials were used without purification. Flash chromatography (FC) was performed using E Merck silica gel 60 (240-400 mesh). Thin layer chromatography (TLC) was performed using pre-coated plates purchased from E. Merck (silica gel 60 PF254, 0.25 mm). Nuclear magnetic résonance (NMR) spectra were recorded on Varian 300, 400 or 500 spectrometers at operating frequencies of 300/400/500 MHz (!H) or 75/100/125 MHz (13C) in CDCI3, unless otherwise stated. Nuclear magnetic résonance (NMR) splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), and broad (br); the values of Chemical shifts (δ) are given in ppm relative to residual solvent (chloroform δ = 7.27 for ’H NMR or <5 = 77.23 for proton decoupled l3C NMR), and coupling constants (J) are given in Hertz (Hz). Melting points were determined using an OptiMelt (Stanford Research Systems) and are uncorrected. The Notre Dame University Mass Spectroscopy Facility or Prof. Kasem Nithipatikom (Medical College of Wisconsin) kindly provided high-resolution mass spectral analyses.
Table 1: 33 EET analogs and measured vascular relaxation and sEH inhibition activity,
Compd | Analog | Vascular Relax. % ec50 (10 uM) (uM) | sEHi Xo (nM) | Compd | Analog | Vascular Relax. % ec50 (10 uM) (uM) | sEHi ic50 (nM) | ||
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 | x^xvVoXT \-An\AzV / v Y3 \ a X a / a — N N H H O > z . X . yOH / v οΧΧΖ V...... HO Q X^V^0^ OH \z^ λ AA/ — N N HH O __ U OH / V N V 9 - OH / Z N V \a a X 0 '— N N Me Me q CO2H Χ^ΧΧ^νΆ \ A A XA/' CO2H '— N N H H O NHSO,Pn \a A AA/ '— N N HH O NHSO2Me \ A A zv,-v “ N N ΧΧ H A p-ONa XA^X7^ 'ONa \ .A A A^z ....... N N H H Ok ,0 /= .--. z. V / a ov 77 ONa Vaaa/ H H V Z=A /—x AN-S-Pb / V OV H \ A A AA/ '— N N v _ XH aX czvY B K X.X /=\y—\XS X3 \ /X A X> HH N-n /=x/—\asA' π / v ov n-n \ a A A a/H '— N N v H H N-i /=\/—\/—s-<z II / \z 0\z N.N \_A A — N N V X HH O 11 z,N71 /=A/—\ /--s A !' / V ov HN X Va A aa/ N n H H X°N-, /=XÆV-sY il / v ον N‘n Va A a/vh '— N N H H | 86 72 104 49 95 92 91 73 61 71 63 75 48 76 85 53 92 92 | 2.9 5.1 1.5 0.63 1.9 2.75 1.6 6.0 6.7 >10 7.6 3.4 >10 5.0 3.7 9.8 3.5 3.1 | >500 255 >500 237 >500 >500 392 41 71 >500 57 32 6 11 22 32 96 23 | 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 | N π V Z \Z θΧ/χΛ^ \_/A,.V/\/A/ Z X H N XXvXn Va A h H A ï N /_\Z ( ? H H ΑΛ'α H 0 - N / XXn-n Va A aX — N N v H H * >0 \x A /wz — N N HH 0 JL-nh S^o \ X X XAZ λ— N N HH ,0 h V° /—V N V>x X/V — N N HH ,0 E /^vxvVn / 0 H X—Z /Pr .0 h ‘S^° rxxx V\N^ H 0 T°>s cxv v......N N H H >^0 ΛΛΛλΛ/'Ν V/\ A /xxj' — N N v H H Ox r- 0 N'VhAc ( 0 /Pt Ç^’S /—Q N'^NHAc / o v_/x λ ζχχν — N N H H Οχ 1—0 N NHAc / oH \ A A ,N A z ÎZZ N'NHAc / v 0 V^ A x/\z — N N H H | 74 119 96 110 89 47 109 109 116 93 54 96 73 96 73 | 1.0 0.18 1.7 1.1 1.1 >10 0.34 0.32 0.36 3.3 2.4 1.3 0.9 2.4 3.3 | >500 11 >500 32 65 57 10 >500 >500 31 231 >500 >500 >500 282 |
[0096]
The synthesis of the EET-compounds of Table 1 are provided as follows:
[0097]
Synthesis of Analog 25
TH PO D ·\Α/νθ7Β0Ρδ
BrTHp0
OTBDPS
[0098] fôrZ-ButyldiphenyI-[ 12-(tetrahydro-2Ef-pyran-2-yloxy)dodec-7-ynyloxy)]silane.
A-Butyllithium (12.0 mL of 2.5 M solution in hexanes, 30.0 mmol) was added dropwise with stirring to a-78 °C solution of 2-(hex-5-ynyloxy)tetrahydro-277-pyran (5.0 g, 27.43 mmol, G. F. Smith Chem. Co.) in THF/HMPA (4:1, 150 mL) under an argon atmosphère. After 30 min, the reaction mixture was warmed to 0 °C and maintained at this température for 2 h. After re-cooling to -78 °C, a solution of l-fôrZ-butyldiphenylsilyloxy-6-bromohexane1 (11.50 g, 27.43 mmol) in THF (55 mL) was added and the température was raised over 3 h to 23 °C. After an additional 12 h, the reaction mixture was quenched with saturated aq. NH4CI solution (25 mL). The mixture was extracted with EtOAc (2 x 100 mL) and the combined extracts were washed with water (2 x 150 mL), brine (50 mL), dried, and concentrated under reduced pressure. The residue was purified by S1O2 column chromatography to give the title compound (11.14 g, 78%), obtained as a colorless oil, whose spectral data matched literature values. TLC: 15% EtOAc/hexanes, 7?f ~ 0.60; 'H NMR (400 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 4.57 (t, J= 4.3 Hz, 1H), 3.783.86 (m, 2H), 3.65 (t, J = 6.3 Hz, 2H), 3.32-3.54 (m, 2H), 2.10-2.22 (m, 4H), 1.24-1.84 (m, 18H), 1.04 (s, 9H); l3C NMR (100 MHz) δ 130.61, 129.17, 124.54, 122.62, 93.82, 75.48, 74.89, 72.41, 72.10, 71.78, 62.11, 58.93, 57.32, 27.51, 25.79, 24.18, 23.99, 23.68, 21.96, 21.87, 21.0, 20.55,20.40, 14.26, 13.77, 13.67.
TH PO. a ,--==-, A A OTBDPS
HO. a .--==-χ a OTBDPS
[0099] 12-(/er/-Butyldipheny!silyloxy)dodec-5-yn-l-ol. A mixture of tert-butyldiphenyl[12-(tetrahydro-2Æ-pyran-2-yloxy)dodec-7-ynyloxy)]silane (11.0 g, 21.14 mmol) and ptolunesulfonic acid (165 mg) in MeOH (110 mL) was stirred at room température for 10 h. The reaction mixture was quenched with sat. aq. NaHCOa solution (10 mL). The methanol was evaporated, then more water (50 mL), and the mixture extracted with EtOAc (3 x 75 mL). The combined organic extracts were washed with water (2 x 50 mL), brine (40 mL), dried and concentrated under reduced pressure. The residue was purified by S1O2 chromatography to give the title compound (7.93 g, 86%), obtained as a colorless oil, whose spectral data matched literature values.1 TLC: EtOAc/hexanes (3:7), Rf ~ 0.44; *H NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 3.62 (t, J = 6.3 Hz, 4H), 2.06-2.22 (m, 4H), 1.50-1.64 (m, 12H), 1.04 (s,
9H); l3C NMR (100 MHz) δ 135.81, 134.36, 129.74, 127.82, 80.89, 80.01, 64.14, 62.71, 32.71, 32.10, 29.34,28.86, 27.11,25.59, 25.57, 19.46, 18.93, 18.77.
[00100] 12-(ter/-Butyldiphenylsilyloxy)dodec-5(Z)-en-l-ol. NaBH4 (82 mg, 2.28 mmol) was added in portions with vigorously stirring to a room température solution of Ni(OAc)2-4H2O (567 mg, 2.28 mmol) in absolute éthanol (20 mL) under a hydrogen atmosphère (1 atm). After 15 min, freshly distilled ethylenediamine (0.30 mL, 4.56 mmol) was added to the black suspension, followed after a further 15 min by a solution of H-(tertbutyldiphenylsilyloxy)dodec-5-yn-l-ol (4.0 g, 9.16 mmol) in absolute EtOH (10 mL). After 1 h, the reaction mixture was quenched with Et2O (20 mL) and passed through a small bed of silica gel. The bed was rinsed with another portion of Et2O (5 mL). The combined ethereal filtrâtes were concentrated under reduced pressure to afford the title compound (3.85 g, 96%) as a colorless oil sufficiently pure to be used directly in the next step. TLC: EtOAc/hexanes (3:7), Rf ~ 0.46. 'H NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 5.42-5.28 (m, 2H), 3.653.60 (t, J= 6.4 Hz, 4H), 2.08-1.96 (m, 4H), 1.50-1.60 (m, 4H), 1.40-1.24 (m, 10H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 135.81, 134.40, 130.61, 129.71, 129.60, 127.80, 64.21, 63.14, 32.78, 32.60, 29.98, 29.27, 27.42, 27.14, 27.10, 26.08, 25.92, 19.48. HRMS calcd for C28H43O2Si [M+1 ]+ 439.3032, found 439.3027.
—<A OTBDPS /=\z—\/\OTBDpS λH N3
[00101] 1 -/erAButyldiphenylsiIyloxy-12-azidododec-7(Z)-ene. Diisopropyl azodicarboxylate (DIAD; 1.46 mL, 7.35 mmol) was added dropwise to a-20 °C solution of PPI13 (2.10 g, 8.0 mmol) in dry THF (45 mL) under an argon atmosphère. After 10 min, a solution of 12-(ierLbutyldiphenylsilyloxy)dodec-5(Z)-en-l-ol (3.20 g, 7.35 mmol) from above in dry THF (10 mL) was added dropwise. After 30 min, the mixture was warmed to 0 °C and diphenylphosphoryl azide (1.58 mL, 7.35 mmol) was added dropwise. After stirring 4 h at rt, the reaction mixture was quenched with water (150 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were washed with brine (100 mL), dried (Na2SO4), and concentrated under reduced pressure. The residue was purifîed by S1O2 column chromatography eluting with 4% EtOAc/hexane to afford the title compound (2.45 g, 72%). TLC: EtOAc/hexanes (1:9), 7?f ~ 0.55; ‘H NMR (400 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 5.28-5.42 (m, 2H), 3.70 (t, J=5.8 Hz, 2H), 3.27 (t, 6.3 Hz, 2H), 1.96-2.10 (m, 4H), 1.24-1.64 (m, 12H), 1.04 (s,
9H); l3C NMR (100 MHz) δ 135.84, 134.41, 130.93, 129.75, 129.12, 127.83, 64.22, 51.62, 32.81, 29.93, 29.30, 28.68, 27.46, 27.14, 27.02, 26.90, 25.96, 19.49; IR (neat) 2930, 2783, 2331, 2097, 1106 cm'1. HRMS calcd for C28H42N3OSi [M+l]+ 464.3097, found 464,3099.
[00102] l-te^ButyldiphenylsilyIoxy-12-aminododec-7(Z)-ene. Triphenylphosphine (1.18g, 4.50 mmol) was added to a stirring solution of azide l-/ert-butyldiphenylsilyloxy-12azidododec-7(Z)-ene (1.90 g, 4.10 mmol) in THF (12 mL) containing 4 drops of deionized water. After 12 h, the reaction mixture was diluted with CH2C12 (10 mL), dried, and concentrated in vacuo to give the title compound (1.36 g, 76%) as a viscous, colorless oil that was used directly in the next reaction without further purification. TLC: MeOH/CH2Cl2 (1:4), Rf ~ 0.25; ’H NMR (400 MHz) δ 7.62-7.68 (m, 4H), 7.32-7.40 (m, 6H), 5.30-5.40 (m, 2H), 3.63 (t, J= 5.2 Hz, 2H), 2.62 (t, J= 4.8 Hz, 2H), 1.92-2.06 (m, 4H), 1.40-1.58 (m, 4H), 1.20-1.40 (m, 8H), 1.03 (s, 9H); 13C NMR (100 MHz) δ 135.79, 134.37, 130.42, 129.70, 127.78, 64.19, 42.28, 33.44, 32.77, 29.93, 29.28, 27.40, 27.21, 27.10, 25.92, 19.44. HRMS calcd for C28H44NOSi [M + 1]+ 438.3192, found 438.3186.
[00103] l-(12-(ter/-ButyldiphenylsiIyIoxy)dodec-5(Z)-enyl)-3-n-pentylurea. A solution of l-tert-butyldiphenylsilyloxy-12-aminododec-7(Z)-ene (1.32 g, 3.0 mmol) in THF (5 mL) was added dropwise to a stirring solution of w-pentyl isocyanate (0.386 mL, 3.0 mmol) in THF (10 mL). After 3 h stirring at room température, ail volatiles were removed under reduced pressure and the residue was purified by SiO2 column chromatography eluting with 20% EtOAc/hexane to afford the title compound (1.26 g, 76%) as a viscous oil. TLC: EtOAc/hexanes (2:3), Rf ~ 0.40; 'H NMR (300 MHz) δ 7.60-7.70 (m, 4H), 7.35-7.42 (m, 6H), 5.28-5.42 (m, 2H), 5.16 (br s, -NH, 2H), 3.65 (t, J = 6.5 Hz, 2H), 3.08-3.20 (m, 4H), 1.96-2.08 (m, 4H), 1.22-1.60 (m, 18H), 1.02 (s, 9H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 159.23, 135.80, 134.24, 130.52, 129.74, 129.49, 127.82, 64.22, 40.62, 40.54, 32.80, 30.33, 29.95, 29.37, 29.32, 27.46, 27.34, 27.18, 27.11, 25.97, 22.71, 19.46, 14.29. HRMS calcd for C34H55N2O2Si [M+l]+ 551.4033, found 551.4032.
HH HH
[00104] l-(12-Hydroxydodec-5(Z)-enyl)-3-«-pentylurea. A mixture of \-(\2-(tertbutyldiphenylsilyloxy)dodec-5(Z)-enyl)-3-77-pentylurea (1.12 g, 2.0 mmol) and tetra-wbutylammonium fluoride (2.20 mL of 1 M soin in THF, 2.2 mmol) in dry THF (10 mL) was stirred at room température under an argon atmosphère for 12 h, and then evaporated to dryness in vacuo. The residue was dissolved in EtOAc (50 mL) and washed with water (30 mL), brine (30 mL), dried and evaporated in vacuo. Purification of the residue via SiO2 column chromatography gave the title compound (0.56 g, 89%) as a colorless solid, mp 63.7-63.8 °C. TLC: EtOAc/hcxanes (7:3), Rf ~ 0.30; ]H NMR (300 MHz) δ 5.25-5.42 (m, 2H), 4.40-4.56 (br s, -NH, 2H), 3.60-3.68 (d, J = 6.5 Hz, 2H), 3.08-3.20 (m, 4H), 1.96-2.14 (m, 4H), 1.22-1.60 (m, 18H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 159.26, 130.23, 129.62, 63.72, 40.33, 40.29, 32.92, 30.30, 30.26, 29.74, 29.35, 29.13, 27.26, 27.20, 27.13, 25.82, 22.69, 14.27. HRMS calcd for C18H37N2O2 [M+l]+ 313.2855, found 313.2857.
[00105] l-(12-Bromododec-5(Z)-enyl)-3-«-pentylurea. CBr4 (0.55 g, 1.66 mmol) and PPh3 (0.43 g, 1.66 mmol) were added to a 0 °C solution of l-(12-hydroxydodec-5(Z)-enyl)-3-rzpentylurea (0.43 g, 1.38 mmol) in CH2CI2 (20 mL). After 2 h at room température, the reaction mixture was concentrated in vacuo and the residue was purified via SiO2 column chromatography to give l-(12-bromododec-5(Z)-enyl)-3-/7-pentylurea (0.43 g, 83%) as a viscous oil, mp 46.7-46.8 °C. TLC: EtOAc/hexanes (2:3), Rf ~ 0.60; 'H NMR (300 MHz) δ 5.22-5.42 (m, 2H), 4.40 (br s, 2H), 3.42 (t, J = 9.3 Hz, 2H), 3.10-3.20 (m, 4H), 1.98-2.10 (m, 4H), 1.80-1.90 (m, 2H), 1.25-1.55 (m, 16H), 0.92 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz) δ 159.51, 130.14, 129.69, 40.48, 40.39, 34.20, 32.96, 30.34, 29.67, 29.36, 28.58, 28.25, 27.31, 27.27, 27.17, 22.68, 14.26. HRMS calcd for Ci8H36BrN2O [M+l]+ 375.2011, found 375.2014.
[00106] l-(12-Cyanododec-5(Z)-enyl)-3-n-pentylurea. A mixture of potassium cyanide (0.23 g, 3.54 mmol) and l-(12-bromododec-5(Z)-enyl)-3-77-pentylurea (0.90 g, 2.40 mmol) was stirred in DMSO (5 mL) at room température. After 12 h, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with water (2 x 25 mL), brine (25 mL), dried (Na2SO4) and was passed through a silica gel column to give the title compound (0.62 g, 81%) as a colorless solid, mp 56-57 °C. TLC: EtOAc/hexanes (2:3), Rf -0.45. Ή NMR (300 MHz) δ 5.29-5.40 (m, 2H), 4.27 (br s, -NH, 2H), 3.10-3.20 (m, 4H), 2.34 (t, J = 7.0 Hz, 2H), 1.98-2.08 (m, 4H) 1.24-1.70 (m, 18H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 159.41, 129.94, 129.86, 120.14, 40.45, 40.35, 30.30, 29.50, 29.33, 28.70, 28.51, 27.26, 27.16, 25.47, 22.66, 17.28,14.24; IR (neat) 2930, 2281, 2184, 2042, 1936, 1613, 1197, 1042 cm'1. HRMS calcd for Ci9H36N3O [M+l]+ 322.2858, found 322.2867.
[00107] M-Hydroxy-13-(3-n-pentylureido)tridec-8(Z)-enimidamide. To a suspension of 1(12-cyanododec-5(Z)-enyl)-3-«-pentylurea (350 mg, 1.09 mmol) in MeOH/H2O (4:1; 12 mL) was added H2NOH-HC1 (228 mg, 3.28 mmol) and Na2CO3 (344 mg, 3.25 mmol). The reaction mixture was heated at 60 °C for 18 h, then cooled to room température and ail volatiles were removed in vacuo. The residue was diluted with water (30 mL) and extracted into ethyl acetate (2 x 25 mL). The combined organic extracts were washed with water (2 x 10 mL), brine (10 mL), dried and purified via flash silica gel column chromatography using 5% MeOH/CH2Cl2 to give the title compound (239 mg, 62%) as a colorless solid, mp 94.6-94.7 °C. TLC: MeOH/CH2Cl2 (1:4), R{-0.20; 'H NMR (CD3OD, 300 MHz) δ 5.34-5.42 (m, 2H), 3.33 (s, 2H), 3.08-3.16 (m, 3H), 2.02-2.10 (m, 6H), 1.52-1.60 (m, 2H), 1.44-1.52 (m, 5H), 1.30-1.44 (m, 10H), 0.92 (t, J = 7.2 Hz, 3H); 13C NMR (CD3OD, 125 MHz) δ 160.14, 155.23, 129.95, 129.42, 39.86, 39.76, 30.70, 29.95, 29.89, 29.59, 29.06, 28.91, 27.18, 26.97, 26.95, 26.78, 22.39, 13.34. HRMS calcd for Ci9H39N4O2 [M+l]+ 355.3073, found 355.3078.
[00108] Analog 25. To an ice cooled solution of IV-hydroxy-13-(3-H-pentylureido)tridec-8(Z)enimidamide (100 mg, 0.28 mmol) and pyridine (45 pL, 0.56 mmol) in THF (100 mL) was added dropwise a solution of thionyl chloride (20 pL, 0.28 mmol) in CH2C12 (2 mL). After 1 h, the reaction mixture was concentrated in vacuo, diluted with water (25 mL), and extracted with
CH2Q2 (2 χ 10 mL). The combined organic extracts were washed with water and dried. The solvent was evaporated in vacuo and the residue was purified by SiO2 column chromatography using 10% MeOH/CH2Cl2 to give 25 (80 mg, 72%) as a sticky solid. TLC: MeOH/CH2Cl2 (1:9), Rf -0.60; 'H NMR (CD3OD, 300 MHz) δ 5.33-5.36 (m, 2H), 3.04-3.13 (m, 4H), 2.57 (t, J= 7.4 Hz, 2H), 2.00-2.10 (m, 4H), 1.62-1.74 (m, 2H), 1.25-1.54 (m, 16H), 0.92 (t, J = Ί2 Hz, 3H); 13C NMR (CD3OD, 125 MHz) δ 160.16, 153.94, 129.83, 129.47, 39.83, 39.71, 29.89, 29.82, 29.40, 29.01, 28.59, 28.52, 26.87, 26.85, 26.71, 26.30, 23.37, 22.33, 13.25. HRMS calcd for C20H38N4O2S [M+l]+ 398.2716, found 398.2720.
[00109] Synthesis of Analog 20.
[00110] Analog 20. A mixture of l-(12-cyanododec-5(Z)-enyl)-3-n-pentylurea (500 mg, 1.55 mmol), sodium azide (100 mg, 1.55 mmol) and zinc bromide (335 mg, 1.48 mmol) was heated at 110 °C in isopropanol/H2O (1:3, 8 mL) while stirring vigorously in a sealed tube. After 18 h, the mixture was cooled to room température and the pH was adjusted to 1 using aq. HCl (3 N, 4 mL). Ethyl acetate (10 mL) was added and the stirring was continued until no solid was présent. The organic layer was isolated and the aqueous layer extracted with EtOAc (2 x 25 mL). The combined organic fractions were washed with water (3 x 25 mL), dried and concentrated in vacuo. The residue was purified by flash silica gel column chromatography to give the analog 20 (431 mg, 76%) as a colorless solid, mp 205.6-205.8 °C. TLC: 10% MeOH/CH2Cl2, 7?f~O.3O; !H NMR (CD3OD, 300 MHz) δ 5.40-5.30 (m, 2H), 3.06-3.11 (m, 4H), 2.93 (t, J = 8.0 Hz, 2H), 1.98-2.10 (m, 4H), 1.70-1.82 (m, 2H), 1.24-1.50 (m, 16H), 0.90 (t, J= 7.6 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 160.16, 156.81, 129.77, 129.47, 39.81, 39.68, 29.88, 29.80, 29.35, 28.99, 28.69, 28.55, 27.48, 26.85, 26.81, 26.68, 22.96, 22.31, 13.22. HRMS calcd for Ci9H37N6O [M+l]+ 365.3029, found 365.3030.
[00111] Synthesis of Analog 29.
[00112] Analog 29. A mixture of Y-hydroxy-13-(3-w-pentylureido)tridec-8(Z)-enimidamide (150 mg 0.42 mmol) and Ι,Γ-thiocarbonyl diimidazole (90%; 91 mg, 0.51 mmol) in THF (5 mL) was stirred at room température. After 45 min, the mixture was diluted with water (10 mL) and extracted with ethyl acetate (3x5 mL). The combined extracts were washed with water, dried, and concentrated in vacuo. The residue was dissolved in dry THF (5 mL) and boron trifluoride , 10 diethyl etherate (103 pL, 0.84 mmol) was added. After another 1 h, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2x10 mL). The combined extracts were washed with water, dried (Na2SO4), and the solvent was evaporated in vacuo. The residue was purified by column chromatography to give 29 (104 mg, 63%) as a colorless solid, mp 124.2-125.1 °C. TLC: MeOH/CH2Cl2 (1:9), Rf~0.60; ‘HNMR (CD3OD, 300 MHz) δ 5.30-5.40 (m, 2H), 3.02-3.12 (m, 4H), 2.54 (t, J= 8.0 Hz, 2H), 1.98-2.10 (m, 4H), 1.62-1.74 (m, 2H), 1.241.52 (m, 16H), 0.90 (t, J= 7.0 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 181.12, 160.13, 159.12, 129.48, 128.84, 39.85, 39.73, 30.90, 29.91, 29.83, 29.41, 29.03, 28.69, 28.65, 26.89, 26.86, 26.73, 26.23, 22.35, 13.29; IR (neat) 2924, 1724, 1603, 1464, 1375 cm’1. HRMS calcd for C20H37N4O2S [M+l]+ 397.2637, found 397.2638.
1 20 [00113] Synthesis of Analog 28.
[00114] Analog 28. A mixture of W-hydroxy-13-(3-n-pentylureido)tridec-8(Z)-enimidamide (150 mg 0.42 mmol) and l,l'-thiocarbonyl diimidazole (90%; 91 mg, 0.51 mmol) in THF (5 mL) was stirred at room température for 45 min. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were washed with water, dried, and the solvent was evaporated in vacuo. The residue was dissolved in acetonitrile (5 mL) to which was then added DBU (147 mg, 0.96 mmol). After stirring at room température for 1 h, the mixture was diluted with water 10 mL), adjusted pH~4 with IN HCl, and extracted with ethyl acetate (3 x 10 mL). The combined extracts were washed with water, dried over
Na2SO4, and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography to give 28 (101 mg, 61%) as a colorless syrup. TLC: MeOH/CH2Cl2 (1:9), Y ~ 0.55; 'H NMR (CD3OD, 300 MHz) δ 5.30-5.40 (m, 2H), 3.04-3.14 (m, 4H), 2.62 (t, J= 7.7 Hz, 2H), 2.00-2.10 (m, 4H), 1.62-1.74 (m, 2H), 1.22-1.54 (m, 16H), 0.91 (t, J = 6.7 Hz, 3H); 13C NMR (CD3OD, 125 MHz) δ 188.49, 161.91, 160.15, 129.82, 129.53, 39.88, 39.75, 29.92, 29.85,
29.37, 29.05, 28.63, 28.55, 26.90, 26.86, 26.75, 25.91, 23.67, 22.37, 13.31. HRMS calcd for
C20H37N4O2S [M+l]+ 397.2637, found 397.2645.
[00115] Synthesis of Analog 11.
HH H H
[00116] Analog 11. A solution of l-(12-bromododec-5(Z)-enyl)-3-«-pentylurea (300 mg, 0.79 mmol), sodium sulfite (352 mg, 2.8 mmol) and cyclohexene (649 mg, 7.9 mmol) in éthanol (5 mL) was refluxed ovemight. The volatiles were removed under reduced pressure and the residue was dissolved in de-ionized water. BioRad SM-2 Bio-beads (5 g; pre-washed with 0.1 N NH4OH and H2O) were added, gently stirred for 30 min, and then collected on a sintered glass funnel. The beads were washed with deionized water (2 x 10 mL) and then EtOH (3 x 10 mL). Concentration of the ethanolic washes afforded 11 (235 mg, 75%) as a colorless solid, mp 133.6133.8 °C. 'H NMR (CD3OD, 300 MHz) δ 5.30-5.40 (m, 2H), 3.02-3.14 (m, 4H), 2.78 (t, J = 8.0 Hz, 2H), 1.98-2.12 (m, 4H), 1.72-1.84 (m, 2H), 1.22-1.50 (m, 16H), 0.91 (t, J = 7.0 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 160.12, 129.86, 129.49, 51.46, 39.01, 38.92, 29.92, 29.32, 29.02, 28.69, 28.42, 26.93, 26.62, 25.78, 24.78, 22.34, 12.02. HRMS calcd for Ci8H35N2NaO4S [M]+ 398.2215, found 398.2220.
[00117] Synthesis of Analog 10.
O \\ ,OMe __ Br __ / V OMe
A \ ^. A zx/x/ — N N — N N
HH H H
[00118] Dimethyl (12-(3-n-pentylureido)dodec-7(Z)-en-l-yl)phosphonate. A solution of 1(12-bromododec-5(Z)-enyl)-3-n-pentylurea (250 mg, 0.67 mmol) and trimethyl phosphite (10 mL) in THF (10 mL) was heated under reflux. After for 48 h, ail volatiles were removed in vacuo and the residue was purified by silica gel column chromatography using 60% EtOAc/CH2Cl2 to give dimethyl (12-(3-«-pentylureido)dodec-7(Z)-en-l-yl)phosphonate (160 mg, 59%) as a viscous oil. TLC: EtOAc, Af ~ 0.55; *H NMR (400 MHz) δ 5.30-5.40 (m, 2H), 5.10 (br s, -NH, 1H), 5.02 (br s, -NH, 1H), 3.70 (s, 3H), 3.68 (s, 3H), 3.06-3.14 (m, 4H), 1.972.20 (m, 4H), 1.63-1.78 (m, 2H), 1.20-1.60 (m, 18H), 0.88 (t, J = 7.2 Hz, 3H); l3C NMR (100 MHz) δ 159.11, 130.17, 129.93, 52.59, 52.56, 40.49, 30.49, 30.32, 30.28, 29.34, 29.33, 28.58, 27.21, 27.15, 27.11, 25.32, 23.93, 22.66, 22.35, 22.30, 14.24. HRMS calcd for C2oH42N204P [M+l]+ 405.2882, found 405.2883.
[00119] Analog 10. Trimethylsilyl bromide (37 pL) was added to a solution of the above phosphonate diester (100 mg, 0.25 mmol) in dry CHCI3 (4 mL). After 2 h at rt, the solution was concentrated and the residue was suspended in ethyi acetate (5 mL). The résultant precipitate was collected and dissolved in de-ionized water. BioRad SM-2 Bio-beads (5 g; pre-washed with 0.1 N NH4OH and H2O) were added, gently stirred for 1 h, and then collected on a sintered glass funnel. The beads were washed with deionized water (2x10 mL) and then EtOH (3x10 mL). Concentration of the ethanolic washes afforded disodium phosphonate 10 (68 mg, 65%). ]H NMR (CD3OD, 300 MHz) δ 5.30-5.42 (m, 2H), 3.18-3.24 (m, 4H), 1.97-2.20 (m, 4H), 1.50-1.78 (m, 8H), 1.20-1.60 (m, 12H), 0.92 (t, J= 7.2 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 159.48, 130.10, 129.25, 40.85, 40.76, 30.48, 30.25, 29.38, 29.13, 29.06, 28.81, 28.67, 27.62, 26.92, 26.70, 26.64, 25.80, 22.65, 22.58, 22.25, 13.02. HRMS calcd for Ci8H35N2Na2O4P [M]+ 420.2130, found 420.2122.
[00120] Synthesis of Analog 16.
H H
[00121] Analog 16. Sodium methoxide (180 pL, 30% methanolic solution) was added to a solution of l,2,4-triazole-3-thiol (101 mg, 0.99 mmol) in dry DMF (5 mL). After stirring for 10 min, l-(12-bromododec-5(Z)-enyl)-3-n-pentylurea (250 mg, 0.66 mmol) was added. After stirring ovemight, the reaction mixture was poured into ice water (100 mL) and the résultant precipitate was collected by filtration and dried in vacuo. The crude solid was suspended in dichloromethane (100 mL), stirred for 1 h and filtered to give 16 (222 mg, 85%) as a colorless solid, mp 76.1-76.2 °C. TLC: EtOAc, -0.30; 'H NMR (CD3OD, 300 MHz) δ 8.26 (br s, 1H), 5.29-5.40 (m, 2H), 3.04-3.14 (m, 6H), 1.98-2.10 (m, 4H), 1.62-1.72 (m, 2H), 1.22-1.50 (m, 16H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 160.15, 157.16, 146.90, 129.86, 129.44, 39.84, 39.73, 32.10, 29.91, 29.84, 29.65, 29.49, 29.02, 28.60, 28.30, 26.88, 26.73, 22.34, 13.28. HRMS calcd for C2oH38N5OS [M+l]+ 396.2797, found 396.2805.
[00122] Synthesis of Analog 17.
[00123] Analog 17. Ammonium molybdate (160 mg, 0.13 mmol) and hydrogen peroxide (0.6 mL, 30% aq. soin) were combined at 0 °C and stirred for 15 min. An aliquot of the résultant bright yellow solution (0.15 mL) was added dropwise to a stirring, 0 °C solution of sulfide 16 (77 mg, 0.2 mmol) in éthanol (1.0 mL) resulting in a light yellow precipitate. Over the next 15 min, aliquots (0.15 mL) of the oxidizing solution were added every 5 min. After another 10 min, the reaction mixture was partitioned between H2O and dichloromethane (10 mL). The aqueous phase was extracted with dichloromethane (10 mL) and the combined organic extracts were washed with brine and dried (Na2SO4). The residue was purified by flash SiO2 chromatography (70% EtOAc/hexanes) to provide sulfoxide 17 (43 mg, 52%) as a colorless solid, mp 88.2-88.4 °C. TLC: MeOH/EtOAc (1:9), Æf-0.30; 'H NMR (CD3OD, 300 MHz) δ 8.38 (br s, 1H), 5.265.36 (m, 2H), 5.18 (br s, 2H), 3.04-3.26 (m, 6H), 1.92-2.08 (m, 2H), 1.70-1.84 (m, 2H), 1.201.50 (m, 18H), 0.86 (t, J = 72 Hz, 3H); !3C NMR (CD3OD, 75 MHz) δ 163.82, 160.15, 146.98, 129.73, 129.54, 52.62, 39.81, 39.71, 29.90, 29.84, 29.25, 29.01, 28.57, 28.22, 26.88, 26.77, 26.73, 22.33, 21.92, 13.24. HRMS calcd for C20H38N5O2S [M+l]+ 412.2746, found 412.2741.
[00124] Synthesis of Analog 18.
[00125] Analog 18. Ammonium molybdate (960 mg, 0.77 mmol) and hydrogen peroxide (3.6 mL, 30% aq. soin) were combined at 0 °C and stirred for 15 min. An aliquot of the bright yellow solution (0.45 mL) was added dropwise to a 0 °C solution of sulfide 16 (154 mg, 0.39 mmol) in éthanol (3.6 mL) resulting in a light yellow precipitate. Over the next 90 min, aliquots (0.5 mL) of the oxidizing solution were added every 15 min. After another 15 min, the reaction mixture was partitioned between H2O and dichloromethane (10 mL). The aqueous phase was extracted with dichloromethane (10 mL) and the combined organic phases were washed with brine and dried (Na2SO4). The residue was purified by flash SiO2 chromatography (70% EtOAc/hexanes) to provide sulfone 18 (129 mg, 78%) as a white solid, mp 90.6-90.8 °C. TLC: MeOH/EtOAc (1:9), Rf - 0.50; ’H NMR (CD3OD, 300 MHz) δ 8.44 (br s, 1H), 5.25-5.30 (m, 2H), 5.02 (br s, 1H), 4.90 (br s, 1H), 3.35 (t, J= 7.9 Hz, 2H), 3.22-3.10 (m, 4H), 1.90-2.60 (m, 4H), 1.66-1.80 (m, 2H), 1.20-1.54 (m, 16H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 161.15, 160.13, 145.87, 129.73, 129.56, 54.26, 39.85, 39.74, 29.90, 29.83, 29.21, 29.02, 28.46, 27.80, 26.89, 26.79, 26.73, 22.34, 22.19, 13.30. HRMS calcd for C20H38N5O3S [M+l]+ 428.2695, found 428.2701.
[00126] Synthesis of Analog 23.
^0HrV
Λ1
NH2 H \/X A /^NZ \z\ A — N N x v N N v z
HH HH
[00127] Analog 23. To a solution of 7V-hydroxy-13-(3-«-pentylureido)tridec-8(Z)enimidamide (50 mg, 0.14 mmol) in dry dioxane (3 mL) was added 1,1-carbonyldiimidazole (CDI; 27 mg, 0.16 mmol) followed by l,8-diazabicycloundec-7-ene (DBU; 23 mg, 0.15 mmol). After stirring for 15 min, the reaction mixture was warmed to 110 °C for 15 min, then returned to room température. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3x5 mL). The combined organic extracts were washed with water, brine, dried (Na2SO4), and concentrated in vacuo. The residue was purified by SiO2 column chromatography to give 23 (36 mg, 67%) as a sticky solid. TLC: EtOAc/hexanes (4:1), Rf ~ 0.40; *H NMR (CD3OD, 300 MHz) δ 5.30-5.40 (m, 2H), 3.02-3.14 (m, 4H), 2.52 (t, J = 7.7 Hz, 2H), 2.00-2.10 (m, 4H), 1.60-1.70 (m, 2H), 1.24-1.50 (m, 16H), 0.90 (t, J = 6.7 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 158.30, 157.33, 126.98, 126.68, 37.02, 36.90, 26.97, 26.53, 26.19, 25.76, 25.72, 24.02, 23.89, 22.68, 21.84, 19.52, 10.43; IR (neat) 2929, 2854, 1809, 1776, 1738, 1620, 1580, 1467, 1257, 981 cm’1. HRMS (ESI-neg) calcd for C2oH35N403 [M-l]' 379.2715, found 379.2731.
[00128] Synthesis of Analog 27.
. OTBDPS /=\ >—< OTBDPS
[00129] y-n-Butyl-Az2-(12-(/er/-butyldiphenylsilyloxy)dodec-5(Z)-enyl)oxalamide. A mixture of 2-(«-butylamino)-2-oxoacetic acid2 (0.40 g, 2.70 mmol), the above \-tertbutyldiphenylsilyloxy-12-aminododec-7(Z)-ene (1.20 g, 2.70 mmol), 1-hydroxybenzotriazole (HOBt; 0.44 g, 3.30 mmol) and [l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride] (0.63 g, 3.30 mmol) in dry DMF (5 mL) was stirred at room température overnight. The reaction mixture was quenched with water (30 mL) and extracted into ethyl acetate (3 x 20 mL). The combined organic extracts were washed with water (2 x 10 mL), brine (10 mL), dried and concentrated in vacuo. The residue was purified by SiO2 column chromatography to give N'-nbutyl-A2-(12-(/er/-butyldiphenylsilyloxy)dodec-5(Z)-enyl)oxalamide (1.10 g, 73%). TLC: EtOAc/hexanes (2:3), Rf - 0.55; Ή NMR (400 MHz) δ 8.05 (br s, -NH, 2H), 7.66-7.74 (m, 4H), 7.32-7.42 (m, 6H), 5.30-5.42 (m, 2H), 3.67 (t, J = 3.9 Hz, 2H), 3.31 (q, J = 52 Hz, 4H), 1.962.10 (m, 4H), 1.50-1.64 (m, 6H), 1.22-1.44 (m, 10H), 1.06 (s, 9H), 0.92 (t, J = 7.8 Hz, 3H); 13C NMR (100 MHz) δ 160.33, 135.80, 134.35, 130.73, 129.74, 129.20, 127.83, 64.17, 39.89, 39.69, 32.79, 31.48, 29.94, 29.29, 29.07, 27.46, 27.23, 27.14, 27.0, 25.96, 20.29, 19.46, 13.96. HRMS calcd for C34H53N2O3Si [M+1 ]+ 565.3826, found 565.3824.
[00130] 7V1-H-Butyl-A2-(12-hydroxydodec-5(Z)-enyl)oxalamide. Nx-n-QvXy\-N2-(\2-(tertbutyldiphenylsilyloxy)dodec-5(Z)-enyl)oxalamide (1.20 g, 2.12 mmol) was de-silylated as described above to give A1-/?-butyl-A2-(12-hydroxydodec-5(Z)-enyl)oxalamide (0.568 g, 82%) as a colorless solid, mp 102.8-102.9 °C. TLC: EtOAc/hexanes (7:3), Rf - 0.55; Ή NMR (400 MHz) δ 7.69 (br s, 2H), 5.20-5.35 (m, 2H), 3.56 (t, J= 4.2 Hz, 2H), 3.26 (q, J = 5.6 Hz, 4H), 2.17 (br s,
-OH), 1.95-2.02 (m, 4H), 1.44-1.56 (m, 6H), 1.20-1.40 (m, 10H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz) δ 160.15, 130.66, 129.21, 62.98, 39.80, 39.63, 32.93, 31.39, 29.77, 29.18, 28.95, 27.26, 27.0, 26.88, 25.80, 20.18, 13.85. HRMS calcd for Ci8H35N2O3 [M+l]+ 327.2648, found 327.2648.
[00131] W^12-Bromododec-5(Z)-enyl)-.ZV2-H-butyloxalamide. Α’-^-ΒυΐγΙ-Λ^-ζΠhydroxydodec-5(Z)-enyl)oxalamide (330 mg, 1.0 mmol) was brominated as described above to give AE(12-bromododec-5(Z)-enyl)-A2-n-butyloxalamide (330 mg, 84%) as a white solid, mp 46.0-46.3 °C. TLC: EtOAc/hexanes (3:2), Rf ~ 0.55; 'H NMR (400 MHz) δ 7.79 (br s, -NH, 1H), 7.77 (br s, -NH, 1H), 5.20-5.32 (m, 2H), 3.32 (t, J = 6A Hz, 2H), 3.22 (q, J = 7.2 Hz, 4H), 1.90-2.00 (m, 4H), 1.72-1.82 (m, 2H), 1.42-1.56 (m, 4H), 1.20-1.40 (m, 10H), 0.85 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 160.17, 160.15, 130.40, 129.34, 39.77, 39.59, 34.12, 32.93, 31.40, 29.62, 29.0, 28.54, 27.25, 27.24, 27.0, 26.91, 20.18, 13.85. HRMS calcd for C18H34BrN2O2 [M + 1]+ 389.1804, found 389.1809.
[00132] ALn-Butyl-A^-ilZ-cyanododec-SiZj-enyljoxalamide. .M-(12-bromododec-5(Z)enyl^/An-butyloxalamide (250 mg, 0.642 mmol) was treated as described above with potassium cyanide to give 7V1-«-butyl-A2-(12-cyanododec-5(Z)-enyl)oxalamide (168 mg, 78%) as a colorless solid, mp 83.0-83.3 °C. TLC: EtOAc/hexanes (3:2), Rf ~ 035; 'H NMR (400 MHz) δ 7.45 (br s, -NH, 2H), 5.30-5.40 (m, 2H), 3.34 (q, J= 8.6 Hz, 4H), 2.32 (t, J = 7.6 Hz, 2H), 1.982.08 (m, 4H), 1.30-1.68 (m, 16H), 0.92 (t, J= 7.2 Hz, 3H); 13C NMR (100 MHz) δ 160.03 (2C), 130.03, 129.08, 120.10, 39.88, 39.42, 31.22, 29.40, 28.82, 28.60, 28.42, 27.07, 27.06, 26.82, 25.54, 20.06, 17.01, 13.80. HRMS calcd for C]9H34N3O2 [M+l]+ 336.2651, found 336.2650.
[00133] Λ'η |3_\nijno-13-(h\ (lroxyiniino)tridec-5(Z)-enyl)-\'-//-biityloxalamide.
Following the procedure described above, a mixture of /V’-n-butyl-A^H-cyanododec-SÎZ)35 enyl)oxalamide, H2NOH-HCl, and Na2CO3 was converted to A1-(13-amino-13(hydroxyimino)tridec-5(Z)-enyl)-A2-/7-butyloxalamide (102 mg, 62%) as a colorless solid, 116.3116.4 °C. TLC: MeOH/CH2Cl2 (1:4), Rf - 0.20; 'H NMR (CD3OD, 400 MHz) δ 5.28-5.40 (m, 2H), 3.24 (t, J= 6A Hz, 4H), 1.98-2.00 (m, 6H), 1.50-1.60 (m, 6H), 1.26-1.40 (m, 10H), 0.92 (t, J = Ί.3 Hz, 3H); 13C NMR (CD3OD, 100 MHz) δ 160.55 (2C), 156.31, 130.05, 129.18, 39.23, 10 39.09, 31.18, 30.63, 29.51, 28.83, 28.69, 27.10, 26.87, 26.59,19.88, 12.88. HRMS calcd for Ci9H37N4O3 [M+l]+ 369.2866, found 369.2864.
[00134] Analog 27. Treatment of A1-(13-amino-13-(hydroxyimino)tridec-5(Z)-enyl)-A2-/7butyloxalamide (100 mg, 0.27 mmol) with l,l'-thiocarbonyl diimidazole gave 27 (71 mg, 63%) as a white solid, mp 110.6-110.8 °C. TLC: MeOH/CH2Cl2 (1:9), Rf - 0.55; ]H NMR (400 MHz) δ 8.90 (br s, NH, 1H), 7.52 (br s, NH, 2H), 5.28-5.40 (m, 2H), 3.20-3.40 (m, 4H), 2.59 (t, J= 7.5 Hz, 2H), 1.98-2.10 (m, 4H), 1.21-1.70 (m, 16H), 0.92 (t,J=7.3 Hz, 3H); 13CNMR(100 MHz) δ 160.12, 160.08, 153.31, 130.62, 129.46, 39.93, 39.85, 31.35, 29.33, 28.94, 28.89, 28.68, 27.02, 26.84, 26.69, 23.96, 20.23, 13.90. HRMS calcd for Ci9H35N4O4S [M+l]+ 415.2379, found
415.2372.
[00135] Synthesis of Analog 21.
2
[00136] Analog 21. Following the procedure used to préparé 22, a mixture of N -n-butyl-A (12-cyanododec-5(Z)-enyl)oxalamide (30 mg, 0.10 mmol), sodium azide (11 mg, 0.20 mmol) and zinc bromide (40 mg, 0.20 mmol) was heated in isopropanol/methanol/H2O (1:1:3, 4 mL) to give tetrazole 21 (25 mg, 74%) as a colorless solid, mp 113-114 °C. TLC: 10% MeOH/CH2Cl2, Rf-0.26; 'H NMR (CD3OD, 400 MHz) δ 5.40-5.35 (m, 2H), 3.26 (t, J= 7.0 Hz, 4H), 2.44 (t, J= 7.0 Hz, 2H), 2.05-2.15 (m, 4H), 1.65-1.60 (m, 6H), 1.40-1.30 (m, 10H), 0.94 (t, J = 7.3 Hz, 3H); l3C NMR (CD3OD, 100 MHz) δ 160.12, 160.05, 156.80, 130.35, 129.50, 39.20, 39.08, 31.15,
29.33, 28.66, 28.65, 28.53, 27.38, 26.83, 26.79, 26.55, 22.86, 19.85, 12.84. HRMS calcd for C,9H35N6O2 [M+l]+ 379.2822, found 379.2814.
[00137] Synthesis of Analog 26.
[00138] l-(ZerAButyIdiphenylsilyloxy-12-Iodododec-7(Z)-ene. Triphenylphosphine (504 mg, 1.14 mmol) and imidazole (156 mg, 2.30 mmol) were added to a 0 °C solution of the above n-ffôrAbutyldiphenylsilyloxyjdodec-SfZj-en-l-ol (500 mg, 1.14 mmol) in dry THF (25 mL) under an argon atmosphère. After 10 min, solid iodine (252 mg, 1.2 equiv) was added in portions. After stirring at room température for 3 h, the reaction mixture was quenched with sat. aq. sodium bisulfite solution (10 mL). After an additional 1 h, the solution was washed with water (2 x 30 mL) and concentrated under reduced pressure. The residue was purified by flash SiO2 column chromatography using 10% EtOAc/hexanes as eluent to give the title compound (474 mg, 76%) as a colorless oil. TLC: 20% EtOAc/hexanes, Rf~ 0.65; ’H NMR (300 MHz) δ 7.65-7.70 (m, 4H), 7.35-7.45 (m, 6H), 5.30-5.40 (m, 2H), 3.64 (t, J = 6.4 Hz, 2H), 3.18 (t, J= 5.5 Hz, 2H), 1.95-2.10 (m, 4H), 1.85-1.90 (m, 2H), 1.22-1.50 (m, 10H), 1.20 (s, 9H); l3C NMR (75 MHz) δ 135.87, 130.42, 130.22, 130.20, 129.95, 127.89, 64.15, 38.35, 36.20, 32.50, 29.90, 28.62, 28.32, 27.25, 27.20, 27.18, 26.22, 19.12. HRMS calcd for C28H42IOSi [M+l]+ 549.2050, found 549.2044.
[00139] l-(/er/-ButyldiphenylsilyIoxy-12-7V-isopropylamino-dodec-7(Z)-ene.
Isopropylamine (464 pL, 5.45 mmol) and K2CO3 (373 mg, 2.73 mmol) were added sequentially to a room température solution of l-(/ert-butyldiphenylsilyloxy-12-iodododec-7(Z)-ene (500 mg, 0.91 mmol) in dry tetrahydrofuran (8 mL). The mixture was heated in a sealed tube at 90 °C for 12 h, then cooled to rt, diluted with water (5 mL), filtered and the filtrate was extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were dried, concentrated under reduced pressure, and the residue was purified by SiO2 column chromatography using a gradient from 2% to 5% MeOH/ CH2C12 as eluent to give the title amine (335 mg, 77%) as a colorless oil. TLC: 5% MeOH/CH2Cl2, Rf ~0.3; ’H NMR (300 MHz) δ 7.62-7.70 (m, 4H), 7.34-7.44 (m, 6H), 5.30-5.40 (m, 2H), 3.64 (t, J = 6.4 Hz, 2H), 2.72-2.84 (m, 1H), 2.58 (t, J = 7.0 Hz, 2H), 1.942.08 (m, 4H), 1.20-1.60 (m, 12H), 1.05 (d, J = 7.2 Hz, 6H), 1.04 (s, 9H); 13C NMR (75 MHz) δ 135.81, 134.40, 132.0, 129.72, 127.81, 64.21, 48.96, 47.75, 32.80, 30.33, 29.97, 29.31, 27.85,
27.44, 27.33, 27.11, 25.95, 23.27, 19.46. HRMS calcd for C3iH50NOSi [M+l]+ 480.3662, found
480.3666.
[00140] V-(12-(/c'/7-Butyldiphenylsilyloxy)dodec-5(Z)-enyl)-\-isopropyl n-heptanamide. Solid [l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride] (EDCI; 131 mg, 0.69 mmol) was added in portions to a room température solution of l-(/erEbutyldiphenylsilyloxy-127V-isopropylamino-dodec-7(Z)-ene (300 mg, 0.63 mmol), DMAP (84 mg, 0.69 mmol), Nhydroxybenzotriazole (HOBt; 93 mg, 0.69 mmol), and 77-heptanoic acid (90 mg, 0.68 mmol) in dry DMF (5 mL). After 12 h, the reaction mixture was diluted with water (10 mL) and extracted with ether (3x5 mL). The combined ethereal extracts were washed with brine, dried, and evaporated in vacuo. The residue was purified via SiO2 column chromatography to give the title compound (281 mg, 76%) as a colorless oil. TLC: EtOAc/hexanes (1:4), Rf ~ 0.65; *H NMR (300 MHz, 1:1 mixture of rotamers) δ 7.62-7.70 (m, 4H), 7.34-7.44 (m, 6H), 5.30-5.40 (m, 2H), 4.60-4.70 and 4.00-4.05 (m, 1H for two rotamers), 3.05 (t, J = 5.2 Hz, 2H), 3.02-3.19 (m, 2H), 2.20-2.40 (m, 2H), 1.95-2.10 (m, 4H), 1.20-1.60 (m, 20 H), 1.18 and 1.08 (d, J = 7.0 Hz, 6H for two rotamers), 1.02 (s, 9H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz) δ 177.24, 173.35, 172.25, 136.16, 135.80, 135.14, 134.37, 134.34, 130.97, 130.31, 129.74, 129.73, 129.54, 129.04, 127.82, 127.75, 64.21, 64.18, 48.42, 45.68, 43.62, 41.19, 34.46, 34.02, 32.81, 32.79, 31.95, 31.94, 31.75, 31.28, 30.0, 29.92, 29.55, 29.46, 29.31, 29.09, 27.87, 27.52, 27.49, 27.45, 27.21, 27.13, 26.94, 26.88, 25.97, 25.95, 25.79, 25.15, 22.81, 22.75, 21.63, 20.77, 19.46, 19.33, 14.34, 14.30. HRMS calcd for C38H62NO2Si [M+l]+ 592.4550, found 592.4552.
[00141] 7V-(12-Hydroxydodec-5(Z)-enyl)-/V-isopropyl n-heptanamide. Following the desilylation procedure above, /V-(12-(/erEbutyldiphenylsilyloxy)dodec-5(Z)-enyl)-?/-isopropyl nheptanamide (275 mg, 0.464 mmol) was converted to the title alcohol (155 mg, 94%) as a syrup. TLC: 40% EtOAc/hexanes, Àf ~ 0.45; 'H NMR (300 MHz, 45/55 mixture of rotamers) δ 5.305.46 (m, 2H), 4.62-4.72 and 4.00-4.08 (m, 1H for two rotamers), 3.63 (t, J = 5.4 Hz, 2H), 3.063.14 (m, 2H), 2.22-2.36 (m, 2H), 1.98-2.10 (m, 4H), 1.24-1.70 (m, 20 H), 1.17 and 1.10 (d, J = 6.8 Hz, 6H for two rotamers), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz) δ 173.23, 172.67,
130.83, 130.12, 129.71, 128.96, 62.69, 62.64, 48.34, 45.56, 43.52, 41.07, 34.0, 33.91, 32.91, 32.88, 31.84, 31.81, 31.18, 29.82, 29.74, 29.46, 29.33, 29.11, 27.78, 27.37, 27.35, 27.16, 27.13, 26.84, 25.89, 25.81, 25.66, 22.69, 21.51, 20.65, 14.21. HRMS calcd for C22H44NO2 [M+l]+ 354.3372, found 354.3380.
[00142] .V-(l2-Bromododee-5(Z)-envl)-V-isoprop) l-u-hexanamide. Following the procedure above, /V-(12-hydroxydodec-5(Z)-enyl)-7V-isopropyl zz-heptanamide (150 mg, 0.43 mmol) was transformed as described above into the corresponding bromide (144 mg, 82%) as a syrup. TLC: 30% EtOAc/hexanes, R{ - 0.65; ’H NMR (300 MHz, 45/55 ratio of rotamers) δ 5.30-5.42 (m, 2H), 4.60-4.70 and 4.00-4.10 (m, 1H for two rotamers), 3.42 (t, J = 5.3 Hz, 2H), 3.02-3.20 (m, 2H), 2.20-2.38 (m, 2H), 1.80-2.10 (m, 4H), 1.20-1.70 (m, 20H), 1.16 and 1.12 (d, J = 7.2 Hz, 6H for two rotamers), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz) δ 173.20, 172.64, 130.61, 130.46, 129.96, 129.94, 129.24, 48.34, 45.56, 43.54, 41.09, 34.20, 34.16, 34.05, 33.97, 32.98, 32.93, 32.60, 31.90, 31.88, 31.26, 29.78, 29.68, 29.62, 29.51, 29.40, 28.94, 28.55, 28.25, 28.20, 27.81, 27.69, 27.45, 27.30, 27.25, 27.18, 26.92, 25.87, 25.20, 22.75, 21.59, 20.72, 14.72. HRMS calcd for C22H43BrNO [M+l]+ 416.2528, found 416.2523.
[00143] A-(12-Cyanododec-5(Z)-enyl)-AMsopropyl-H-hexanamide. Following the cyanide displacement procedure above, 7V-(12-bromododec-5(Z)-enyl)-/V-isopropyl-n-hexanamide (500 mg, 1.20 mmol) gave the titie nitrile (339 mg, 78%) as a syrup. TLC: EtOAc/hexanes (3:7), R^~ 0.40; 'H NMR (500 MHz, 45/55 ratio of rotamers) δ 5.20-5.34 (m, 2H), 4.52-4.62 and 3.90-4.02 (m, 1H for two rotamers), 3.00-3.10 (m, 2H), 2.16-2.30 (m, 4H), 1.90-2.05 (m, 4H), 1.60-1.70 (m, 8H), 1.22-1.50 (m, 12H), 1.18 and 1.11, (d, J = 6.8 Hz, 6H for two rotamers), 0.88 (t, J= 7.2 Hz, 3H); 13C NMR (75 MHz) δ 173.22, 172.66, 130.42, 130.04, 129.78, 129.35, 120.04, 119.99, 48.34, 45.58, 43.54, 41.07, 34.02, 33.95, 31.89, 31.86, 31.22, 29.53, 29.49, 29.37, 28.73, 28.70, 28.57, 28.53, 27.78, 27.39, 27.26, 27.18, 27.17, 26.91, 25.85, 25.70, 25.52, 25.49, 22.73, 21.56, 20.70, 17.26, 14.27. HRMS calcd for C23H43N2O [M+l]+ 363.3375, found 363.3375.
[00144] 2V-(13-Amino-13-(hydroxyimino)tridec-5(2)-enyl)-7V-isopropyl-/t-heptanamide.
Following the procedure above, a mixture of N-(12-cyanododec-5(Z)-enyl)-TV-isopropyl-/7hexanamide, H2NOH-HC1, and Na2CO3 was converted into the title compound (64%). TLC: MeOH/CH2Cl2 (3:7), Y ~ 0.30; ’H NMR (500 MHz, 1:1 ratio of rotamers) δ 5.24-5.40 (m, 2H), 4.62-4.68 (m, 0.5H), 4.50-4.60 (-NH, 2H), 3.96-4.40 (m, 0.5H), 3.02-3.14 (m, 2H), 2.18-2.28 (m, 2H), 1.90-2.16 (m, 6H), 1.46-1.64 (m, 8H), 1.20-1.36 (m, 12 H), 1.15 andl.08 (d, J = 7.3 Hz, 6H for two rotamers), 0.85 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz) δ 173.22, 172.58, 154.26, 154.21, 130.82, 130.13, 129.79, 129.08, 48.32, 45.50, 43.52, 41.09, 36.03, 34.05, 33.97, 31.89, 31.86, 31.459, 31.25, 29.72, 29.67, 29.53, 29.39, 29.21, 29.19, 29.11, 29.03, 27.83, 27.41, 27.24, 27.17, 26.90, 26.84, 25.87, 25.70, 22.74, 21.58, 20.73, 14.26. HRMS calcd for C23H46N3O2 [M+1]T 396.3590, found 396.3698.
[00145] Analog 26. Y(13-Amino-13-(hydroxyimino)tridec-5(Z)-enyl)-7V-isopropyl-ttheptanamide (150 mg, 0.38 mmol) was treated with thionyl chloride at 0 C as described above to give 26 (133 mg, 68%) as a syrup. TLC: EtOAc/hexanes (1:1), Rî~ 0.30; ’H NMR (400 MHz, 35/65 ratio of rotamers) δ 5.22-5.40 (m, 2H), 4.48-4.70 and 4.00-4.12 (m, 1H for two rotamers), 3.04-3.20 (m, 2H), 2.50 and 2.64 (t, J = 6.9 Hz, 2H for two rotamers), 2.22,2.38 (t, J = 8.0 Hz, 2H for two rotamers), 1.90-2.10 (m, 4H), 1.50-1.78 (m, 8H), 1.20-1.40 (m, 12H), 1.22 and 1.12 (d, J= 6.7 Hz 6H for two rotamers), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz) δ 173.82, 173.40, 153.39, 153.26, 131.03, 130.02, 129.97, 129.10, 48.85, 46.04, 43.82, 41.50, 34.13, 34.02, 31.85, 31.80, 31.23, 29.58, 29.32, 29.11, 29.09, 29.02, 28.80, 28.17, 27.96, 27.32, 27.24, 27.19, 26.03, 26.75, 26.64, 26.10, 24.02, 29.96, 22.75, 21.56, 21.53, 20.74, 20.72, 14.27, 14.25. HRMS calcd for C24H44N3O3S [M+l]+ 442.3103, found 442.3106.
[00146] Synthesis of Analog 19.
[00147] Analog 19. N-(12-Cyanododec-5(Z)-enyl)-N-isopropyl-n-hexanamide (350 mg, 0.97 mmol) was treated with sodium azide as described above to give tetrazole 19 (250 mg, 64/o) as a sticky solid. TLC: EtOAc, Rf ~ 0.40; Ή NMR (300 MHz, 35/65 ratio of rotamers) δ 5.22-5.40 (m, 2H), 4.58-4.68 and 4.02-4.18 (m, 1H for two rotamers), 3.10-3.24 (m, 2H), 2.98 (t, J = 7.6 Hz, 2H), 2.44 and 2.30 (t, J = 7.3 Hz, 2H for two rotamers), 1.94-2.10 (m, 4H), 1.72-1.84 (m, 2H), 1.50-1.70 (m, 4H), 1.18-1.40 (m, 14H), 1.21 and 1.10 (d, J = 7.2 Hz, 6H for two rotamers), 0.82-0.87 (m, 3H); 13C NMR (75 MHz) δ 174.06, 173.80, 130.85, 130.04, 129.79, 129.08, 48.94, 46.32, 43.97, 41.55, 34.11, 34.05, 31.79, 31.72, 31.12, 29.61, 29.61, 29.51, 29.25, 29.05, 28.85, 28.22, 27.98, 27.89, 27.32, 27.19, 26.92, 25.97, 23.70, 22.67, 21.51, 20.67, 14.02. HRMS calcd for C23H44N5O [M+l]+ 406.3546, found 406.3547.
[00148] Synthesis of Analog 22.
Br. OTBDPS n-BuLi -------------—>. THPO^^^=
THPO.
OTBDPS
[00149] l-iÉ,rAButyldiphenylsilyloxy-13-(tetrahydro-2Hr-pyran-2-yloxy)tridec-8-yne.
Following the procedure applied in the synthesis of analog 25, 2-(hex-5-ynyloxy)tetrahydro-2#pyran1 (5.0 g, 27.40 mmol) was coupled with l-fôrAbutyldiphenylsilyloxy-7-bromoheptane (11.90 g, 27.40 mmol) to give l-/er/-butyldiphenylsilyloxy-13-(tetrahydro-27f-pyran-2yloxy)tridec-8-yne3 (10.50 g, 72%) as a colorless syrup whose spectral data matched literature values.3 TLC: EtOAc/hexanes (1:4), Rf ~ 0.60; 'H NMR (400 MHz) δ 7.64-7.68 (m, 4H), 7.347.42 (m, 6H), 4.57 (t, J = 4.3 Hz, 1H), 3.78-3.86 (m, 2H), 3.65 (t, J = 6.3 Hz, 2H), 3.32-3.54 (m, 2H), 2.10-2.22 (m, 4H), 1.24-1.84 (m, 20H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 135.80, 134.38, 129.72, 127.81, 99.0, 80.72, 80.10, 67.30, 64.17, 62.49, 32.77, 30.99, 29.34, 29.18, 29.13, 29.0, 27.11, 26.19, 25.91, 25.74, 19.87, 19.45, 19.0, 18.86.
THPO^ .
^^^^^OTBDPS OTBDPS
[00150] 13-(terAButyldiphenylsilyIoxy)tridec-5-yn-l-ol. Following the procedure applied in the synthesis of analog 25, 1 -iert-butyldiphenylsilyloxy-13-(tetrahydro-2Æ-pyran-2-yloxy)tridec41
8-yne (10.0 g, 18.70 mmol) was deprotected with PPTS to give 13-(Wbutyldiphenylsilyloxy)tridec-5-yn-l-ol (7.70 g, 91%) as a colorless syrup. TLC: EtOAc/hexanes (3:7), Rf-0.43; ’HNMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 3.62 (t, J = 5.6 Hz, 4H), 2.06-2.22 (m, 4H), 1.50-1.64 (m, 14H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 135.82, 134.37, 129.76, 127.85, 80.93, 80.04, 64.21, 62.63, 32.77, 32.09, 29.33, 29.13, 29.10, 27.14, 25.92, 25.63, 19.47, 19.0, 18.81. HRMS calcd for C29H43O2Si [M+l]+ 451.3032, found 451.3032.
[00151] (Z)-13-(to7-ButyldiphenylsilyIoxy)tridec-5-en-l-ol. Following the procedure applied in the synthesis of analog 25, 13-(/urt-butyldiphenylsilyloxy)tridec-5-yn-l-ol (7.50 g, 16.60 mmol) was subjected to semi-hydrogenation to give 13-(/ert-butyldiphenylsilyloxy)tndec5(Z)-en-l-ol (6.90 g, 92%) as a syrup whose spectral values matched literature data.2 TLC: EtOAc/hexanes (3:7), Rf - 0.45; ]H NMR (400 MHz) δ 7.64-7.68 (m, 4H), 7.42-7.34 (m, 6H), 5.28-5.42 (m, 2H), 3.68-3.67 (t, J = 6.4 Hz, 4H), 1.98-2.12 (m, 4H), 1.50-1.60 (m, 4H), 1.401.24 (m, 10H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 135.83, 134.40, 130.61, 129.74, 129.60, 127.83, 64.21, 63.08, 32.83, 32.60, 29.94, 29.54, 27.50, 27.18, 27.14, 26.12, 26.01, 19.48.
[00152] l-/ô'F/-BuHldiphenylsilyIoxy-13-azidotridec-8(Z)-ene. Following the procedure applied in the synthesis of analog 25, 13-(/ert-butyldiphenylsilyloxy)tridec-5(Z)-en-l-ol (7.0 g, 15.48 mmol) was converted to l-fôrLbutyldiphenylsilyloxy-13-azidotridec-8(Z)-ene (5.30 g, 72%) obtained as a syrup. TLC: EtOAc/hexanes (1:9), Rf - 0.55; ’H NMR (400 MHz) δ 7.687.64 (m, 4H), 7.42-7.34 (m, 6H), 5.28-5.42 (m, 2H), 3.64 (t, J = 6A Hz, 2H), 3.26 (t, J= 5.6 Hz, 2H), 1.96-2.10 (m, 4H), 1.64-1.24 (m, 14H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 135.86, 134.44, 131.0, 129.77, 129.12, 127.85, 64.27, 51.63, 32.87, 29.95, 29.56, 28.70, 27.54, 27.17, 27.05, 26.93, 26.05, 19.51. IR (neat) 2930, 2783, 2361, 2331, 2094, 1109 cm'1. HRMS calcd for C29H44N3OSi [M+l]+ 478.3254, found 478.3250.
[00153] l-terLButyldiphenyIsiIyIoxy-13-aminotridec-8(Z)-ene. Following the procedure applied in the synthesis of analog 25, l-fôr/-butyldiphenylsilyloxy-13-azidotridec-8(Z)-ene (3.50 g, 7.32 mmol) was reduced with triphenylphosphine to give l-fer/-butyldiphenylsilyloxy-13 aminotridec-8(Z)-ene (2.44 g, 74%) as a colorless oil. TLC: MeOH/CH2Cl2 (1:4), Rf~ 0.25; ]H NMR (400 MHz) δ 7.62-7.68 (m, 4H), 7.32-7.40 (m, 6H), 5.30-5.40 (m, 2H), 3.63 (t, J= 5.2 Hz, 2H), 2.62 (br s, 2H), 1.92-2.06 (m, 4H), 1.40-1.58 (m, 4H), 1.20-1.40 (m, 10H), 1.03 (s, 9H); 13C NMR (100 MHz) δ 135.79, 134.39, 130.46, 129.70, 127.78, 64.22, 42.02, 32.80, 29.92, 29.52, 27.46, 27.23, 27.10, 25.98, 19.44. HRMS calcd for C29H46NOSi [M+l]+ 452.3349, found 452.3357.
[00154] l-(13-(ter/-Butyldiphenylsilyloxy)tridec-5(Z)-enyI)-3-H-pentylurea. Following the procedure applied in the synthesis of analog 25, l-fô^butyldiphenylsilyloxy-13-aminotridec8(Z)-ene (2.35 g, 5.20 mmol) was reacted with n-pentyl isocyanate to give \-(Y3-(tertbutyldiphenylsilyloxy)tridec-5(Z)-enyl)-3-tt-pentylurea (2.23 g, 76%) as a syrup. TLC: EtOAc/hexanes (1:4), Rf ~ 0.65; 'H NMR (500 MHz) δ 7.62-7.70 (m, 4H), 7.32-7.44 (m, 6H), 5.28-5.44 (m, 2H), 4.37 (br s, 2H), 3.66 (t, J = 4.2 Hz, 2H), 3.08-3.20 (m, 4H), 1.98-2.08 (m, 4H), 1.20-1.60 (m, 20H), 1.05 (s, 9H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz) δ 159.22, 135.80, 134.12, 130.24, 129.88, 129.76, 127.81, 64.21, 40.62, 40.54, 32.82, 30.31, 29.95, 29.56, 29.39, 27.51, 27.35, 27.20, 27.13, 26.01, 22.72, 19.43, 14.30. HRMS calcd for C35H57N2O2Si [M+l]+ 565.4189, found 565.4186.
HH HH
[00155] l-(13-Hydroxytridec-5(Z)-enyl)-3-//-pentylurea. Following the procedure applied in the synthesis of analog 25, l-(13-(/er/-butyldiphenylsilyloxy)tridec-5(Z)-enyl)-3-/7-pentylurea (2.30 g, 4.07 mmol) was desilylated using TBAF to give l-(13-hydroxytridec-5(.Z)-enyl)-3-npentylurea (1.22 g, 92%) as a white solid, mp 63.1-63.3 °C. TLC: EtOAc/hexanes (7:3), Rf ~ 0.55; 'H NMR (400 MHz) δ 5.24-5.38 (m, 2H), 4.74 (br s, -NH, 2H), 3.62 (t, J = 5.6 Hz, 2H), 3.06-3.18 (m, 4H), 1.98-2.06 (m, 4H), 1.20-1.60 (m, 20H), 0.86 (t, J = Ί3 Hz, 3H); 13C NMR (100 MHz) δ 159.31, 130.38, 129.63, 62.90, 40.51, 40.46, 32.93, 30.30, 30.29, 29.79, 29.41, 29.34, 29.23, 27.30, 27.24, 27.15, 25.98, 22.67, 14.25. HRMS calcd for C19H39N2O2 [M+l]+ 327.3012, found 327.3011.
HH HH
[00156] l-(13-Bromotridec-5(Z)-enyl)-3-n-pentyIurea. Following the procedure appiied in the synthesis of analog 25, l-(13-hydroxytridec-5(Z)-enyl)-3-N-pentylurea (1.20 g, 3.68 mmol) was transformed into l-(13-bromotridec-5(Z)-enyl)-3-n-pentyhirea (1.17 g, 82%), obtained as a sticky solid. TLC: EtOAc/hexanes (2:3), - 0.60; lH NMR (500 MHz) δ 5.28-5.40 (m, 2H),
4.71 (br s, -NH, 2H), 3.40 (t, J = 4.2 Hz, 2H), 3.10-3.20 (m, 4H), 1.98-2.06 (m, 4H), 1.82-1.88 10 (m, 2H), 1.26-1.50 (m, 18H), 0.87 (t, J = 7.2 Hz, 3H); l3C NMR (125 MHz) δ 159.38, 130.34, 129.59, 40.55, 40.46, 34.29, 33.02, 30.34, 29.81, 29.38, 29.30, 28.89, 28.35, 27.39, 27.33, 27.18, 22.71, 14.29. HRMS calcd for C19H37BrN2O [M]+ 388.2089, found 388.2090.
[00157] l-(13-Cyanotridec-5(Z)-enyl)-3-n-pentylurea. l-(13-Bromotridec-5(Z)-enyl)-3-n15 pentylurea (1.10 g, 2.82 mmol) was reacted with potassium cyanide as described above in the synthesis of analog 25 to give l-(13-cyanotridec-5(Z)-enyl)-3-n-pentylurea (0.69 g, 73%) as a colorless solid, mp 44.3-44.4 °C. TLC: EtOAc/hexanes (1:1), Rf ~ 0.32; lH NMR (500 MHz) δ 5.30-5.42 (m, 2H), 4.35 (br s, 2H), 3.04-3.20 (m, 4H), 2.34 (t, J = 7.6 Hz, 2H), 1.98-2.10 (m, 4H), 1.60-1.72 (m, 2H), 1.24-1.56 (m, 18H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz) δ
159.24, 130.23, 129.68, 120.02, 40.24, 40.13, 30.27, 29.69, 29.32, 29.07, 28.82, 28.78, 27.29, 27.26, 27.13, 25.49, 22.64, 17.30, 14.24. HRMS calcd for C2oH38N30 [M+l]+ 336.3015, found 336.3019.
[00158] l-(13-(lZZ-Tetrazol-5-yl)tridec-5(Z)-enyl)-3-n-pentylurea (22). Following the procedure described above in the synthesis of analog 20, a mixture of l-(13-cyanotridec-5(Z)enyl)-3-N-pentylurea, sodium azide, and zinc bromide was heated at 110 °C to give analog 22 (66%) as a colorless solid, mp 86.0-86.2 °C. TLC: MeOFI/CH2Cl2 (1:9), 7% ~ 0.30; fH NMR (CD3OD, 300 MHz) δ 5.30-5.40 (m, 2H), 3.06-3.11 (m, 4H), 2.93 (t, J = 8.0 Hz, 2H), 1.98-2.10 (m, 4H), 1.70-1.82 (m, 2H), 1.24-1.50 (m, 18H), 0.90 (t, J=7.6Hz, 3H);13C NMR (CD3OD, 100
MHz) δ 160.15, 156.21, 129.89, 129.39, 39.84, 39.71, 29.89, 29.82, 29.53, 29.01, 29.00, 28.81, 27.45, 26.90, 26.70, 22.89, 22.33, 13.25. HRMS calcd for C20H38N6O [M]+ 378.3107, found 378.3111.
[00159] Synthesis of Analog 13.
n-BuLl ΤΗΡΟ —
Br OTBDPS THpo Γ = \x^^0TBDps
[00160] l-(fer/-ButyldiphenylsiIyloxy)-ll-(tetrahydro-2.iZ-pyran-2-yloxy)undec-6-yne.
Following the procedure applied in the synthesis of analog 25, 2-(hex-5-ynyloxy)tetrahydro-2Ffpyran1 was treated with π-BuLi and l-(/er/-butyldiphenylsilyloxy-5-bromopentane4 to give the title compound (73%) as a colorless liquid. TLC: EtOAc/hexanes (1:4), Rf ~ 0.60; *H NMR (400 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 4.57 (t, J = 4.3 Hz, 1H), 3.78-3.86 (m, 2H), 3.65 (t, J = 6.3 Hz, 2H), 3.32-3.54 (m, 2H), 2.10-2.22 (m, 4H), 1.24-1.84 (m, 16H), 1.04 (s, 9H); l3C NMR (125 MHz) δ 135.80, 134.32, 129.74, 127.84, 99.01, 80.54, 80.16, 67.30, 64.02, 62.50, 32.34, 30.98, 29.18, 29.12, 27.32, 27.10, 26.17, 25.73, 25.32, 19.87, 18.99, 18.86. HRMS calcd for C3iH45O3Si [M+l]+493.3138, found 493.3144.
THPO., = ..► HO^.—=—
OTBDPS OTBDPS
[00161] ll-(ter/-Butyldiphenylsilyloxy)undec-5-yn-l-ol. Following the procedure reported to préparé analog 25, l-ffôrt-butyldiphenylsilyloxy)-!l-(tetrahydro-2//-pyran-2-yloxy)undec-6yne was cleaved with a catalytic amount of PPTS to give the title compound (72%) as a colorless liquid. TLC: EtOAc/hexanes (3:7), Rf ~ 0.43; *H NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.347.42 (m, 6H), 3.62 (t, J = 5.6 Hz, 4H), 2.06-2.22 (m, 4H), 1.64-1.50 (m, 10H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 135.82, 134.33, 129.77, 127.84, 80.77, 80.11, 64.06, 62.69, 32.35, 32.10, 29.10, 27.12, 25.60, 25.33, 18.97, 18.78. HRMS calcd for C27H39O2Si [M+l]+ 423.2719, found 423.2718.
OTBDPS - s, (
[00162] ll-(ter/-ButyldiphenylsiIyloxy)undec-5(Z)-en-l-ol. 1 \-(tertButyldiphenylsilyloxy)undec-5-yn-l-ol (6.50 g, 15.40 mmol) was subjected to semihydrogenation as described above to give the title olefin (6.07 g, 93%) as a colorless oil. TLC: EtOAc/hexanes (3:7), Rf ~ 0.45; *Η NMR (300 MHz) δ 7.68-7.64 (m, 4H), 7.34-7.32 (m, 6H), 5.28-5.42 (m, 2H), 3.68-3.60 (t, J = 6.4 Hz, 4H), 2.08-1.96 (m, 4H), 1.60-1.50 (m, 4H), 1.401.24 (m, 6H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 135.79, 134.36, 130.45, 129.71, 129.63, 127.79, 64.16, 63.15, 32.69, 32.59, 29.94, 29.67, 27.43, 27.13, 27.08, 26.06, 25.68, 19.45. HRMS calcd for C27H4iO2Si [M+l]+ 425.2876, found 425.2874.
Workspace Webmail :: Print https://email01.secureserver.net/view_g||i^^Jit^^uidArray=737...
[00163] l-(/e/7-ButykliphenylsiIyloxy-ll-azidoundec-6(Z)-ene. Following the protocol described above, 1 l-(/erLbutyldiphenylsilyloxy)undec-5(Z)-en-l-ol (6.0 g, 14.24 mmol) was converted into the title azide (4.60 g, 72%), a colorless liquid. TLC: EtOAc/hexanes (1:9), Rf ~ 0.55; 'H NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 5.28-5.42 (m, 2H), 3.65 (t, J = 6.4 Hz, 2H), 3.25 (t, J = 7.1 Hz, 2H), 1.96-2.10 (m, 4H), 1.24-1.64 (m, 10H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 136.63, 135.85, 134.41, 130.83, 129.79, 129.22, 127.88, 64.20, 51.62, 32.77, 29.73, 28.70, 27.53, 27.18, 27.05, 26.94, 25.77, 19.52; IR (neat) 2931, 2857, 2094, 1589, 1110 cm'1. HRMS calcd for C27H40N3OSi [M + 1]+ 450.2940, found 450.2941.
—OTBDPS OTBDPS
[00164] l-Ammo-ll-(terZ-butyldiphenylsilyloxy)undec-5(Z)-ene. l-(terF
Butyldiphenylsilyloxy-1 l-azidoundec-6(Z)-ene (4.30 g, 9.57 mmol) was reduced with triphenylphosphine as described above to give the title amine (2.96 g, 74%) as a colorless oil. TLC: MeOH/CH2Cl2 (1:4), Rf ~ 0.25; !H NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 5.28-5.42 (m, 2H), 3.64 (t, J = 6.4 Hz, 2H), 2.82 (t, J = 4.8 Hz, 2H), 1.96-2.10 (m, 4H), 1.52-1.64 (m, 4H), 1.30-1.42 (m, 6H), 1.04 (s, 9H); l3C NMR (100 MHz) δ 135.82, 134.37, 132.37, 132.27, 130.70, 129.78, 129.21, 128.93, 128.81, 127.86, 64.19, 40.88, 32.77, 29.89, 29.73, 27.52, 27.37, 27.17, 27.12, 27.03, 25.76, 19.47. HRMS calcd for C27H42NOSi [M + 1]+ 420.3046, found 420.3050.
[00165] l-(ll-(/erAButyldiphenylsilyloxy)undec-5(Z)-enyl)-3-w-pentylurea. 76% as a colorless oil. TLC: EtOAc/hexanes (2:3), Rf ~ 0.45; 'H NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 5.28-5.42 (m, 2H), 4.13 (br s, 2H), 3.65 (t, J = 6.4 Hz, 2H), 3.02-3.20 (m, 4H), 1.96-2.08 (m, 4H), 1.20-1.60 (m, 16H), 1.04 (s, 9H), 0.89 (t, J = 7.2 Hz, 3H); I3C NMR (100 MHz) δ 158.02, 135.79, 134.36, 130.06, 129.74, 127.90, 127.82, 64.17, 40.42, 40.32, 32.52, 30.28, 29.71, 29.35, 27.62, 27.54, 27.16, 27.11, 25.71, 22.69, 19.45, 14.28. HRMS calcd for C33H53N2O2Si [M + 1]+ 537.3876, found 537.3876.
H H
[00166] 1-(1 l-Hydroxyundec-5(Z)-enyl)-3-«-pentyIurea. 94%, mp 62.2-62.5 °C. TLC:
EtOAc/hexanes (7:3), R{~ 0.55; *H NMR (300 MHz) δ 5.28-5.42 (m, 2H), 4.37 (br s, 2H), 3.64 (t, J = 6.4 Hz, 2H), 3.02-3.20 (m, 4H), 1.96-2.10 (m, 4H), 1.20-1.60 (m, 16H), 0.89 (t, J = 72 Hz, 3H); 13C NMR (75 MHz) δ 159.41, 130.30, 129.73, 62.77, 40.50, 40.34, 32.75, 30.27, 30.10, 29.56, 29.33, 27.23, 27.15, 27.04, 25.56, 22.66, 14.24. HRMS calcd for C17H35N2O2 [M + 1]+ 10 299.2699, found 299.2705.
[00167] l-(ll-Bromoundec-5(Z)-enyl)-3-w-pentylurea. 84%, colorless oil. TLC:
EtOAc/hexanes (2:3), Rf ~ 0.60; lH NMR (300 MHz) δ 5.28-5.42 (m, 2H), 4.36 (br s, 2H), 3.32 (t, J = 6.4 Hz, 2H), 3.02-3.20 (m, 4H), 1.96-2.10 (m, 4H), 1.20-1.60 (m, 16H), 0.89 (t, J = 7.2 15 Hz, 3H); 13C NMR (75 MHz) δ 159.20, 129.94, 40.60, 40.49, 34.19, 32.91, 30.29, 29.35, 29.02,
28.01, 27.26, 27.16, 22.67, 14.26. HRMS calcd for C17H33BrN2O [M]+ 360.1776, found 360.1773.
[00168] l-(ll-(2-Hydroxyphenylthio)undec-5(Z)-enyl)-3-n-pentylurea (13). To a solution of 2-mercaptophenol (100 mg, 0.79 mmol) in DMF (3 mL) was added K2CO3 (161 mg, 1.18 mmol) and 1-(1 l-bromoundec-5(Z)-enyl)-3-/7-pentylurea (0.29 g, 0.79 mmol). After 12 h at rt, the solution was diluted with water (10 mL) and extracted with ethyi acetate (3x5 mL). The combined organic extracts were washed with water, brine and dried (Na2SO4). The residue was purified by SiO2 column chromatography to give the analog 13 (230 mg, 69%) as a sticky solid. 25 TLC: EtOAc/hexanes (1:1), Rf - 0.32; 'H NMR (300 MHz) δ 7.45 (dd, J = 1.9, 7.6 Hz, 1H), 7.22-7.28 (m, 1H), 6.99 (dd, J = 1.2, 8.2 Hz, 1H), 6.88 (dt, J = 1.2, 7.6 Hz, 1H ), 5.28-5.42 (m, 2H), 4.26 (br s, 2H), 3.02-3.20 (m, 4H), 2.69 (t, J = 7.7 Hz, 2H), 1.94-2.08 (m, 4H), 1.20-1.60 (m, 16H), 0.89 (t, J= 7.2 Hz, 3H); 13C NMR (75 MHz) δ 159.05, 157.10, 135.60, 130.76, 130.11, 129.82, 120.78, 119.74, 115.02, 40.70, 40.60, 36.50, 30.23, 29.68, 29.32, 28.38, 27.21, 30 27.11,22.66, 14.27. HRMS (ESI-neg) calcd for C23H37N2O2S [M-l]' 405.2576, found 405.2575.
[00169] Synthesis of Analog 14.
[00170] l-(ll-(2-Hydroxyphenylsu!fonyl)undec-5(Z)-enyI)-3-n-pentyIurea (14). Following the procedure utilized to préparé analog 18, analog 13 was oxidized to give 14 (60 mg, 75%) as a colorless liquid. TLC: EtOAc/hexanes (2:3), Rf ~ 0.32; 'H NMR (300 MHz) δ 9.08 (br s, -OH), 7.72 (dd, J = 1.9,7.4 Hz, 1 H), 7.44 (dt, J= 1.2,7.3 Hz, 1H), 7.10 (d, J = 7.9 Hz, 1H), 7.12 (t, J= 6.4 Hz, 1H), 5.28-5.42 (m, 2H), 4.70-4.85 (m, 2H), 3.40-3.60 (t, J = 6.2 Hz, 2H), 3.20-3.40 (m, 4H), 1.90-2.10 (m, 4H), 1.70-1.80 (m, 2H), 1.20-1.50 (m, 14H), 0.85 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz) δ 159.25, 156.66, 136.23, 130.22, 129.78, 129.52, 122.78, 120.22, 118.55, 55.97, 40.08, 40.62, 30.07, 30.02, 29.25, 28.82, 27.62, 27.15, 27.05, 26.62, 22.61, 22.20, 14.24. HRMS (ESI-neg) calcd for C23H37N2O4S [M-l]’ 437.2474, found 437.2454.
[00171] Synthesis of Analog 15.
[00172] l-n-Pentyl-3-(ll-thiocyanatoundec-5(Z)-enyI)urea. A mixture of 1-(11bromoundec-5(Z)-enyl)-3-w-pentylurea (191 mg, 0.53 mmol) and potassium thiocyanate (154 mg, 1.58 mmol) in dry DMSO (4 mL) were stirred at rt. After 24 h, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 5 mL). The combined organic extracts were washed with water, brine and dried (Na2SO4) and concentrated in vacuo. The residue was purified by SiO2 column chromatography to give the title urea (116 mg, 65%) as a colorless syrup. TLC: EtOAc/hexanes (2:3), Rf ~ 0.32; 'H NMR (300 MHz) δ 5.28-5.42 (m, 2H), 4.42 (br s, 2H), 3.10-3.20 (m, 4H), 2.94 (t, J = 7.0 Hz, 2H), 2.00-2.10 (m, 4H), 1.70-1.80 (m, 2H), 1.20-1.56 (m, 14H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz) δ 158.92, 130.20, 129.68, 112.84, 40.67, 40.54, 34.23, 30.22, 30.03, 29.31, 29.08, 27.66, 27.19, 27.15, 27.04, 22.66, 14.27; IR (neat) 2929, 2856, 2153, 1630, 1573, 1456, 1256 cm’1. HRMS calcd for Ci8H34N3OS [M+l]+ 340.2423, found 340.2421.
[00173] 1-(11-(1 H-Tetrazol-5-ylthio)undec-5(Z)-enyl)-3-pentylurea (15). Following the procedure utilized to préparé analog 19, l-n-pentyl-3-(l l-thiocyanatoundec-5(Z)-enyl)urea (150 mg, 0.44 mmol) was treated with sodium azide to give analog 15 (104 mg, 62%) as a sticky solid. TLC: 5% MeOH/CH2Cl2, Àf ~ 0.40; ‘H NMR (300 MHz) δ 5.28-5.42 (m, 2H), 4.63 (br s, 2H), 3.30 (t, J = 6.7 Hz, 2H), 3.17-3.23 (m, 4H), 1.95-2.04 (m, 4H), 1.44-1.80 (m, 6H), 1.24-1.42 (m, 10H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 160.17, 155.38, 129.65, 129.58, 39.81, 39.69, 32.38, 29.87, 29.79, 29.36, 28.99, 28.96, 27.84, 26.84, 26.72, 26.69, 22.31, 13.21. HRMS (ESI-neg) calcd for Ci8H33N6OS [M-l]' 381.2442, found 381.2348.
[00174] Synthesis of Analog 12.
[00175] W-(ll-(3-n-Pentylureido)undec-6(Z)-enyl)benzenesulfonamide (12). To a solution of benzenesulfonamide (50 mg, 0.31 mmol) in THF/HMPA (4:1; 5 mL) was added nbutyllithium (2.5 M soin in hexane, 125 pL, 0.31 mmol) at -78 °C under an argon atmosphère. A solution of 1-(1 l-bromoundec-5(Z)-enyl)-3-w-pentylurea (115 mg, 0.32 mmol) in THF (2 mL) was added dropwise. After 2 h at the same température, the réaction was quenched with saturated aq. NH4CI (5 mL). The mixture was extracted with EtOAc (3x5 mL) and the combined extracts were washed with water, brine, dried, and concentrated under reduced pressure. The residue was purified by SiO2 column chromatography to give analog 12 (44 mg, 32%) as a colorless solid, mp 73.5-73.6 °C. TLC: 5% MeOH/CH2Cl2, Rf ~ 0.40; ’H NMR (300 MHz) δ 7.84-7.90 (m, 2H), 7.46-7.60 (m, 3H), 5.48 (br s, -NH, 1H), 5.24-5.38 (m, 2H), 4.70 (br s, -NH, 1H), 4.60 (br s, NH, 1H), 3.08-3.20 (m, 4H), 2.88-2.94 (q, J = 6.4 Hz, 2H), 1.94-2.40 (m, 4H), 1.20-1.58 (m, 16 H), 0.88 (t, J = 6.8 Hz, 3H); l3C NMR (75 MHz) δ 159.90, 140.06, 132.69, 130.03, 129.98, 129.27, 127.19, 43.26, 40.80, 40.52, 30.09, 29.99, 29.61, 29.28, 29.16, 27.02, 26.99, 26.96, 26.13, 22.63, 14.25. HRMS calcd for C23H40N3O3S [M + 1]+ 438.2790, found 438.2782.
[00176] Synthesis of Analog 24.
[00177] 1-(11-(2,4-Dioxothiazolidin-5-yl)undec-5(Z)-enyl)-3-«-pentylurea (24). nButyllithium (1.10 mL, 2.76 mmol, 2.5 M solution in hexanes) was added dropwise to a -78 °C solution of thiazolidine-2,4-dione (0.16 g, 1.38 mmol) in dry THF/HMPA (50 mL, 4:1) under an argon atmosphère. After 30 min, the reaction mixture was warmed to 0 °C over Ih, kept at that température for 2h, and then re-cooled to -78 °C. Following the addition of a solution of 1-(11bromoundec-5(Z)-enyl)-3-w-pentylurea (0.50 g, 1.38 mmol) in THF (15 mL), the reaction température was slowly increased to rt over 3h and stirred further for 12 h. The reaction mixture was quenched with sat. aq. NH4C1 (5 mL), the pH was adjusted to 4 using 1 M oxalic acid, and the reaction mixture was extracted with EtOAc (3 x 125 mL). The combined extracts were washed with water (2 x 100 mL), brine (100 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified by SiO2 column chromatography using 5% MeOH/CH2Cl2 to afford analog 24 (169 mg, 31%) as a colorless solid, mp 92.8-93 °C. TLC: 10% MeOH/CH2Cl2, Rf ~ 0.20; ‘H NMR (CD3OD, 300 MHz) δ 5.30-5.40 (m, 2H), 4.42 (dd, J = 3.4, 4.2 Hz, 1H), 3.043.13 (m, 4H), 2.00-2.16 (m, 4H), 1.80-1.96 (m, 2H), 1.24-1.58 (m, 16H), 0.91 (t, J = 6.7 Hz, 3H); 13C NMR (75 MHz) δ 177.09, 172.56, 160.15, 129.68, 129.60, 51.89, 39.69, 32.57, 29.90, 29.83, 29.23, 29.02, 28.43, 26.88, 26.73, 26.47, 22.35, 13.27. HRMS calcd for C20H36N3O3S [M+l]+ 398.2477, found 398.2477.
[00178] Synthesis of Analog 7.
[00179] (5)-Dimethyl 2-(13-(3-n-pentylureido)tridec-8(Z)-enamido)succinate. L-Aspartic acid dimethyl ester hydrochloride (38 mg, 0.19 mmol) and HATU (67 mg, 0.18 mmol) were added to a stirring solution of 13-(3-w-pentylureido)tridec-8(Z)-enoic acid (50 mg, 0.15 mmol) in anhydrous DMF (20 mL) under an argon atmosphère. After 5 min, 1 -ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride (EDCI; 33 mg, 0.17 mmol) was added followed by diisopropylethylamine (33 pL, 0.19 mmol). After 12 h, the reaction mixture was diluted with EtOAc (30 mL), washed with water (30 mL), and brine (20 mL). The combined aqueous layers were back-extracted with EtOAc (3 x 30 mL). The combined organic extracts were dried over Na2SO4, concentrated under reduced pressure, and the residue was purified by SiO2 column chromatography using 50% EtOAc/hexanes as eluent to give the title diester (60 mg, 84%) as a viscous oil. TLC: EtOAc/hexanes (3:2), Rf -0.30; lH NMR (300 MHz) δ 6.62 (d, J =7.0 Hz, 1H), 5.22-5.40 (m, 2H), 4.85-5.04 (m, 1H), 4.80-4.88 (m, 2H), 3.75 (s, 3H), 3.66 (s, 3H), 3.10-3.20 (m, 4H), 3.01 (dd, J = 4.3, 10 Hz, 1H), 2.82 (dd, J= 4.6, 10 Hz, 1H), 2.25 (t, J = 8.3 Hz, 2H), 1.98-2.07 (m, 4H), 1.60-1.68 (m, 4H), 1.20-1.50 (m, 14H), 0.88 (t, J = 6.7 Hz, 3H); 13C NMR (75 MHz) δ 173.51, 171.81, 171.52, 159.02, 130.33, 129.76, 53.05, 52.30, 48.57, 40.61, 40.55, 36.61, 36.28, 30.24, 30.20, 29.51, 29.31, 29.10, 28.88, 27.20, 27.12, 25.72, 22.66, 14.26.
[00180] (^)-2-(13-(3-«-Pentylureido)tridec-8(Z)-enamido)succinic acid (7). LiOH (2 mL, 2 M aqueous solution) was added to a 0 °C solution of the above (5)-dimethyl 2-(13-(3-npentylureido)tridec-8(Z)-enamido)succinate (60 mg, 0.12 mmol) in THF (25 mL) and deionized H2O (4 mL). After stirring at room température overnight, the reaction mixture was cooled to 0 °C, the pH was adjusted to 4 with 1 M aq. oxalic acid, and the mixture was extracted with EtOAc (3x15 mL). The combined extracts were washed with water (30 mL), brine (25 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by SiO2 column chromatography using 25% EtOAc/hexanes as eluent to give analog 7 (48 mg, 85%) as a colorless oil. TLC: 5% MeOH/EtOAc (3:2), Rf ~ 0.30; ]H NMR (CD3OD, 300 MHz) δ 5.30-5.38 (m, 2H), 4.72 (t, J = 4.2 Hz, ÎH), 3.26-3.32 (m, 4H), 2.86 (dd, J = 4.3, 10 Hz, ÎH), 2.77 (dd, J= 4.6, 10 Hz, 1H), 2.22 (t, J= 7.7 Hz, 2H), 1.98-2.10 (m, 4H), 1.54-1.64 (m, 4H), 1.20-1.52 (m, 14H), 0.89 (t, 6.7 Hz, 3H); 13C NMR (CD3OD, 75 MHz) δ 174.93, 173.01, 172.83, 160.17,
129.94, 129.39, 49.0, 39.81, 39.73, 35.78, 35.60, 29.90, 29.82, 29.49, 29.02, 28.87, 26.90, 26.73, 25.70, 22.35, 13.29. HRMS calcd for C23H42N3O6 [M+l]+ 456.3074, found 456.3071.
[00181] Synthesis of Analog 3.
[00182] 2-(2-(2-Hydroxyethoxy)ethoxy)ethyll3-(2-(n-butylamino)-2 oxoacetamido)tridec8(Z)-enoate (3). Triethylene glycol (0.12 g, 0.8 mmol; dried over molecular sieves) was added to a solution of 13-(2-(/7-butylamino)-2-oxoacetamido)tridec-8(Z)-enoic acid2 (30 mg, 0.08 mmol) and Α,Α-dimethylaminopyridine (DMAP, llmg, 0.09 mmol) in anhydrous dichloromethane (10 mL) under an argon atmosphère at room température. After 3 min, solid EDCI (18 mg, 0.09 mmol) was added. After 12 h, the reaction mixture was diiuted with EtOAc (10 mL), washed with water (5 mL), and concentrated in vacuo. The residue was purified by SiO2 column chromatography using EtOAc to give analog 3 (33 mg, 82%) as a colorless solid, mp 71.7-71.9 °C. TLC: EtOAc/hexanes (4:1), Rf ~ 0.30; *H NMR (300 MHz) δ 7.46 (br s, 2H), 5.24-5.40 (m, 2H), 4.23 (t, J = 4.6 Hz, 2H), 3.58-3.78 (m, 10H), 3.27 (apparent q, J = 6.7 Hz, 4H), 2.32 (t, J = 7.6 Hz, 2H), 1.50-1.66 (m, 6H), 1.24-1.44 (m, 14H), 0.92 (t, J = 6.7 Hz, 3H); 13C NMR (100 MHz) δ 174.10, 160.09, 130.66, 129.24, 72.70, 70.76, 70.55, 69.42, 39.80, 39.61, 34.35, 31.45, 29.69, 29.21, 29.12, 29.02, 27.36, 27.07, 26.92, 25.04, 20.21, 13.90. HRMS calcd for C25H47N2O7 [M+l]+ 487.3383, found 487.3379.
[00183] Synthesis of Analog 2.
[00184] 2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 13-(3-n-pentyhireido)tridec-8(Z)-enoate (2). 13-(3-«-Pentylureido)tridec-8(Z)-enoic acid2 (80 mg, 0.20 mmol) was condensed with triethylene glycol as described above to give analog 2 (86 mg, 78%) as a colorless solid, mp 42.4-42.6 °C. TLC: EtOAc, Rf ~ 0.20; *H NMR (300 MHz) δ 5.24-5.40 (m, 2H), 4.28 (br s, 2H), 4.23 (dd, J= 4.9, 1.0 Hz, 2H), 3.58-3.68 (m, 10H), 3.10-3.20 (m, 4H), 2.52 (br s, -OH, 1H), 2.33 (t, J = 7.6 Hz, 2H), 1.90-2.10 (m, 4H), 1.44-1.64 (m, 4H), 1.22-1.40 (m, 14), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz) δ 174.22, 158.50, 130.41, 129.62, 72.76, 70.75, 70.51, 69.38, 63.47, 61.94, 40.78, 40.71, 34.33, 30.13, 30.08, 29.57, 29.25, 29.09, 28.94, 27.23, 27.15, 27.06, 25.03, 22.61, 14.24. HRMS calcd for C25H49N2O6 [M+l]+ 473.3591, found 473.3588.
[00185] Synthesis of Analog 1.
[00186] 2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 13-(Æ-isopropylheptanamido)tridec-8(Z)enoate (1). 13-(7V-Isopropylheptanamido)tridec-8(Z)-enoic acid (60 mg, 0.16 mmol) was condensed with triethylene glycol as described above to give analog 1 (58 mg, 73%) as a viscous, colorless oil. TLC: EtOAc (4:1), Rf ~ 0.40; 'H NMR (300 MHz, 65/35 mixture of rotamers) δ 5.26-5.40 (m, 2H), 4.62-4.70 (m, 0.5H), 4.20-4.26 (m, 2H), 3.98-4.08 (m, 0.5H), 3.58-3.76 (m, 10H), 3.04-3.16 (m, 2H), 2.20-2.36 (m, 4H for the two rotamers), 1.98-2.10 (m, 4H), 1.46-1.66 (m, 6H), 1.24-1.38 (m, 14H), 1.18 and 1.10 (d, J = 7.3 Hz, 6H for two rotamers), 0.87 (t, J =12 Hz, 3H); 13C NMR (75 MHz) δ 174.05, 174.01, 173.10, 172.55, 130.75, 130.11, 129.85, 129.15, 72.70, 70.76, 70.55, 69.40, 63.43, 61.94, 48.30, 45.52, 43.53, 41.09, 34.36, 34.32, 34.10, 34.0, 31.93, 31.89, 31.28, 29.90, 29.75, 29.69, 29.56, 29.43, 29.23, 29.12, 27.84, 27.48, 27.42, 27.35, 27.18, 26.93, 25.88, 25.70, 25.05, 25.02, 22.76, 21.60, 20.75, 14.28. HRMS calcd for C^HjôNOô [M+l]+ 514.4108, found 514. 4111.
[00187] Synthesis of Analog 8.
O O
H H
[00188] N-Hydroxysuccinimidyl 13-(3-n-pentylureido)tridec-8(Z)-enoate. A mixture of 13-(3-/?-pentylureido)tridec-8(Z)-enoic acid2 (100 mg, 0.29 mmol) and /V-hydroxysuccinimide (37 mg, 0.31 mmol) were azeotropically dried using anhydrous benzene (2 χ 5 mL), then dissolved in dry CH2CI2 (5 mL). To this was added EDCI (67 mg, 0.35 mmol) and DMAP (38 mg, 0.31 mmol) under an argon atmosphère. After 12 h at rt, the reaction mixture was diluted with more CH2C12 (20 mL), washed with water, brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified by SiO2 column chromatography to give the title NHS ester (110 mg, 86%) as a sticky solid that was used immediately without further purification. TLC: EtOAc/hexanes (7:3), Rf-0.40; *H NMR (400 MHz) δ 5.27-5.36 (m, 2H), 4.48 (br s, 2H), 3.093.15 (m, 4H), 2.81 (br s, 4H), 2.58 (t, J = 7.8 Hz, 2H), 1.94-2.06 (m, 4H), 1.68-1.74 (m, 2H), 1.20-1.50 (m, 16 H), 0.86 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz) δ 169.40, 168.96, 158.62, 130.29, 129.71, 40.75, 40.68, 31.12, 30.18, 30.14, 29.51, 29.28, 28.80, 27.21, 27.19, 27.10, 25.81,24.72, 22.62, 14.24.
o o o
HH HH
[00189] 13-(3-n-Pentylureido)-A-(phenyIsulfonyl)tridec-8(Z)-enamide (8). A mixture of N-hydroxysuccinimidyl 13-(3-«-pentylureido)tridec-8(Z)-enoate (150 mg, 0.34 mmol) from above, benzenesulfonamide (78 mg, 0.49 mmol) and 4-dimethylaminopyridine (DMAP; 50 mg, 0.40 mmol) were heated in dry hexamethylphosphoramide (HMPA; 3 mL) at 80 °C for 24 h. After cooling to rt, the reaction mixture was diluted with water and extracted into EtOAc (3><10 mL). The combined extracts were washed with water, brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified by SiO2 column chromatography to give analog 8 (105 mg, 65%) as a colorless solid, mp 91.4-91.6 °C. TLC: EtOAc/hexanes (3:2), Rf- 0.30; *H NMR (300 MHz) δ 8.00-8.10 (dd, J = 0.9, 7.3 Hz, 2H), 7.44-7.60 (m, 3H), 5.28-5.42 (m, 2H), 5.03 (br s, NH, 1H), 4.57 (br s, -NH, 1H), 3.21 (t, J = 6.8 Hz, 2H), 3.12 (t, J = 6.5 Hz, 2H), 2.29 (t, J = 7.9 Hz, 2H), 1.98-2.10 (m, 4H), 1.18-1.60 (m, 18H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz) δ 172.66, 159.28, 139.67, 133.57, 130.69, 129.65, 128.93, 128.40, 41.41, 40.53, 36.22, 29.89, 29.61, 29.24, 28.87, 28.33, 27.69, 26.91, 26.69, 26.47, 24.70, 22.588, 14.22. HRMS calcd for C25H42N3O4S [M+l]+ 480.2896, found 480.2899.
[00190] Synthesis of Analog 9.
O O
H H
O
H H
[00191] 7V-(MethyIsuIfonyl)-13-(3-w-pentylureido)tridec-8(Z)-enamide (9). NHydroxysuccinimidyl 13-(3-n-pentylureido)tridec-8(Z)-enoate from above (150 mg, 0.34 mmol) was reacted with methanesulfonamide (48 mg, 0.50 mmol) as described above to give analog 8 (102 mg, 72%) as a colorless solid, mp 113.5-113.6 °C. TLC: EtOAc/hexanes (1:1), Rf - 0.30; ’H NMR (300 MHz) δ 5.30-5.40 (m, 2H), 3.21 (s, 3H), 3.04-3.12 (m, 4H), 2.29 (t, J = 7.3 Hz, 2H), 2.00-2.10 (m, 4H), 1.22-1.66 (m, 18H), 0.90 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz) δ 175.14, 161.50, 131.17, 130.78, 41.44, 41.10, 41.02, 37.13, 31.22, 31.15, 30.73, 30.34, 30.07, 30.05, 28.19, 28.17, 28.03, 25.80, 23.66, 14.56. HRMS calcd for C20H40N3O4S [M+l]+ 418.2740, found 418.2739.
[00192] Synthesis of Analog 6.
O O
Me Me Me Me
[00193] Methyl 2-(13-(1,3-dimethyl-3-n-pentyIureido)tridec-8(Z)-enamido)acetate.
Glycine hydrochloride (32 mg, 0.29 mmol) and 1-hydroxybenzotriazole (32 mg, 0.23 mmol; HOBt) were added to a solution of 13-(1,3-dimethyl-3-«-pentylureido)tridec-8(Z)-enoic acid2 (70 mg, 0.19 mmol) and diisopropylethylamine (50 pL, 0.29 mmol) in anhydrous DMF (20 mL) under an argon atmosphère. After 5 min, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (45 mg, 0.23 mmol; EDCI) was added as a solid. After stirring for 12 h at room température, the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic extracts were dried over Na2SC>4, concentrated under reduced pressure, and the residue was purified by S1O2 column chromatography using 30% EtOAc/hexanes as eluent to give the title methyl ester (65 mg, 79%) as a viscous oil. TLC: EtOAc/hexanes (7:3), Rf-0.40; 'HNMR (300 MHz) δ 6.18 (br s, -NH, 1H), 5.26-5.40 (m, 2H), 4.04 (d, J = 5.2 Hz, 2H), 3.75 (s, 3H), 3.11 (apparent q, J = 7.6 Hz, 4H), 2.77 (s, 3H), 2.76 (s, 3H), 2.24 (t, J = 7.6 Hz, 2H), 1.96-2.08 (m, 4H), 1.46-1.70 (m, 6H), 1.20-1.38 (m, 12H), 0.88 (t, J =12 Hz, 3H); l3C NMR (100 MHz) δ 170.69, 170.07, 165.65, 130.36, 129.38, 52.45, 50.43, 50.42, 41.23, 35.86, 30.09, 29.62, 29.26, 29.22, 29.05, 27.32, 27.15, 26.67, 25.74, 25.38, 21.65, 14.48. HRMS Calcd for C24H46N3O4 [M+l]+ 440.3488, found 440.3485.
O O
Me Me Me Me
[00194] 2-(13-(1,3-Dimethyl-3-w-pentyIureido)tridec-8(Z)-enamido)acetic acid (6).
Following the ester hydrolysis conditions described above, methyl 2-( 13-(1,3-dimethyl-3-«pentylureido)tridec-8(Z)-enamido)acetate was converted into analog 6 (87%), obtained as a colorless liquid. TLC: EtOAc/hexanes (4:1), ~ 0.40; NMR (300 MHz) δ 6.39 (br s, -NH,
1H), 5.24-5.40 (m, 2H), 4.03 (d, J = 4.5 Hz, 2H), 3.16 (apparent q, J = 5.8 Hz, 4H), 2.79 (s, 3H), 2.77 (s, 3H), 2.25 (t, J = 7.0 Hz, 2H), 1.90-2.10 (m, 4H), 1.48-1.70 (m, 6H), 1.20-1.40 (m, 12H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz) δ 174.31, 171.97, 166.01, 130.44, 129.51, 50.79, 50.61, 41.72, 36.86, 36.72, 36.42, 29.64, 29.18, 29.05, 27.36, 27.26, 27.09, 27.04, 25.76, 22.63, 14.24. HRMS Calcd for C23H44N3O4 [M+l]+ 426.3332, found 426.3315.
[00195] Synthesis of Analog 5.
O O
/Pr /Pr
[00196] Methyl 2-(13-(7V-Isopropylheptanamido)tridec-8(Z)-enamido)acetate. 13-(/VIsopropyl heptanamido)tridec-8(Z)-enoic acid2 (100 mg, 0.26 mmol) was condensed with glycine methyl ester as described above to give the corresponding amide (97 mg, 82%) as a colorless syrup that was used directly in the next step. TLC: EtOAc (2:1), Rf - 0.45; ’H NMR (300 MHz, 1:1 mixture of rotamers) δ 6.25 (br s, -NH, 0.5 H), 6.08 (br s, -NH, 0.5 H), 5.24-5.42 (m, 2H), 4.60-4.72 (m, 1H), 4.05 (d, J= 2.4 Hz, 2H), 3.76 (s, 1.5 H), 3.75 (s, 1.5 H), 3.06-3.15 (m, 2H), 2.20-2.38 (m, 4H), 1.90-2.10 (m, 4H), 1.40-1.68 (m, 6 H), 1.24-1.38 (m, 14 H), 1.19 (d, J = 6.7 Hz, 3 H), 1.10 (d, 6.7 Hz, 3 H), 0.88 (t, J = 7.1 Hz, 3H); ,3C NMR (100 MHz) δ 173.60,
173.46, 173.16, 172.60, 170.82, 130.84, 130.12, 129.88, 129.16, 53.66, 52.58, 52.53, 48.35, 45.52, 43.55, 41.38, 41.15, 36.57, 34.11, 34.02, 31.95, 31.92, 31.32, 29.92, 29.72, 29.63, 29.60, 29.45, 29.40, 29.26, 29.21, 28.97, 27.94, 27.45, 27.41, 27.26, 27.16, 26.96, 25.91, 25.80, 25.75, 22.79,21.62, 20.78, 14.31.
/Pr /Pr
[00197] 2-(13-(A-Isopropylheptanamido)tridec-8(Z)-enamido)acetic acid (5). Following the ester hydrolysis conditions described above, methyl 2-(13-(7V-isopropylheptanamido)tridec8(Z)-enamido)acetate (50 mg, 0.10 mmol) was hydrolyzed to give analog 5 (44 mg, 91%) obtained as a colorless liquid. TLC: EtOAc (4:1), Rf - 0.20; ’H NMR (300 MHz, 65/35 mixture of rotamers) δ 6.47 and 6.35 (br s, -NH, IH for the two rotamers), 5.24-5.42 (m, 2H), 4.60-4.70 (m, 1H), 4.05 and 4.06 (d, J = 2.8 Hz, 2H for the two rotamers), 3.06-3.18 (m, 2H), 2.20-2.38 (m, 4H), 1.90-2.10 (m, 4H), 1.50-1.68 (m, 6H), 1.24-1.38 (m, 14H), 1.20 and 1.10 (d, J= 7.3 Hz, 6H for the two rotamers), 0.87 (t, J= 7.2 Hz, 3H); 13C NMR (75 MHz) δ 174.35, 174.23, 174.18, 173.64, 172.0, 171.93, 130.98, 130.25, 129.75, 129.0, 48.86, 45.99, 43.77, 41.79, 41.62, 41.48, 10 34.05, 33.95, 31.85, 31.79, 31.13, 29.62, 29.51, 29.35, 29.31, 29.23, 28.85, 28.81, 27.83, 27.44, 27.34, 27.21, 27.02, 26.90, 26.03, 25.87, 25.80, 25.75, 22.75, 21.54, 20.70, 14.29. HRMS calcd for C25H47N2O4 [M+l]+ 439.3536, found 439.3531.
[00198] Synthesis of Analog 31.
H H
[00199] l-(5-(ter/-Butyldiphenylsilyloxy)pentyl)-3-n-pentyIurea. 5-(tertButyldiphenylsilyloxy)pentan-1 -amine5 (3.0 g, 8.78 mmol) was reacted with n-pentyl isocyanate (995 mg, 8.78 mmol) as described above to give the title urea (85%) as a colorless oil. TLC: EtOAc/hexanes (2:3), Rf ~ 0.40; ’H NMR (300 MHz) δ 7.60-7.70 (m, 4H), 7.30-7.40 (m, 6H), 4.24 (br s, -NH, 2H), 3.64 (t, J = 7.9 Hz, 2H), 3.06-3.20 (m, 4H), 1.20-1.60 (m, 12 H), 1.03 (s, 9H), 0.89 (t, J= 72 Hz, 3H); 13C NMR (75 MHz) δ 159.7, 134.90, 132.47, 132.40, 129.70, 128.81, 128.71, 127.92, 63.2, 40.91, 40.81, 32.42, 29.60, 29.28, 27.11, 23.30, 22.35, 19.38. HRMS calcd for C27H43N2O2Si [M+l]+ 455.3094, found 455.3093.
OTBDPS O
A
N N
H H
H H
[00200] l-(5-Hydroxypentyl)-3-n-pentylurea. 1 -(5-(tert-Butyldiphenylsilyloxy)pentyl)-3-npentylurea (3.0 g, 6.60 mmol) was de-silylated as described above to give the title alcohol (1.31 g, 92%) as a colorless solid, mp 81.4-81.8 °C. TLC: EtOAc/hexanes (7:3), Rf ~ 0.40; *H NMR (CD3OD, 300 MHz) δ 3.54 (t, J = 5.8 Hz, 2H), 3.06 (q, J = 6.4 Hz, 4H), 1.22-1.60 (m, 12H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (CD3OD, 100 MHz) δ 160.17, 61.67, 39.82, 39.77, 32.17, 30.02, 29.91, 29.03, 23.04, 22.34, 13.25. HRMS calcd for CHH25N2O2 [M+l]+ 217.1916, found 217.1916.
[00201] l-(5-Bromopentyl)-3-n-pentylurea. Following the protocol described above, l-(5hydroxypentyl)-3-w-pentylurea (1.30 g, 6.02 mmol) was converted into the corresponding bromide (1.45 g, 87%), obtained as a colorless oil. TLC: EtOAc/hexanes (2:3), Rf ~ 0.40; *H NMR (300 MHz) δ 4.44 (br s, -NH, 2H), 3.40 (t, J = 6.7 Hz, 2H), 3.10-3.20 (m, 4H), 1.82-1.92 (m, 2H), 1.40-1.58 (m, 6H), 1.24-1.38 (m, 4H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 159.46, 40.02, 33.88, 33.02, 30.29, 29.92, 29.36, 25.83, 22.12, 14.02. HRMS calcd for CI1H24BrN2O [M+l]+ 279.1072, found 279.1073.
[00202] /V-(4-(5-(3-«-Penty hireido)pentyloxy)benzo[d] thiazol-2-yl)acetamide (31). A mixture of l-(5-bromopentyl)-3-«-pentylurea (100 mg, 0.37 mmol), commercial N-(4hydroxybenzo[d]thiazol-2-yl)acetamide (100 mg, 0.48 mmol), and K2CO3 (67 mg, 0.48 mmol) in DMF (5 mL) was heated at 60 °C. After 6 h, the reaction mixture was cooled to rt, diluted with 10 water (25 mL), and extracted into EtOAc (3 x 10 mL). The combined organic extracts were washed with water (2 χ 5 mL), brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The residue thus obtained was purified by silica gel column chromatography to give 31 (61 mg, 40%), mp 61.6-61.8 °C. TLC: EtOAc/hexane (3:2), Rf ~ 0.40; ’H NMR (300 MHz) δ 7.39 (dd, J = 0.9, 7.3 Hz, 1H), 7.20 (dd, J = 7.8, 7.3 Hz, 1H), 6.86 (dd, J = 0.9, 7.8 Hz, 1H), 4.42 (br s, -NH, 15 2H), 4.17 (t, J = 5.4 Hz, 2H), 3.19-3.30 (m, 4H), 2.33 (s, 3H), 1.82-1.98 (m, 2H), 1.64-1.80 (m,
4H), 1.42-1.60 (m, 2H), 1.24-1.40 (m, 4H), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz) δ 170.16, 159.91, 158.94, 151.37, 139.10, 133.67, 124.40, 113.94, 108.68, 68.21, 40.64, 39.98, 30.27, 29.30, 28.33, 26.54, 23.25, 22.64, 22.33, 14.26. HRMS (ESI-neg) calcd for C20H29N4O3S
[M-l]' 405.1960, found 405.1938.
[00203] Synthesis of Analog 32.
[00204] TV^n-Butyl-^-ÎS-^errtbutyldiphenylsilyloxyjpentyOoxalamide. A mixture of 2-(nbutylamino)-2-oxoacetic acid (22 mg, 0.15), 5-(ierLbutyldiphenylsilyloxy)pentan-l-amine3 (50 mg, 0.15 mmol), 7V,N-diisopropylethylamine (40 mg, 0.30 mmol), and 2-(l/7-7-azabenzotriazol25 l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate methanaminium (HATU, 72 mg, 0.19 mmol) in dry DMF (5 mL) was stirred at rt ovemight under an argon atmosphère, then quenched with water (2 mL). The reaction mixture was extracted with EtOAc (3x5 mL). The combined organic extracts were washed with water, dried and concentrated in vacuo. The residue was purified by flash SiO2 column chromatography using EtOAc/hexanes (1:3) as eluent to give the title oxamide (65 mg, 91%) as a colorless oil. TLC: 50% EtOAc/hexane, Rf ~ 0.56; ’H NMR (400 MHz) δ 7.55-7.70 (m, 4H), 7.60 (br s, -NH, 2H), 7.35-7.40 (m, 6H), 3.65 (t, J = 6.0 Hz,
2H), 3.35-3.25 (m, 4H), 1.55-1.35 (m, 10H), 1.05 (s, 9H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 160.28, 160.25, 135.80, 134.20, 129.85, 127.90, 63.80, 40.0, 39.70, 32.40, 31.50, 29.20, 27.10, 27.05, 23.40, 20.30, 19.45, 14.0. HRMS calcd for C27H41N2O3Si [M+l]+ 469.2886, found 469.2892.
[00205] /V'-n-ButyL/V^S-hydroxypenty^oxalamide. A mixture of A1-z?-butyl-A2-(5-(/ertbutyldiphenylsilyloxy)pentyl)oxalamide (65 mg, 0.14 mmol) and «-tetrabutylammonium fluoride (0.41 mL, 1 M soin, 0.42 mmol) in dry THF solution was stirred at room température under an argon atmosphère for 12 h. Ail volatiles were evaporated in vacuo, the residue was dissolved in EtOAc (30 mL) and the organic layer was washed with water (10 mL), brine (15 mL), dried and evaporated. Purification of the residue via SiO2 column chromatography using EtOAc/hexanes (1:2) as eluent gave the title compound (30 mg, 92%) as a colorless solid, mp 136-137 °C. TLC: 50% EtOAc/hexane, Rf - 0.28; JH NMR (300 MHz) δ 7.65 (br s, NH, 1H), 7.60 (br s, -NH, 1H), 3.65 (t, J = 6.0 Hz, 2H), 3.35-3.25 (m, 4H), 1.90 (br s -OH, 1H), 1.60-1.50 (m, 6H), 1.40-1.35 (m, 4H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 160.25, 160.10, 62.70, 39.80, 39.65, 32.40, 31.45, 29.20, 23.25, 20.20, 13.85. HRMS calcd for CiiH23N2O3 [M+l]+ 231.1709, found 231.1701.
[00206] /^-(S-BromopentyP-M-H-butyloxalamide. A solution of carbon tetrabromide (51 mg, 0.15 mmol) in CH2C12 (5 mL) was stirred into a 0 °C solution of triphenylphosphine (48 mg, 0.18 mmol) and N -zz-butyl-A -(5-hydroxypentyl)oxalamide (30 mg, 0.130 mmol) in dry CH2C12 (5 mL) under an argon atmosphère. After 2 h, the reaction mixture was washed with water (5 mL), brine (10 mL), dried over anhydrous Na2SO4, and ail volatiles were removed under reduced pressure. The residue was purified by SiO2 column chromatography using EtOAc/hexane (1:4) to give compound the title compound (32 mg, 84%) as a colorless solid, mp 109-110 °C. TLC: 50% EtOAc/hexanes, Rf ~ 0.50; 'H NMR (300 MHz) δ 7.55 (br s, NH, 1H), 7.50 (br s, -NH, 1H), 3.40 (t, J=6.0 Hz, 2H), 3.25-3.35 (m, 4H), 1.80-1.85 (m, 2H), 1.40-1.60 (m, 6H), 1.25-1.35 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 160.30, 160.15, 39.65, 33.65, 32.45, 31.40, 28.60, 25.60, 20.20, 13.90. HRMS calcd for CnH22BrN2O2 [M+l]+ 293.0865, found 293.0870.
[00207] jV1-(5-(2-Acetamidobenzo[d]thiazol-4-yloxy)pentyl)-IV2-n-butyloxalamide. A mixture of ^-(S-bromopentylj-^-w-butyloxalamide (32 mg, 0.11 mmol), commercial A-(4hydroxybenzo[d]thiazol-2-yl)acetamide (22 mg, 0.11 mmol), and K2CO3 (45 mg, 0.32 mmol) in DMF (3 mL) was heated at 80 °C for 3h, then cooled to room température, diluted with water (15 mL) and extracted into EtOAc (3x10 mL). The combined organic extracts were washed with water (2x5 mL), brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified by silica gel column chromatography using EtOAc/hexanes (1:2) as eluent to give analog 32 (35 mg, 76%) as a colorless solid, mp 154-155 °C. TLC: 70% EtOAc/hexanes, Rf ~ 0.35; Ή NMR (300 MHz) δ 11.05 (br s, NH, 1H), 8.30 (br s, NH, 1H), 7.70 (br s, NH, 1H), 7.40 (d, J - 7.4 Hz, 1H), 7.25 (dd, J = 7.4, 7.8 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 4.20 (t, J = 6.0 Hz, 2H), 3.50 (q, J = 7.2 Hz, 2H), 3.35 (q, J = 7.0 Hz, 2H), 2.35 (s, 3H), 1.95-1.90 (m, 2H), 1.851.80 (m, 2H), 1.70-1.65 (m, 2H), 160-1.55 (m, 2H), 1.40-1.35 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H); 13 C NMR (75 MHz) δ 169.40, 160.55, 159.90, 157.85, 151.50, 139.10, 134.00, 124.75, 113.75, 108.10, 68.90, 39.80, 39.30, 31.35, 28.20, 27.40, 23.70, 23.45, 20.25, 13.90. HRMS calcd for C20H29N4O4S [M+l]+ 421.1910, found 421.1906.
[00208] Synthesis of Analog 30.
æ—OTBDPS / NH(iPr)
[00209] 5-(/erAButyldiphenylsilyloxy)-7V-isopropylpentan-l-amine. Following literature precedent,2 a mixture of l-(/ert-butyldiphenylsilyloxy)-5-iodopentane6 (1.50 g, 3.32 mmol), isopropylamine (1.70 mL, 19.92 mmol) and K2CO3 (1.37 g, 10.03 mmol) was reacted to give the title amine (0.92 g, 72%) as a colorless liquid. TLC: MeOH/CH2Cl2 (1:4), Rf ~ 0.30; 'H NMR (300 MHz) δ 7.65-7.67 (m, 4H), 7.30-7.40 (m, 6H), 3.65 (t, J = 6.4 Hz, 2H), 2.70-2.82 (m, 1H), 2.55 (t, J = 7.3 Hz, 2H), 1.50-1.64 (m, 2H), 1.32-1.48 (m, 4H), 1.05 (d, J = 5.8 Hz, 3H), 1.04 (s, 9H); 13C NMR (100 MHz) δ 135.68, 134.21, 129.63, 127.70, 63.95, 48.81, 47.64, 32.60, 30.27, 27.0, 23.76, 23.15, 19.34. HRMS calcd for C24H38NOSi [M+l]+ 384.2723, found 384.2724.
[00210] ^-(S-^erAButyldiphenylsilyloxyjpentylj-W-isopropylheptanamide. Following literature precedent, 5-(/er/-butyldiphenylsilyloxy)-V-isopropylpentan-l-amine (0.90 g, 2.30 mmol) was condensed with heptanoic acid (0.26 g, 2.0 mmol) to give the titie amide (0.90 g, 79%) as a viscous oil. TLC: EtOAc/hexanes (3:8), Rf~ 0.60; ’HNMR (300 MHz, 1:1 mixture of rotamers) δ 7.65-7.67 (m, 4H), 7.30-7.40 (m, 6H), 4.62-4.72 (m, 0.5 H), 4.00-4.80 (m, 0.5H), 3.62 (t, J = 4.8 Hz, 1H), 3.68 (t, J = 4.8 Hz, 1H), 3.02 (t, J = 5.2 Hz, 1H), 3.16 (t, J = 5.2 Hz, 1H), 2.38 (t, J = 5.3 Hz, 1H), 2.24 (t, J = 5.3 Hz, 1H), 1.50-1.68 (m, 6H), 1.26-1.44 (m, 8H), 1.18 (d, 7= 7.3 Hz 3H), 1,12, (d, J = 7.3 Hz 3H), 1.03 (s, 4.5 H), 1.04 (s, 4.5H ), 0.88 (t, J = 7.3 Hz, 3H); ,3C NMR (125 MHz) δ 173.38, 172.76, 135.80, 135.78, 134.36, 134.12, 129.85, 129.73, 127.88, 127.82, 64.22, 63.68, 48.43, 45.62, 43.64, 41.27, 34.13, 34.05, 32.61, 32.36, 31.96, 31.93, 31.51, 29.63, 29.47, 27.10, 27.03, 25.94, 25.78, 24.03, 23.77, 22.81, 21.63, 20.78, 19.47, 14.33, 14.28. HRMS calcd for C31H50NO2S1 [M+l]+ 496.3611, found 496.3615.
[00211] 7V-(5-Hydroxypentyl)JV-isopropylheptanamide. N-(5-(tertButyldiphenylsilyloxy)pentyl)-/V-isopropylheptanamide (0.70 g, 1.37 mmol) was de-silylated as described above to give the titie alcohol (0.34 g, 96%) as a colorless solid. TLC: EtOAc/hexanes (2:3), Rf ~ 0.30; ]H NMR (300 MHz, 53/47 mixture of rotamers) δ 4.58-4.66 and 3.96-4.08 (m, 1H for the two rotamers), 3.56 and 3.70 (t, J = 5.4 Hz, 2H for the two rotamers), 3.02-3.16 (m, 2H), 2.30 and 2.26 (t, J = 6.3 Hz, 2H for the two rotamers), 1.50-1.64 (m, 6H), 1.22-1.40 (m, 8H), 1.13 and 1.09 (d, J = 7.5 Hz, 6H for the two rotamers), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 172.81 62.66, 62.60, 48.41, 45.55, 43.56, 41.04, 34.08, 34.0, 32.46, 32.43, 31.86, 31.57, 29.40, 25.87, 25.70, 23.77, 23.73, 22.75, 21.57, 20.72, 14.26. HRMS calcd for Ci5H32NO2 [M+l]+ 258.2433, found 258.2436.
[00212] 7V-(5-BromopentyI)-A-isopropylheptanamide. A-(5-Hydroxypentyl)-Aisopropylheptanamide (0.25 g, 0.97 mmol) was converted to the corresponding bromide as described above to give the title compound (0.25 g. 82%) as a colorless oil. TLC: EtOAc/hexanes (3:7), Rf ~ 0.40; *H NMR (300 MHz, 55/45 mixture of rotamers) δ 4.60-4.70 and 3.96-4.10 (m, 1H for two rotamers), 3.46 and 3.36 (t, J = 5.8 Hz 2H for two rotamers), 3.02-3.10 (m, 2H), 2.30 and 2.22 (t, J = 7.9 Hz, 2H for two rotamers), 1.80-1.97 (m, 2H), 1.40-1.70 (m, 6H), 1.20-1.40 (m, 6H), 1.16 and 1.10, (d, J= 7.3 Hz, 6H for two rotamers), 0.86 (t, J=7.3 Hz, 3H); 13C NMR (75 MHz) δ 172.79, 172.39, 48.17, 45.47, 43.32, 40.70, 33.89, 33.87, 33.49, 32.48, 32.30, 31.81, 31.78, 30.78, 29.27, 28.74, 26.05, 25.84, 25.69, 25.54, 22.64, 21.47, 20.62, 14.17. HRMS calcd for C]5H3iBrNO [M+l]+ 320.1589, found 320.1588.
[00213] A-(5-(2-Acetamidobenzo[d]thiazol-4-yloxy)pentyl)-A-isopropylheptanamide (30). A-(5-Bromopentyl)-A-isopropylheptanamide (75 mg, 0.23 mmol) was alkylated with commercial A-(4-hydroxybenzo[d]thiazol-2-yl)acetamide (54 mg, 0.26 mmol) as described above to give analog 30 (43 mg, 42%) as a sticky solid. TLC: EtOAc/hexanes (1:4), Rf - 0.30; ’H NMR (300 MHz, 45/55 mixture of rotamers) δ 11.50 (br s, -NH, 1H), 7.37-7.42 (m, 1H), 7.18-7.26 (m, 1H), 6.84-6.88 (m, 1H), 4.58-4.78 and 4.00-4.10 (m, 1H for two rotamers), 4.02 (t, J = 6.3 Hz, 2H), 3.12 (t, J = 7.3 Hz, 2H), 2.22-2.45 (m, 5H), 1.82-1.92 (m, 2H), 1.44-1.70 (m, 4H), 1.20-1.40 (m, 8H), 1.11-1.19 (m, 6H), 0.82-0.95 (m, 3H); 13C NMR (75 MHz) δ 173.94, 172.78, 169.40, 169.36, 157.89, 151.62, 138.43, 138.32, 133.91, 133.87, 124.92, 124.85, 114.02, 113.87, 109.66, 108.35, 69.46, 69.08, 48.53, 48.33, 45.94, 43.61, 41.20, 34.26, 34.09, 31.91, 31.88, 31.39, 29.55, 29.45, 29.37, 29.30, 25.88, 25.77, 25.71, 24.43, 24.16, 23.55, 22.77, 21.59, 20.80, 14.28. HRMS (ESI-neg) calcd for C24H36N3O3S [M-l]‘ 446.2477, found 446.2434.
[00214] Synthesis of Analog 33.
OTBDPS
THPO
OTBDPS
[00215] l-(ter/-Butyldiphenylsilyloxy)-8-(tetrahydro-2Æ-pyran-2-yloxy)oct-3-yne. 4-(tertButyldiphenylsilyloxy)-l-butyne7 (5.0 g, 16.23 mmol) was coupled with 2-(4bromobutoxy)tetrahydro-2//-pyran8 (4.59 g, 19.48 mmol) as described above to give the title acetylene (5.57 g, 74%) as a colorless oil. TLC: EtOAc/hexanes (1:9), Rf ~ 0.40; ’H NMR (300 MHz) δ 7.66-7.69 (m, 4H), 7.34-7.42 (m, 6H), 4.57 (t, J = 4.3 Hz, 1H), 3.78-3.86 (m, 2H), 3.733.90 (m, 3H), 3.32-3.40 (m, 3H), 2.40-2.45 (m, 2H), 2.06-2.10 (m, 2H), 1.93-2.02 (m, 2H), 1.401.80 (m, 6H), 1.02 (s, 9H); 13C NMR (100 MHz) δ 137.87, 133.96, 129.70, 128.0, 99.0, 81.0, 77.41, 67.32, 63.15, 62.51, 30.97, 29.20, 27.0, 26.98, 26.0, 25.74, 23.18, 19.83, 19.44, 18.88. HRMS calcd for C29H4iO3Si [M+l]+ 465.2825, found 465.2829.
™P°\^-OTBDPS --► HOW-^^OTBDPS
[00216] 8-(/er/-ButyldiphenylsilyIoxy)oct-5-yn-l-ol. l-(/ert-Butyldiphenylsilyloxy-8(tetrahydro-2H-pyran-2-yloxy)oct-3-yne (5.50 g, 11.84 mmol) was de-silylated as described above to give the title compound (3.87 g, 86%) as a colorless oil. TLC: EtOAc/hexanes (2:3), Rf ~ 0.40; 'H NMR (300 MHz) δ 7.60-7.68 (m, 4H), 7.30-7.40 (m, 6H), 3.77 (t, J = 7.4 Hz, 2H), 3.60-3.72 (m, 2H), 2.40-2.48 (m, 2H), 2.22-2.40 (m, 2H), 1.50-1.70 (m, 4H), 1.03 (s, 9H); 13C NMR (100 MHz) δ 135.83, 133.96, 129.90, 127.92, 81.31, 63.16, 62.60, 32.0, 27.0, 25.43, 23.17, 19.43, 18.78. HRMS calcd for C24H33O2Si [M+l]+ 381.2250, found 381.2256.
[00217] 8-(/e/7-Butyldiphenylsilyloxy)oct-5(Z)-cn-1-ol. 8-(/eH-Butyldiphenylsilyloxy)oct-5yn-l-ol (5.32 g, 14.0 mmol) was semi-hydrogenated as described above to give ^-(tertbutyldiphenylsilyloxy)oct-5(Z)-en-l-ol (5.18 g, 97%) as a colorless oil whose spectral values were in agreement with literature data.9 TLC: EtOAc/hexanes (2:3), Rf ~ 0.45; ’H NMR (300 MHz) δ 7.60-7.70 (m, 4H), 7.30-7.40 (m, 6H), 5.34-5.44 (m, 2H), 3.65 (t, J = 7.0 Hz, 2H), 3.583.64 (m, 2H), 2.23 (q, J = 4.2 Hz, 2H), 1.98-2.20 (m, 2H), 1.30-1.60 (m, 4H), 1.03 (s, 9H); 13C NMR (100 MHz) δ 135.84, 134.21, 131.64, 129.82, 127.87, 126.28, 63.94, 63.12, 32.54, 31.12, 27.23,27.11,26.02.
[00218] l-(fôr/-ButyldiphenyIsiIyloxy-8-azido-oct-3(Z)-en. Following the procedure described above, 8-(/ert-butyldiphenylsilyloxy)-oct-5(Z)-en-l-ol (5.20 g, 13.61 mmol) was transformed into the title azide (3.98 g, 72%), obtained as a colorless oil. TLC: EtOAc/hexanes (1:9), Rt-~ 0.60; *H NMR (300 MHz) δ 7.60-7.70 (m, 4H), 7.30-7.40 (m, 6H), 5.34-5.44 (m, 2H), 3.63 (t, J= 7.0 Hz, 2H), 3.22 (t, J = 6.4 Hz, 2H), 2.31 (q, J = 3.6 Hz, 2H), 1.95-2.05 (m, 2H), 1.50-1.60 (m, 2H), 1.30-1.40 (m, 2H), 1.03 (s, 9H); 13C NMR (100 MHz) δ 135.98, 135.90,
134.28, 131.24, 130.05, 129.79, 128.10, 127.87, 126.76, 63.98, 51.64, 31.24, 28.74, 27.29, 27.16, 27.07, 27.0, 19.55; IR (neat) 2931, 2858, 2095, 1111 cm'1. HRMS calcd for C24H34N3OSi [M+1 ]+ 408.2471, found 408.2470.
/=\^-OTBDPS /=\/~ OTBDPS / __V O
V Λ
N3 N N
H H
[00219] l-(8-(/er/-ButyldiphenyIsilyloxy)oct-5(Z)-enyl)-3-n-pentylurea. ï-(tert10 Butyldiphenylsilyloxy-8-azido-oct-3(Z)-en was reduced to the corresponding amine using triphenylphosphine as described above. The crude amine was reacted with w-pentyl isocyanate in THF as noted above and the product was purified by SiO2 column chromatography eluting with 20% EtOAc/hexane to afford the title compound (1.94 g, 84%) as a viscous oil. TLC: EtOAc/hexanes (2:3), Rf ~ 0.45; !H NMR (300 MHz) δ 7.60-7.70 (m, 4H), 7.30-7.40 (m, 6H),
5.35-5.42 (m, 2H), 4.65 ( br s, -NH, 2H), 3.64 (t, J = 5.5 Hz, 2H), 3.06-3.18 (m, 4H), 2.24-2.34 (q, J= 3·9 Hz, 2H), 1.94-2.02 (q, J = 3.6 Hz, 2H), 1.20-1.50 (m, 10H), 1.03 (s, 9H), 0.83 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 159.52, 135.85, 134.21, 131.53, 129.85, 127.90, 126.28, 63.93, 40.58, 40.50, 31.13, 30.43, 30.41, 29.45, 27.35, 22.77, 19.47, 14.36. HRMS calcd for C3oH47N202Si [M+l]+ 495.3407, found 495.3406.
/=\ /- OTBDPS ^-OH / O ____ /
Vy x yn/ VA a y/nz
H H fl fl
[00220] l-(8-Hydroxyoct-5(Z)-enyl)-3-n-pentylurea. 1 -(8-(/er/-Butyldiphenylsilyloxy)oct5(Z)-enyl)-3-n-pentylurea (3.0 g, 6.07 mmol) was de-silylated as described above to give the title alcohol (1.44 g, 93%) as a colorless solid, mp 57.8-57.9 °C. TLC: EtOAc/hexanes (1:4), Rf 0.30; 'H NMR (300 MHz) δ 5.30-5.60 (m, 2H), 4.40 (br s, -NH, 2H), 3.63 (t, J = 6.4 Hz, 2H),
3.08-3.22 (m, 4H), 2.29 (q, J = 5.3 Hz, 2H), 2.09 (q, J = 5.2 Hz, 2H), 1.20-1.58 (m, 10H), 0.88 (t, J= 7.3 Hz, 3H); 13C NMR (100 MHz) δ 159.48, 132.35, 126.21, 62.28, 40.54, 40.15, 31.12, 30.28, 29.96, 29.35, 27.02, 26.98, 22.68, 14.27. HRMS calcd for Ci4H29N2O2 [M+l]+ 257.2229, found 257.2236.
H H
H H
[00221] l-(8-Bromooct-5(Z)-enyl)-3-/i-pentylurea. Obtained in 82% yield as a colorless oil.
TLC: EtOAc/hexanes (2:3), Rf ~ 0.60; 'H NMR (300 MHz) δ 5.30-5.58 (m, 2H), 4.70 (br s, 2H),
3.35 (t, J = 6.8 Hz, 2H), 3.08-3.19 (m, 4H), 2.60 (q, J = 5.6 Hz, 2H), 2.05 (q, J = 5.4 Hz, 2H), 1.24-1.54 (m, 10H), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 159.54, 132.73, 126.45, 40.53, 40.33, 32.85, 30.98, 30.33, 30.30, 29.36, 27.36, 27.0, 22.69, 14.28. HRMS calcd for Ci4H28BrN2O [M+l]+ 319.1385, found 319.1392.
[00222] A-(4-(8-(3-M-Pentylureido)oct-3(Z)-enyIoxy)benzo[d]thiazoI-2-yl)acetamide (33).
Obtained in 40% yield as a colorless solid, mp 113.7-113.8 °C. TLC: EtOAc/hexane (3:2), Rf ~ 0.40; ‘H NMR (300 MHz) δ 12.10 (br s, -NH, 1H), 7.40 (dd, J = 0.8, 7.8 Hz, 1H), 7.22 (dt, J = 0.6, 8.9 Hz, 1H), 6.90 (dd, J = 0.5, 6.9 Hz, 1H), 5.40-5.50 (m, 2H), 4.60 (br s, -NH, 2H), 4.20 (t, J= 5.3 Hz, 2H), 3.05-3.20 (m, 4H), 2.65 (q, J = 3.9 Hz, 2H), 2.29 (s, 3H), 2.15 (q, J= 3.9 Hz, 15 2H), 1.40-1.70 (m, 10 H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz) δ 170.07, 159.21, 158.52, 151.46, 138.41, 133.84, 132.26, 126.13, 124.81, 113.81, 108.29, 68.46, 40.75, 40.64, 30.20, 29.30, 27.78, 26.84, 26.47, 23.42, 22.62, 14.24. HRMS calcd for C23H35N4O3S [M+l]+ 447.2430, found 447.2431.
[00223] Synthesis of Analog 4,
OTHP
Br
OTBDPS
THPO — OTBDPS
[00224] l-(Tetrahydro-27/-pyran-2-yloxy)-10-(tert-butyldiphenylsilyloxy)dec-5-yne.
Obtained in 73% yield as a colorless oil. TLC: 15% EtOAc/hexanes, Rf ~ 0.50; ’H NMR (500 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 4.62 (t, J = 4.3 Hz, 1H), 3.78-3.92 (m, 2H), 3.68 (t, J = 6.3 Hz, 2H), 3.40-3.56 (m, 2H), 2.14-2.26 (m, 4H), 1.42-1.90 (m, 14H), 1.04 (s, 9H); 13C 25 NMR (75 MHz) δ 135.83, 132.02, 129.80, 127,88, 99.0, 80.52, 80.30, 67.31, 63.74, 62.49, 32.0, 31.06, 29.21, 27.14, 26.21, 25.82, 25.78, 19.89, 18.90, 18.81. HRMS calcd for C3iH45O3Si [M + 1]+ 493.3138, found 493.3140.
THPO
OTBDPS
[00225] 10-(Zer/-ButyIdiphenylsilyloxy)dec-5-yn-l-ol. Obtained in 88% yield as a colorless oil whose spectral values were in agreement with literature data.10 TLC: EtOAc/hexanes (3:7), Rf - 0.40; *H NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.34-7.42 (m, 6H), 3.67 (t, J= 5.3 Hz, 4H), 2.06-2.22 (m, 4H), 1.50-1.64 (m, 8H), 1.04 (s, 9H); l3C NMR (75 MHz) δ 135.82, 135.08,
134.27, 129.80, 127.87, 80.74, 80.60, 63.67, 62.69, 32.09, 31.99, 27.12, 26.83, 25.78, 25.58, 25.48, 19.49, 18.79, 18.76.
[00226] 10-(ter/-Butyldiphenylsilyloxy)dec-5(Z)-en-l-ol. Obtained in 92% yield as a colorless oil whose spectral values were in agreement with literature data. TLC:
EtOAc/hexanes (3:7), Rf ~ 0.45; ’H NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.42-7.25 (m, 6H), 5.30-5.40 (m, 2H), 3.67 (t, J = 5.3 Hz, 4H), 2.06-2.22 (m, 4H), 1.40-1.64 (m, 8H), 1.04 (s, 9H); 13C NMR (75 MHz) δ 135.90, 135.81, 134.37, 129.92, 129.87, 129.84, 127.98, 127.80, 64.09, 63.05, 32.47, 27.24, 27.22, 27.13, 26.21, 26.14, 19.51.
< OTBDPS ^OTBDPS / ------/ / OH λ—Z N3
[00227] l-(10-Azidodec-5(Z)-enyIoxy)(ierZ-buty!diphenylsilane. Obtained in 71% yield as a colorless oil. TLC: EtOAc/hexanes (1:9), Rf ~ 0.60; JH NMR (300 MHz) δ 7.64-7.68 (m, 4H), 7.25-7.42 (m, 6H), 5.30-5.40 (m, 2H), 3.65 (t, J = 5.3 Hz, 2H), 3.24 (t, J = 4.9 Hz, 2H), 2.062.22 (m, 4H), 1.40-1.64 (m, 8H), 1.04 (s, 9H); 13C NMR (75 MHz) δ 137.87, 134.35, 130.69, 129.74, 127.91, 64.02, 51.62, 32.44, 28.67, 27.21, 27.16, 27.08, 26.91, 26.16, 19.48; IR (neat)
2930, 2861, 2331, 2324, 2096, 1106 cm'1. HRMS calcd for C26H38N3OSi [M+l]+ 436.2784, found 436.2784.
/=\/—x OTBDPS /=\/—\ OTBDPS / V
A ζχζχΖ
N3 — N N 3 HH
[00228] l-(10-(t^r/-ButyIdiphenylsilyloxy)dec-5(Z)-enyI)-3-n-pentyIurea. Obtained in 78% yield as a colorless oil. TLC: EtOAc/hexanes (2:3), Rf ~ 0.60; *H NMR (300 MHz) δ 7.64-7.68 25 (m, 4H), 7.34-7.42 (m, 6H), 5.22-5.43 (m, 2H), 4.50 (br s, -NH, 2H), 3.65 (t, J = 6.2 Hz, 2H), 3.10-3.40 (m, 4H), 1.96-2.06 (m, 4H), 1.20-1.60 (m, 14H), 1.03 (s, 9H), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz) δ 159.08, 136.03, 134.02, 130.03, 128.26, 126.82, 63.28, 40.67, 40.47, 32.91, 30.48, 29.28, 27.26, 27.22, 26.93, 26.02, 22.64, 19.39, 14.26. HRMS calcd for C32H51N2O2Si [M+l]+ 523.3720, found 523.3724.
[00229] l-(10-Hydroxydec-5(Z)-enyl)-3-«-pentylurea. Obtained in 94% yield as a colorless oil. TLC: EtOAc/hexanes (7:3), Rf ~ 0.30; *H NMR (400 MHz) δ 5.30-5.43 (m, 2H), 4.28 (br s, 2H), 3.63 (q, J = 4.6 Hz, 2H), 3.10-3.20 (m, 4H), 2.00-2.10 (m, 4H), 1.24-1.64 (m, 14H), 0.88 (t, J =7.3 Hz, 3H); 13C NMR (75 MHz) δ 158.67, 130.17, 129.88, 62.71, 40.59, 40.34, 32.52, 30.23, 30.0, 29.32, 27.09, 26.96, 25.99, 22.52, 14.25. HRMS calcd for C16H33N2O2 [M+l]+ 285.2542, found 285.2545.
o
[00230] 2-(10-(3-«-Pentylureido)dec-5(Z)-enyloxy)acetic acid (4). A solution of 1-(10hydroxydec-5(Z)-enyl)-3-n-pentylurea (66 mg, 0.23 mmol) and tetra-«-butylammonium sulfate (39 mg, 0.12 mmol) in benzene/50% aq. KOH (4 mL, 1:1) was stirred at 10 °C. After 15 min, tert-butyl 2-bromoacetate (136 mg, 0.70 mmol) was added to the reaction mixture and stirred at the same température for an additional 1 h. The reaction mixture was then diluted with water (10 mL) and extracted into EtOAc (2x10 mL). The combined organic extracts were washed with water, brine and dried (Na2SO4) and concentrated in vacuo. The residue was dissolved in CH2CI2 (4 mL), cooled to 0 °C, and trifluoroacetic acid (1 mL) was added dropwise. The reaction mixture was diluted with more CH2C12 (5 mL), washed with water, brine and dried (Na2SO4). The residue was purified by SiO2 column chromatography to give analog 4 (37 mg, 47%) as a sticky solid. TLC: EtOAc, Rf ~ 0.30; *H NMR (400 MHz) δ 5.30-5.42 (m, 2H), 4.06 (s, 2H), 3.54 (t, J = 6.6 Hz, 2H), 3.07-3.15 (m, 4H), 2.00-2.12 (m, 4H), 1.21-1.66 (m, 14H), 0.88 (t, J =7.3 Hz, 3H); l3CNMR (75 MHz) δ 174.32, 160.08, 130.33, 129.71,71.60, 68.12,41.11,41.02, 29.68, 29.40, 29.17, 28.96, 27.20, 27.07, 26.64, 25.96, 22.55, 14.20. HRMS calcd for Ci8H35N2O4 [M+l]+ 343.2597, found 343.2594.
Example 2: Synthesis of Sodiuem (S)-2-(13-(3-pentylureido)tridec-8(Z)-enamido)succinate (NIH-F=EET A or JLJ)
[00231] As set forth in Figures 16A and 16B, the synthesis of EET A is as follows:
---------——.
ΛΛΛΛ ^q_HBr_^ ΑΛΛΑ H0 V v v 0H H0 V v v Br »Z
[00232] 7- bromoheptane-l-ol1 (2): Heptane-l,7-diol (36.0 g, 272 mmol; Alfa Aesar) and aq.
48% HBr (38 mL, 0.9 equiv.) were heated under reflux in benzene (400 mL) with water removal using a Dean-Stark apparatus. After 16 h, ail volatiles were removed in vacuo and the residue was purified by SiO2 column chromatography using a gradient of 10-30% EtOAc/hexanes as eluent to give 7-bromoheptan-l-ol (26.22 g, 62%) as a colorless oil. TLC: 50% EtOAc/hexanes, Rf~0.40; *HNMR (400 MHz, CDC13) δ 3.61 (t, 2H, J =7 λ Hz), 3.39 (t, 2H, 6.8 Hz), 1.801.88 (m, 2H), 1.52-1.58 (m, 2H), 1.30-1.46 (m, 6H).
[00233] 2-(7-BromoheptyIoxy)tetrahydro-2.Hr-pyran2 (3): Dihydropyran (5.20 g, 6.11 mmol) was added to a stirring 0°C solution of 7-bromoheptane-l-ol (2) (11.0 g, 56.7 mmol) and a catalytic amount of PTS A in CH2C12. After stirring at rt for 12 h, the réaction mixture was diluted with CH2C12 (200 mL), washed with water (100 mL x 2), brine (100 mL x 3), dried over anhydrous sodium sulphate, and evaporated. The residue was purified by silica gel column chromatography using a gradient of 10-20% ethyi acetate/hexane as eluent to give 2-(7bromoheptyloxy)tetrahydro-2Zf-pyran (3) (14.50 g, 92%) as a colorless oil. TLC: 10% EtOAc/hexanes, Rf ~ 0.55; !H NMR (400 MHz, CDC13) δ 4.58-4.56 (m, 1H), 3.84-3.88 (m, 1H), 3.68-3.77 (m, 1H), 3.46-3.51 (m, 1H), 3.33-3.43 (m, 3H), 1.80-1.81 (m, 2H), 1.30-1.62 (m, 14 H).
[00234] terAButyl(hex-5-yn-l-yloxy)diphenylsilane3 (5): /er/-Butyldiphenylchlorosilane (3.2 mL, 12.4 mmol) was added dropwise to a stirring, 0°C solution of 5-hexyn-l-ol (4, 1.07 g, 10.9 mmol) and anhydrous imidazole (1.84 g, 27.1 mmol) in anhydrous CH2C12 (20 mL) under an argon atmosphère. After complété addition, the reaction mixture was stirred at room température for 12 hours, then quenched with saturated aq. NH4C1 solution (50 mL) and extracted with Et2O (3 x 50 mL). The combined ethereal extracts were washed with saturated aq. NaCl solution (25 mL), dried over NaSO4, and the solvent was removed in vacuo. The residue was purified by flash chromatography (5% ethyi acetate/hexane) to yield \-tertbutyldiphenylsilyloxy-hex-5-yne (5) (3.54 g, 10.5 mmol, 96%) as a colorless oil. TLC: 5%
EtOAc/hexanes, Rf ~ 0.65; 'H NMR (400 MHz, CDCl3) δ 7.77-7.65 (m, 4H), 7.40-7.30 (m, 6H), 3.70 (t, 2H, J = 5.6 Hz), 2.40-2.25 (m, 2H), 2.05 (t, 1H, J = 2.8 Hz), 1.90-1.70 (m, 4H), 1.18 (s, 9H).
[00235] tert-Butyldiphenyl((tetrahydro-2H-pyran-2-yloxy)tridec-5-yn-l-yl)oxy)silane (6):
n-Butyllithium (14.3 mL, 35.9 mmol, 2.5 M solution in hexanes) was added dropwise to a -78°C solution of ierLbutyl(hex-5-ynyloxy)diphenylsilane (10 g, 29.76 mmol) m THF and dry HMPA (4:1, 200 mL) under an argon atmosphère. After 30 min, the reaction mixture was warmed to 0°C over a period of 1 h and held there for 2 h. The reaction mixture was re-cooled -78°C and a THF solution (50 mL) of bromide 3 (8.20 g, 29.3 mmol) was added. The reaction température was allowed to warm to rt over 3h and was held at this température for 12 h before being quenched by adding saturated aq. NH4C1 solution (5 mL). The pH of the reaction mixture was adjusted to ~ 4 using 1 M oxalic acid and extracted with EtOAc (2 x 250 mL). The combined organic extracts were washed sequentially with water (2 xl00 mL) and brine (100 mL), the organic layer was dried using anhydrous Na2SO4 and concentrated under vacuo. Residue was purified by silica gel column chromatography using 10% EtOAc/hexanes to afford 6 (12.4 g, 78%) as a colorless thick oil. ’H NMR (CDC13, 400 MHz) δ 7.68-7.64 (m, 4H), 7.42-7.34 (m, 6H), 4.57 (t, J = 4.3 Hz, 1H), 3.86-3.78 (m, 1H), 3.65 (t, J = 6.3 Hz, 3H), 3.54-3.32 (m, 4H), 2.22-2.10 (m, 4H), 1.84-1.24 (m, 18H), 1.04 (s, 9H) ; 13C NMR (CDC13, 100 MHz) δ 135.82, 135.77, 134.25, 129.72, 127.85, 127.80, 127.77, 99.09, 99.05, 80.59, 80.22, 67.84, 67.74, 63.70, 25 62.58, 62.54, 31.00, 25.73, 19.92, 19.44, 18.97, 18.77.
[00236] 13-(te/7-Buty ldiphenyIsilyloxy)tridec-8-yn-l-ol (7): A solution of 6 (15.0 g, 0.59 mmol) and a catalytic amount of PPTS (10 mg) in MeOH (20 mL) was stirred ai 0°C for lOh, then quenched with saturated aq. NaHCO3 solution. Most of the methanol was evaporated in 30 vacuo. The residue was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x
3). The combined organic extracts were concentrated under reduced pressure and the residue was purified by silica gel column chromatography using 20-30 % ethyl acetate /hexane as eluent to afford 7 as a colorless oil (8.80 g, 78.7%). TLC: 20% EtOAc/hexanes, Rf ~ 0.36; ‘H NMR (CDCl3, 400 MHz) δ 7.68-7.65 (m, 4H), 7.41-7.35 (m, 6H), 3.66-3.62 (m, 4H), 2.10-1.95 (m, 4H), 1.64-1.50 (m, 2H), 1.48-1.20 (m, 10H), 1.04 (s, 9H); 13C NMR (CDCI3, 100 MHz) δ 135.79, 135.77, 134.26, 129.73, 127.84, 127.83, 127.80, 127.78, 80.56, 80.28, 63.72, 63.22, 32.96, 31.90, 29.01, 25.78, 19.45, 18.95, 18.77.
[00237] 13-(ter/-ButyldiphenylsilyIoxy)tridec-8(Z)-en-l-ol (8): In a two neck round bottom flask, NaBH4 (176 mg, 4.65 mmol) was added in small portions to a solution of Ni(OAc)2-4H2O (1.16 g, 9.3 mmol) in absolute éthanol (10 mL) under a hydrogen atmosphère (1 atm). After 15 min, dry ethylenediamine (0.56 g, 9.3 mmol) was added followed after an additional 15 min by a solution of alcohol 7 (8.0 g, 18.7 mmol) in absolute éthanol (25 mL). The réduction was monitored by TLC until complété and then diluted with ether (50 mL), passed through a small pad of silica gel to remove inorganic impurities. The filtrate was concentrated under reduced pressure to afford 8 as a viscous, colorless oil (7.60 g, 95%). TLC: 50% EtOAc/hexane, Rf ~ 0.42; 'H NMR (CDCI3, 400 MHz) δ 7.68-7.65 (m, 4H), 7.41-7.35 (m, 6H), 5.40-5.30 (m, 2H), 3.58-3.65 m, 4H), 1.88-2.10 (m, 4H), 1.50-1.61 (m, 4H), 1.25-1.45 (m, 10H), 1.04 (s, 9H); 13C NMR (CDCI3, 100 MHz) δ 135.83, 134.36, 130.30, 129.98, 129.77, 127.85, 64.09, 63.17, 32.48, 29.96, 29.53, 27.49, 27.37, 27.21, 27.16, 26.23, 26.01, 19.50.
[00238] 13-(/er/-ButyIdiphenyIsilyloxy)tridec-8(Z)-enoic acid (9): Jones reagent (5.8 mL of a 10 N solution in water) in acetone (25 mL) was added to a stirring, -40°C solution of alcohol 8 (5.0 g, 11.8 mmol) in acetone (75 mL). After 1 h, the reaction mixture was warmed to -10°C and maintained for another 2 h, then quenched with an excess (5.0 equiv) of isopropanol. The green chromium salts were removed by filtration and the filter cake was washed with acetone. The combined filtrâtes and washings were concentrated in vacuo and the résultant residue was dissolved in EtOAc (100 mL), washed with water (50 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The residue was purified by SiO2 column chromatography using 15% EtOAc/hexanes as eluent to give 9 (3.84 g, 74.20%) as a liquid. TLC: 40% EtOAc/hexanes, Rf ~ 0.40. *H NMR (CDCfi, 400 MHz) δ 7.68-7.64 (m, 4H), 7.43-7.34 (m, 6H), 5.40-5.26 (m, 2H), 3.66 (t,J= 6.6 Hz, 2H), 2.35 (t, J= 7.3 Hz, 2H), 2.10-1.90 (m, 4H) 1.64-1.50 (m, 2H), 1.48-1.20 (m, 10H), 1.04 (s, 9H); ,3C NMR (CDCI3, 100 MHz) δ 180.62, 135.81, 10 134.34, 130.10, 130.07, 129.73, 127.82, 127.80, 127.79, 64.06, 32.44, 29.12, 27.38, 27.18, 27.12, 26.19, 24.87, 19.47.
[00239] Methyl 13-hydroxytridec-8(Z)-enoate4 (10): A solution of 9 (7.60 g, 3.49 mmol) and p-toluenesulphonic acid (50 mg; PTSA) in MeOH (50 mL) was stirred at room température 15 for 4 h, and then concentrated in vacuo. The residue was purified by SiO2 column chromatography using 25% EtOAc/hexanes as eluent to give 10 (3.41 g, 87%) as a colorless oil. TLC: 40% EtOAc/hexanes, Rf ~ 0.35; !H NMR (CDCI3, 400 MHz) δ 5.40-5.36 (m, 2H), 3.603.66 (m, 5H), 2.30 (t, J= 7.3 Hz, 2H), 2.10-1.90 (m, 4H) 1.64-1.50 (m, 2H), 1.48-1.20 (m, 10H).
[00240] Methyl 13-azidotridec-8(Z)-enoate5 (11): Diisopropyl azodicaboxylate (DIAD; 3.0 g, 14.8 mmol,) was added dropwise to a -20°C solution of triphenylphosphine (3.9 g, 14.8 mmol) in dry THF (100 mL) under an argon atmosphère. After stirring for 10 min, a solution of 10 (3.0 g, 4.75 mmol) in anhydrous THF (5 mL) was added dropwise. After 30 min at -20°C, the reaction mixture was warmed to 0°C and diphenylphosphorylazide (DPPA, 4.0 g, 14.5 mmol) was added dropwise. After stirring at room température for 6 h, the reaction was quenched with water (3 mL), diluted with ether (100 mL), and washed with brine (40 mL). The aqueous layer was back-extracted with ether (2 x 150 mL). The combined organic extracts were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by SiO2 column chromatography using 5% EtOAc/hexanes as eluent to afford 11 (2.72 g, 82%) as light yellow oil. TLC: 10% EtOAc/hexanes, Rf~ 0.45; *H NMR (CDCI3, 400 MHz) δ 5.40-5.34 (m, 2H), 3.64 (s, 3H), 3.26 (t, J = 6.7 Hz, 2H), 2.30 (t, J = 7.7 Hz, 2H) 2.10-1.98 (m, 4 H) 1.66-1.54 (m, 2H), 1.48-1.24 (m, 10H).
[00241] Methyl 13-(3-pentylureido)tridec-8(Z)-enoate6 (12): Triphenylphosphine (2.7 g., 11.0 mmol) was added to a room température solution of 11 (1.4 g, 5.24 mmol) in dry THF (25 mL). After 2 h, water (200 pL) was added and the stirring was continued for another 8 h. The reaction mixture was then diluted with EtOAc (100 mL), washed with water (20 mL) and brine (25 mL). Aqueous layers were back-extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over Na2SO4, concentrated under reduced pressure and further dried under high vacuum for 4 h. The crude amine was used in the next step without additional purification. Procedure ref: S. Chandrasekhar; S. S. Sultana; N. Kiranmai; Ch. Narsihmulu Tetrahedron Lett. 2007: 48, 2373.
[00242] n-Pentyl isocyanate (0.78 g, 6.9 mmol) was added to a room température solution of the above crude amine (1.4 g, 5.8 mmol) in dry THF (25 mL). After 6 h, reaction mixture was concentrated under reduced pressure and the residue was purified by SiO2 column chromatography using 30% EtOAc/hexanes as eluent to give 12 (1.70 g, 85%) as a colorless, viscous oil. TLC: 50% EtOAc/hexanes, Rf ~ 0.40; 'H NMR (CDCI3, 400 MHz) δ 5.40-5.26 (m, 2H), 4.46-4.32 (m, NH, 2H), 3.66 (s, 3H), 3.18-3.10 (m, 4H), 2.34 (t, J = 7.7 Hz 4H), 2.06-1.94 (m, 4H), 1.66-1.56 (m,2H), 1.54-1.42 (m, 14 H), 0.88 (t, J= 7.0 Hz, 3H).
[00243] Methyl 13-(3-pentylureido)tridec-8(Z)-enoic acid7 (13): LiOH (6.2 mL, 2.0 M aqueous solution, 3.0 equiv) was added to a 0°C solution of 12 (1.80 g, 5.8 mmol) in THF (25 mL) and deionized H2O (4 mL). After stirring at room température 0vernight, the reaction mixture was cooled to 0°C, the pH was adjusted to 4.0 with 1 M aq. oxalic acid, and extracted with ethyl acetate (2 x 20 mL). The combined extracts were washed with water (30 mL), brine (25 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by
SiO2 column chromatography using 25% EtOAc/hexanes as eluent to give 13 (1.48 g, 86%) as white solid, m.p. = 67.1°C. TLC: 80% EtOAc/hexanes, Rf ~ 0.30; NMR (CDC13, 400 MHz) δ 5.40-5.26 (m, 2H), 3.17-3.10 (m, 4H), 2.32 (t, J = 6.7 Hz, 2H), 2.09-1.95 (m, 4H), 1.65-1.48 (m, 6H), 1.44-1.22 (m, 12H), 0.89 (t, J = 7.1 Hz, 3H); I3C NMR (CDCI3, 75 MHz) δ 178.5, 159.6, 130.5, 129.5, 40.9, 40.8, 34.4, 29.9, 29.8, 29.2, 28.7, 28.5, 27.2, 26.7, 24.9, 22.6, 14.2.
[00244] (5)-2-(13-(3-Pentylureido)tridec-8(Z)-enamido)succinate (14): L-Aspartic acid dimethyl ester (38 mg, 0.191 mmol) and HATU (67 mg, 0.176 mmol) were added to a stirring solution of 13 (50 mg, 0.147 mmol) and DIPEA (74 mg, 0.573 mmol) in anhydrous DMF (2 mL) under an argon atmosphère. After 5 min, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (33.8 mg, 0.176 mmol; EDCI) was added as a solid. After stirring for 12 h at room température, the reaction mixture was diluted with EtOAc (15 mL), washed with water (5 mL), and brine (10 mL). The combined aqueous layers were back-extracted with EtOAc (3x10 mL). The combined organic extracts were dried over Na2SO4, concentrated under reduced pressure, and the residue was purified by SiO2 column chromatography using 50% EtOAc/hexanes as eluent to give 14 (60 mg, 84%) as viscous oil. TLC: 60% EtOAc/hexanes, Rf ~ 0.35; ’H NMR (CDC13, 400 MHz) δ 6.64 (d, J = Ί.9 Hz, 1H), 5.38-5.30 (m, 2H), 4.90-4.82(m, 1H), 4.58-4.44 (m, 2H), 3.75 (s, 3H), 3.66 (s, 3H), 3.20-3.10 (m, 4H), 3.04 (dd, Ji = 4.3 Hz, J2 = 13.1 Hz, 1H), 2.84 (dd, = 4.6 Hz, J2 = 12.8 Hz, 1H), 2.22 (t, J = 6.3 Hz, 2H), 2.05-1.98 (m, 4H), 1.70-1.60 (m, 2H), 1.50-1.20 (m, 16H), 0.88 (t, J =6.7 Hz, 3H).
[00245] (5)-2-(13-(3-pentylureido)tridec-8(Z)-enamido)succinic acid (15): An aqueous solution of LiOH (2 mL, 2 M solution, 6.0 equiv) was added to a 0°C solution of 14 (60 mg, 0.124 mmol) in THF (8 mL) and deionized H2O (2 mL). After stirring at room température ovemight, the reaction mixture was cooled to 0°C, the pH was adjusted to 4.0 with 1 M aq. oxalic acid, and extracted with ethyl acetate (2x10 mL). The combined extracts were washed with water (5 mL), brine (5 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by SiO2 column chromatography using 70-90% EtOAc/hexanes as eluent to give 15 (48 mg, 85%) as a viscous, colorless oil. TLC: 5% MeOH/EtOAc, Rf ~ 0.20; Ή NMR (CD3OD, 400 MHz) δ 5.38-5.30 (m, 2H), 4.72 (t, J = 4.3 Hz, 1H), 3.12-3.05 (m, 4H), 2.90-2.72 (m, 2H), 2.22 (t, J = 7.7 Hz, 2H), 2.10-1.98 (m, 4H), 1.60-1.22 (m, 18H), 1.20 (t, J = 7.1 Hz, 3H); 13C NMR (CDC13, 75 MHz) δ 174.9, 173.0, 172.8, 160.1, 129.9, 129.3, 51.8, 49.8, 39.8, 39.7, 35.7, 35.6, 29.9, 29.8, 29.5, 29.0, 28.8, 26.9, 26.7, 25.7, 22.3, 13.2.
[00246] Disodium (5)-2-(13-(3-pentylureido)tridec-8(Z)-enamido)succinate (16): Sodium bicarbonate (93 mg, 1.1 mmol) was added to a stirring solution of 15 (100 mg, 0.22 mmol) in THF/H2O (4:1, 5 mL) at rt. After 2 h, the THF was removed in vacuo and the remaining aqueous phase was stirred with SM-2 Bio-Beads (Bio-Rad, 20-50 mesh; 2 g). After 1 h, the Bio-Beads were collected by filtration on a sintered-glass funnel, washed with water (5 mL x 2) and fmally with 95% éthanol (20 mL x 3). Evaporation of the éthanol washes in vacuo gave 16 (72 mg, 84%) as a white solid, m.p. = 258.5°C. TLC: 10% MeOH/CH2Cl2, Rf - 0.15; ’H NMR (CD3OD, 500 MHz) δ 5.25-5.23 (m, 2H), 4.40 (t, 1H, J = 4.0), 3.01-2.97 (m, 4H), 2.58-2.56 (m, 2H), 2.13 (ΐ, 2H, J = 7.0), 1.96-1.94 (m, 4H), 1.51-1.47 (m, 2H), 1.30-1.19 (m, 16H), 0.83 (t, 3H, J = 7.0); l3C NMR (75 MHz, CDC13) δ 178.52, 178.38, 173.99, 160.21, 129.93, 129.37, 52.66, 39.81, 39.74, 36.27, 29.50, 28.93, 26.76, 22.34, 13.26.
Example 3: Synthesis of /V-Isopropyl-A-(5-(2-pivaIamidobenzo[d]thiazol-4yloxy)pentyl)heptanamide (MV=EET-B or SRD-2)
[00247] As set forth in Figure 15, the synthesis of EET B is as follows:
[00248] 5-(te/7-ButyIdiphenyIsilyIoxy)pentan-l-ol (2): Imidazole (0.65 g, 9.60 mmol) was added to a stirring solution of pentan-l,5-diol (1.00 g, 9.60 mmol) in dry dichloromethane (10 mL) at 0°C under an argon atmosphère followed by the dropwise addition of tertbutylchlorodiphenylsilane (3.85 mL, 9.60 mmol) in CH2C12 (2 mL). The reaction was allowed to slowly reach room température. After 12 hours, the reaction mixture was washed with water (2 x 30 mL), brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue which was purified by SiO2 flash chromatography using 30% ethyl acetate/hexane as eluent to furnish 2 (1.35 g, 46%), recovered SM and di-protected compound. TLC: 30% EtOAc/hexanes, Rf ~ 0.38; 'H NMR (CDC13, 400 MHz) δ 7.67-7.62 (m, 4H), 7.45-7.35 (m, 6H), 3.67 (t, 2H, J= 6.0 Hz), 3.52 (t, 2H, J = 6.7 Hz), 2.03-1.93 (m, 2H), 1.72-1.64 (m, 4H), 1.04 (s, 9H).
I2 TPP, Imidazole .. ..
HO'^^^^'O'TBDPS ---------------► I OTBDPS
DCM
[00249] ter/-Butyl(5-iodopentyloxy)diphenylsilane (3): Imidazole (310 mg, 4.40 mmol), iodine (440 mg, 3.5 mmol), and a solution of 2 (1 g, 2.98 mmol) in CH2C12 (2 mL) were added sequentially to a 0°C solution of PPh3 (450 mg, 3.5 mmol) in CH2C12 (15 mL) and kept in the dark. After 2 h, the reaction mixture was quenched by adding 20% aq. Na2S2O3 (5 mL). The aqueous layer was extracted with CH2C12 (2 χ 50 mL). The combined organic extracts were washed with brine (30 mL), dried over anhydrous Na2SO4, and the solvent was removed in vacuo. The residue was purified by careful column chromatography using 5% EtOAC/hexane to afford iodide 3 (1.25 mg, 92%). TLC: 10% EtOAc/hexane, Rf ~ 0.85; ‘H NMR (CDC13, 400 MHz) δ 7.67-7.62 (m, 4H), 7.45-7.35 (m, 6H), 3.67 (t, 2H, J = 6.0 Hz), 3.41 (t, 2H, J = 6.7 Hz), 2.03-1.93 (m, 2H), 1.72-1.64 (m, 4H), 1.04 (s, 9H).
IPA, K2CO3
[00250] 5-(t^rAButyldiphenylsilyIoxy)-A-isopropyIpentan-l-amine (4): K2CO3 (1.50 g, 11.05 mmol), isopropylamine (0.65 mL, 11.05 mmol) and iodide 3 (2.50 g, 5.83 mmol) in dry THF (15 mL) were heated at 66°C in a sealed tube under an argon atmosphère. After 12 h, water (5 mL) was added to the reaction mixture which was then extracted with EtOAc (3 χ 50 mL). The combined organic extracts were dried over MgSÛ4 and concentrated under reduced pressure to afford 4 as a colorless liquid (1.90 g, 92%) sufficiently pure it was used without further purification. TLC: MeOH/CH2Cl2 (1:4), Rt ~ 0.30; ‘H NMR (400 MHz) δ 7.65-7.67 (m, 4H),
7.30-7.40 (m, 6H), 3.65 (t, J = 6.4 Hz, 2H), 2.70-2.82 (m, 1 H), 2.55 (t, J = 7.3 Hz, 2H), 1.501.64 (m, 2H), 1.32-1.50 (m, 4H), 1.05 (d, 5.8 Hz, 3H), 1.04 (s, 9H); l3C NMR (100 MHz) δ
135.68, 134.21, 129.63, 127.70, 63.95,48.81, 47.64, 32.60, 30.27,27.0,23.76, 23.15, 19.34.
TBDPSO
EDCI/D1PEA/DMF
[00251] N-(5-(iert-Butyldiphenylsilyloxy)pentyl)-A-isopropyIheptanamide (5): Heptanoïc acid (2.06 g, 15.86 mmol), and diisopropylethylamine (2.72 mL, 21.14 mmol; DIPEA) were added to a stirring solution ofthe amine 4 (4.00 g, 10.57 mmol) in anhydrous DMF (20 mL) under an argon atmosphère. After 5 min, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (3.04 g, 15.86 mmol; EDCI) was added as a solid. After stirring for 12 h at room température, the reaction mixture was diluted with EtOAc (100 mL), washed with water (2 x 30 mL), and brine (20 mL). The combined aqueous layers were back-extracted with EtOAc (3 x 30 mL). The combined organic extracts were dried over Na2SO4, concentrated under reduced pressure, and the residue was purified by SiO2 column chromatography using 30% EtOAc/hexanes as eluent to give amide 5 (4.75 g, 91%) as a viscous oil. TLC: EtOAc/hexanes (3:7), Rf ~ 0.60; H NMR (400 MHz, 1:1 mixture of rotamers) δ 7.65-7.67 (m, 4H), 7.30-7.40 (m, 6H), 4.62-4.72 and 3.96-4.80 (m, 1H, rotamers), 3.62 and 3.68 (t, J= 4.8 Hz, 2H, rotamers), 3.02 and 3.16 (t, J= 5.2 Hz, 2H, rotamers), 2.38 and 2.24 (t, J = 5.3 Hz, 2H, rotamers), 1.50-1.68 (m, 6H), 1.26-1.44 (m, 8H), 1.18 and 1,12, (d, J= 7.3 Hz, 6H, rotamers), 1.03 and 1.04 (s, 9H, rotamers), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, 1:1 mixture of rotamers) δ 173.38, 172.76, 135.80, 135.78, 134.36, 134.12, 129.85, 129.73, 127.88, 127.82, 64.22, 63.68, 48.43, 45.62, 43.64, 41.27, 34.13, 34.05, 25 32.61, 32.36, 31.96, 31.93, 31.51, 29.63, 29.47, 27.10, 27.03, 25.94, 25.78, 24.03, 23.77, 22.81, 21.63,20.78, 19.47, 14.33, 14.28.
MeoH/PTSA
[00252] N-(5-hydroxypentyl)-N-isopropylheptanamide (6): A solution of 5 (4.75 g, 9.02 mmol) and p-toluenesulfonic acid in MeOH (50 mL) was stirred at rt for 12 h, then quenched 30 with solid NaHCO3 and filtered. The filtrate was evaporated under vacuum and the residue was dissolved in ethyl acetate (50 mL). The ethyl acetate layer was washed with water (2 x 50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography using 50-60% ethyl acetate/hexane as eluent to afford alcohol 6 (2.35 g, 93%) as a colorless, viscous liquid. TLC: EtOAc/hexanes (1:1), Rf ~ 0.30; *H NMR (400 MHz, 55/45 mixture of rotamers) δ 4.58-4.66 and 3.96-4.08 (m, 1H, rotamers), 3.56 and 3.70 (t, J= 5.4 Hz, 2H, rotamers), 3.02 and 3.16 (t, J = 5.2 Hz, 2H, rotamers), 2.38 and 2.26 (t, J = 6.3 Hz, 2H, rotamers), 1.50-1.64 (m, 6H), 1.22-1.40 (m, 8H), 1.13 and 1.09 (d, J = 7.5 Hz, 6H, rotamers), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, 55/45 mixture of rotamers) δ 172.81, 62.66, 62.60, 48.41, 45.55, 43.56, 41.04, 34.08, 34.0, 32.46, 32.43, 31.86, 31.57, 29.40, 25.87, 25.70, 23.77, 23.73, 22.75, 21.57, 20.72, 14.26.
[00253] Æ-(5-Bromopentyl)-A-isopropylheptanamide (7): TPP (4.45 g, 9.34 mmol) was added to a 0°C solution of alcohol 6 (2.00 g, 7.78 mmol) in dry CH2C12 (50 mL). After 10 min, CBr4 (3.10 g, 9.34 mmol) was added and the stirring was continued at 0°C. After 2 h, water (20 mL) was added and the reaction mixture was extracted with EtOAc (3 x 50 mL). The combined extracts were washed with water (2 x 20 mL), brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by SiO2 column chromatography using 30-35% ethyi acetate/hexane to afford 7 (2.20 g, 91%). TLC: EtOAc/hexanes (3:7), Rf ~ 0.40; 'H NMR (400 MHz, 45/55 mixture of rotamers) δ 4.60-4.70 and 3.96-4.10 (m, 1H, rotamers), 3.46 and 3.36 (t, J = 5.8 Hz, rotamers), 3.02-3.10 (m, 2H), 2.30 and 2.22 (t, J = 7.9 Hz, 2H), 1.80-1.97 (m, 2H), 1.40-1.70 (m, 6H), 1.20-1.40 (m, 6H), 1.16 and 1.10, (d, J = 7.3 Hz, 6H, rotamers), 0.86 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, rotamers) δ 172.79, 172.39, 48.17, 45.47, 43.32, 40.70, 33.89, 33.87, 33.49, 32.48, 32.30, 31.81, 31.78, 30.78, 29.27, 28.74, 26.05, 25.84, 25.69, 25.54, 22.64, 21.47, 20.62, 14.17.
S
NHPiv
N
DMF, K2CO3
[00254] Isopropyl-A-(5-(2-pivaIamidobenzo[d]thiazoI-4-yloxy)pentyl)heptanamide (11):
A solution of bromide 7 (0.35 g, 1.09 mmol), A-(4-hydroxybenzo[d]thiazol-2-yl)pivalamide (10) (0.27 g, 1.09 mmol), and K2CO3 (0.30 g, 2.18 mmol) in DMF (10 mL) was heated at 80°C. After 4 h, the reaction mixture was cooled to rt, water (5 mL) was added and the mixture was extracted using ethyi acetate (3 x 30 mL). The combined organic extracts were washed with H2O (2 χ 20 mL), brine (20 mL), dried over Na2SO4, and filtered. The filtrate was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (50-70% EtOAc/hexanes) to give 11 (0.39 g, 72%) as a viscous liquid. TLC: EtOAc/hexanes (7:3), Rf ~ 0.26; 'H NMR (400 MHz, 45/55 mixture of rotamers) δ 7.24 and 7.20 (d, J = 7.4 Hz, 1H, rotamers), 7.16 and 7.14 (dd, J = 7.4 Hz, J = 7.4 Hz, 1H, rotamers), 6.90 and 6.80 (d, J = 7.4 Hz, 1H, rotamers), 4.58-4.78 and 3.96-4.10 (m, 1H, rotamers), 4.02 (t, J = 6.3 Hz, 2H), 3.12 (t, J = 7.3 Hz, 2H), 2.30 and 2.27 (t, J = 5.6 Hz, 2H, rotamers), 1.82-1.92 (m, 2H), 1.44-1.70 (m, 4H), 1.38-1.32 (m, 8H), 1.20 (d, J = 6.4 Hz, 3H), 1.13 (d, J= 6.4 Hz, 3H), 1.11 (d, J = 6.4 Hz, 3H), 0.88-085 (m, 6H); 13C NMR (100 MHz, 45/55 mixture of rotamers) δ 189.64, 189.62, 173.04, 172.57, 172.55, 167.16, 167.09, 167.06, 146.85, 146.77, 146.67, 128.90, 128.87, 125.90, 125.79, 124.24, 124.13, 115.32, 115.06, 111.00, 110.09, 110.05, 68.97, 68.74, 58.50, 48.34, 45.62, 41.24, 41.10, 40.95, 34.10, 29.52, 29.15, 25.72, 24.28, 21.66, 20.76, 14.30.
[00255] N-(4-hydroxybenzo[d]thiazol-2-yl)pivalamide (10) To a suspension of 2aminobenzo[d]thiazol-4-ol (0.50 g, 3.01 mmol) in toluene (10 mL) was added trimethyacetyl chloride (3.60 mL, 30.10 mmol) at room température. The reaction mixture was stirred at 115 °C for 22 h. The solvents were evaporated and the residue was azeotroped with EtOAc to give 9 (0.78 g, 78%) as a tan solid. The suspension of the above solid (0.78 g) in MeOH (15 mL) was treated with K2CO3 (0.20 g, 3.50 mmol) and stirred at room température for 6 h. MeOH was evaporated and the residue was diluted with H2O. The resulting mixture was neutralized with concd HCl to pH = 7 and extracted with EtOAc (3x30 mL). The combined organic phases were dried over sodium sulfate, filtered, and concentrated in vacuo to provide 10 (0.48 g, 82%) s a tan solid. TLC: EtOAc/hexanes (7:3), Rf ~ 0.32; !H NMR (400 MHz, CDC13) δ 10.25 (br s, 1 H), 9.66 (br s, 1 H), 7.33 (d, J= 7.4 Hz, 1H), 7.09 (dd, J= 7.4, 7.4, Hz, 1H), 6.82 (d, J = 7.4 Hz, 1H), 1.45 (s, 9H). 13C NMR (100 MHz, CDC13) δ 177.15, 159.12, 148.10, 136.55, 133.00, 125.55, 113.40, 111.50, 39.70, 27.38.
Example 4: In Vitro Screening of EET Analog Library
[00256] In this Example, the inventors performed both vascular relaxation assays and a soluble epoxide hydrolase inhibition assay using the newly synthesized compounds. The results of these assays are recorded in the last three columns of Table 1 above and Figure 14. As a resuit of these assays, four compounds, compounds 26, 20, 7 and 30 were selected for further in vivo testing, as outlined in later Examples.
[00257] Soluble Epoxide Hydrolase Inhibition. Compounds were tested for their ability to inhibit recombinant soluble epoxide hydrolase (sEH) protein. The assay utilizes (3-Phhenyloxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester (PHOME), a sensitive substrate for sEH that can be used to monitor the activity of both human and murine enzymes. Hydrolysis of the substrate epoxide yields a highly fluorescent product, 6-methoxy-2Naphthaldehyde, which can be monitored at excitation and émission wavelengths of 330 and 465 nm, respectively. See Wolf et al., Anal Biochem 355:71-80, 2006 PMID: 16729954. Human recombinant sEH was incubated with substrate and compounds ranging in concentration from 0.1 to 1000 nM. The percent activity remaining at each concentration was plotted and an IC50 (concentration at which there is 50% inhibition) determined utilizing statistical software.
[00258] Vasodilator Activity. Vasorelaxant activity was measured in bovine coronary artery. Bovine hearts were obtained and the left anterior descending coronary artery was dissected and cleaned of connective tissue. Vessels of 1 mm diameter were eut into rings of 3 mm width as previously described (3, 27, 39). Vessels were stored in Krebs buffer consisting of (in mM) 119 NaCl, 4.8 KC1, 24 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, 11 glucose, 0.02 EDTA, and 3.2 CaCl2. The vessels were suspended from a pair of stainless Steel hooks in a 6-ml water-jacketed organ chamber. The organ chamber was filled with Krebs buffer and bubbled with 95% O2-5% CO2at 37°C. One hook was anchored to a Steel rod and the other hook to a force transducer (model FT03C; Grass Instruments, West Warwick, RI). Tension of the vessel was measured by an ETH400 bridge amplifier, and the data were acquired with a MacLab 8e analog-to-digital converter and MacLab software version 3.5.6 (AD Instruments, Milford, MA) and stored on a Macintosh computer for subséquent data analysis.
[00259] Basal tension was set at the length-tension maximum of 3.5 g and equilibrated for 1.5 h. KC1 (40 mM) was added to the chamber until reproducible maximal contractions were maintained. U-46619 (10-20 nM), a thromboxane receptor agonist, was used to precontract the vessels from basal tension to between 50% and 90% of the maximal KC1 contraction. Cumulative additions of compounds were added to the chamber. Between concentrationresponse curves, the chambers were rinsed with fresh Krebs buffer, 40 mM KC1 was administered to détermine the maximum contraction, and the vessels were rinsed. Consecutive concentration-response curves were performed with 14,15-EET followed by a concentrationresponse curve to a compund. The experiment was always repeated with the order of the agonists reversed. In control experiments with consecutive concentration-response curves to 14,15-EET, the second concentration-response curve with compound was identical to the first. Tension was represented as percent relaxation where 100% relaxation was basal pre-U-46619 tension. The relaxation was plotted versus compound concentration and the EC50 determined utilizing statistical software.
[00260] Results of Vasodilator and sEH Inhibitory Activity Assays. The results of 10 vasorelaxant and sEH inhibitory activities of the 33 synthesized compounds are summarized in
Table 1. Using the pharmacophoric moiety of EET, a number of EET analogs were designed with improved solubility and résistance to auto-oxidation, éthérification and metabolism by soluble epoxide hydrolase (sEH). It is observed that these compounds possess activity analogous to EET as évident from their vasorelaxant activity in bovine coronary artery and sEH inhibitory 15 (sEHi) activity. Among these, four compounds among those that were designed by replacing
COOH group of the EET pharmacophore with isosteric replacement or a heterocyclic surrogate were studied for potential antihypertensive effect. The results of vasorelaxant and sEH inhibitory activities of these compounds are summarized in Table 2 below.
Table 2: Characteristics of the compounds selected for testing in the in vivo models.
Compound | Structure | Vascular relaxation | SEHi activity | |
% relaxation (ΙΟμΜ) | ec50 (μΜ) | IC50 ( nM) | ||
SRD-I-71-9 | / 0 J \ V^z / 0 II 0 | 109 | .32 | >500 |
LGK-I-119-15 | N---N - /O H | 119 | 0.18 | 11 |
JLJ-I-94-6 | 0 /=\ /--.COOH / Ν' 0 NHihiiiiii/ \ /\ 1 --COOH \___/ \ / N X/ V H H | 91 | 1.6 | 392 |
MV-IV-110-20 | NHAc \__/V A^-^xx N z'Pr | 96 | 1.3 | >500 |
Example 5: In Vitro Testing of Four Compounds Using Rat Models of Hypertension.
[00261] Telemetry Blood Pressure Measurement. To accurately detect changes in blood pressure and heart rate, telemetry transmitters (Data Sciences Inc., St. Paul, MN) were implanted in rats one week prior to the experimental period according to manufacturer's spécifications while under pentobarbital anesthésia. In brief, an incision was made to expose the fémoral artery that was occluded to allow insertion of the transmitter cathéter. The cathéter was secured in place with tissue glue and the transmitter body was sutured in place and the incision line was closed. Rats were allowed to recover from surgery and were retumed to individual housing. A baseline arterial pressure was recorded for prior to the experimental period. Mean arterial pressure was continuously recorded throughout the experimental period.
[00262] Angiotensin Hypertension. Telemetry transmitters were implanted into male Sprague-Dawley rats (225-275 g) as described. After recording basal blood pressure, osmotic pumps were implanted (s.c.) to deliver angiotensin at a dose of 60 ng/min. EET analogs were administered by an osmotic pump (2mg/d, i.p.) and blood pressure was continuously monitored.
[00263] Spontaneously hypertensive rats (SHR). Telemetry transmitters were implanted into male SHR as described. After the surgical recovery period, baseline mean arterial pressure was recorded. In this sériés of experiments, EET analogs were administered by osmotic pump (2 mg/d, i.p.) and blood pressure was continuously monitored.
[00264] Protein excrétion measurements. Animais were placed in a metabolic cage and urine was collected in a conical tube. Samples were stored at -80°C until assayed. Urinary protein excrétion was assessed as an index for rénal injury. Protein was determined by the Bradford colorimétrie method and créatinine was determined by the picric acid colorimétrie method.
[00265] Telemetry and urinary analysis methods are further outlined in the following publications: Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides rénal protection in salt-sensitive hypertension. Hypertension 46:975-981, 2005. PMID: 1615779; Elmarakby AA, Quigley JE, Olearczyk JJ, Srindhar A, Cook AK, Inscho EW, Pollock DM, Imig JD. Chemokine receptor 2b blockade inhibition provides rénal protection in angiotensin II-salt hypertension. Hypertension 50:1069-1076, 2007. PMID: 17938380; and Olearczyk JJ, Quigley JE, Mitchell B, Yamamoto T, Kim IH, Newman JW, Lauria A, Hammock BD, Imig JD. Inhibition of the soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clinical Science 116:61-70, 2009. PMID: 18459944. These publications are incorporated by reference herein.
[00266] Statistical analysis. Ail data are presented as mean ± SEM. Mean arterial blood pressure data were analyzed using analysis of variance (ANOVA) for repeated measurements. Différences were considered statistically significant with p< 0.05 compared to the control. Analyses were performed using GraphPad Prism Version 4.0 software (GraphPad Software Inc, La Jolla, CA).
[00267] Results-Effects on blood pressure and heart rate. Spontaneously hypertensive rat (SHR). In this model of hypertension, blood pressure lowering abilities of four selected compounds were studied. It is observed that two of these four compounds had blood pressure lowering effects. SRD (chemical structure shown in Figure IA) and LGK (chemical structure shown in Figure 2A) lacked blood pressure lowering actions in SHR. In the SRD treated SHR group, after two weeks of treatment the blood pressure was similar to the vehicle treated SHR group (150±5.0 vs. 141±3.0 mmHg) (see Fig. 1B-C). After two weeks of treatment, LGK did not change the blood pressure (137±1.0 vs. 141±3.0 mmHg) compared to the vehicle in SHR (Fig. 2 C-D). Similar to their effects on blood pressure, neither SRD nor LGK affected the heart rate (SRD, 344±23.0 vs. 331±17.0 BPM; LGK, 325±ll.O vs. 33H17.0 BPM) compared to vehicle SHR.
[00268] Two weeks treatment with JLJ (chemical structure shown in Figure 3A) caused a moderate decrease in blood pressure in SHR compared to vehicle treated group (!31±2.0 vs. 141±3.0 mmHg) and its blood pressure lowering effect has been seen from the first week of the treatment (Fig. 3 B-C). The compound MV (chemical structure shown in Figure 4A) also demonstrates a similar blood pressure lowering effect in SHR and caused a 12 mmHg decrease in blood pressure compared to vehicle (129±2.0 vs. 141±3.0 mmHg). Moreover, similar to JLJ, it was observed that MV started to lower blood pressure within four days of the treatment in SHR and maintained this effect until the end of the two-week treatment period (see Fig. 4 B-C). In contrast to their blood pressure lowering effect it was further observed that, neither JLJ nor MV had any affect on the heart rate (JLJ, 316±23.0 vs. 331±17.0 BPM; MV, 318±24.0 vs. 331±17.0 BPM) compared to vehicle SHR. Considering promising blood pressure lowering effects of JLJ and MV in SHR model, we hâve further tested these compounds in another model of hypertension, angiotensin II (Ang II) hypertension.
[00269] Ang II hypertensive rats. The compound JLJ demonstrates an attenuating effect on the Ang II induced élévation in blood pressure from the beginning of the treatment and this was maintained throughout the treatment period. It is observed that at the end of two-week of treatment period JLJ markedly attenuated the Ang II induced hypertension compared to vehicle (135±5.0 vs. 150±3.2 mmHg) (Fig. 5 A-B). Similar to JLJ, the compound MV also demonstrates marked attenuating effect on the Ang II hypertension (107±2.0 vs. 150±3.2 mmHg) and this attenuating effect was observed throughout the treatment period (Fig. 6 A-B). Similar to the SHR, in ANG II hypertension neither JLJ (410±25.0 vs. 396±25.0 BPM) nor MV (385±16.0 vs. 396±25.0 BPM) demonstrates any effect on the heart rate compared to vehicle after two weeks of treatment.
[00270] Effects of MV on sodium excrétion and protein excrétion in Ang II hypertension. In the présent study we hâve observed that the two weeks treatment with compound MV (Chemical structure shown in Figure 4A) caused natriuresis compared to vehicle (2.7±0.3 vs. 1.9±0.7 mmol/d) in Ang II hypertension. It is also observed that the compound MV decreased the urinary protein to créatinine ratio (1.5±0.2 vs. 2.8±0.7), an indicator of rénal injury, in Ang II hypertension.
Example 6: Effect of EET Analogs in treating cisplatin nephrotoxicity
[00271] In this Example, the inventors investigated the kidney protective effect of two newly developed orally active EET analogs in cisplatin-induced nephrotoxicity. It was demonstrated that EET analogs offered marked reno-protection during cisplatin administration and this effect was related to their anti-oxidative, anti-inflammatory, anti-ER stress and anti-apoptotic activities. We hâve further demonstrated that while protecting the kidney from the deleterious nephrotoxic effect of cisplatin, these EET analogs did not compromise cisplatin’s chemotherapeutic effect.
[00272] Nephrotoxicity severely limits the use of the anti-cancer drug cisplatin. Oxidative stress, inflammation and endoplasmic réticulum (ER) stress contribute to cisplatin-induced nephrotoxicity. We developed orally active EET analogs (including without limitation compounds EET-A & EET-B) by modifying the carboxylate, olefïns, and epoxide moieties of EET pharmacophore. We determined if admistering the claimed EET analogs would decrease nephrotoxicity, including cisplatin-induced nephrotoxicity. Cisplatin was administered (7mg/kg i.p.) in rats pretreated for 7 days with EET analogs (lOmg/kg/d p.o., n=5) or vehicle (n=7). On day 5 following cisplatin injection, urine, plasma, and kidneys were collected. Cisplatin-induced nephrotoxicity was manifest by a 3-5-fold increase in BUN, plasma créatinine (PCr), urinary Nacetyl-(D)-glucosaminidase activity (NAG), kidney injury molécule-1 (KIM-1), and rénal tubular cast formation. EET analogs attenuated cisplatin-induced increases in BUN (vehicle: 241±51 vs. EET-A: 108±30 & EET-B: 120±33 mg/dL), PCr (3.1±0.2 vs. 2.0±0.2 & 1.4±0.2 mg/dL), KIM-1 (296±94 vs. 85±29 & 57±13 ng/d), and NAG (3.0±0.6 vs. 0.5±0.1 & 0.6±0.2 U/d) (P<0.05). Cisplatin-induced rénal tubular cast formation was reduced 50% by EET analog treatment. EET analogs attenuated cisplatin-induced kidney TBARS formation (vehicle: 16±2 vs. EET-A: 7±1; EET-B: 8±1 pmol/g) and cause 2-3-folds decrease in kidney expression of
NOXl and gp91phox mRNAs (P <0.0 5). Cisplatin-induced nephrotoxicity was accompanied by elevated rénal inflammation and ER stress resulting in increased kidney mRNA expression of inflammatory (TNF-a, IL-6, IL-Ιβ) and ER stress (caspase 12, GRP78) genes. EET analogs caused 30-70% réductions in the expression of these inflammatory and ER stress genes (P<0.05\ Cisplatin caused apoptotic signalling in the kidney with elevated Bak/Bcl2 and Bax/Bcl2 mRNA expression ratios and rénal cortical caspase 3 activity. EET analogs caused 214-folds réduction in kidney Bak/Bcl2 and Bax/Bcl2 mRNA expression ratios as well as a 50% réduction in rénal caspase 3 activity (P <0.05). In an in vitro study with several cancer cell-lines, we also demonstrate that EET analog’s kidney protective effects dose not compromise cisplatin’s anti-cancer property. Collectively, these data demonstrate that orally active EET analogs protect from nephrotoxcity, including cisplatin-induced nephrotoxicity, by reducing oxidative stress, inflammation, and ER stress without affecting cisplatin’s chemotherapeutic effects. In addition, the EET analogs will also protect against other common cisplatin side effects, including loss of hearing.
[00273] In vivo Animal experiments. Experiments were approved and carried out according to the guidelines of the Institutional Animal Care and Use Committee, Medical College of Wisconsin, Milwaukee, USA. Male Wistar-Kyoto (WKY) rats weighing 180-200 g (Charles River, MA, USA). Ail animais were kept in a temperature-controlled environment with a 12-h light/dark cycle and were allowed free access to food and water at ail times. An acclimatization period of 6 days was allowed for the rats before expérimentation. The rats were assigned into four groups. Group 1 (WKY, n=5-7): Rats received drinking water ad libitum for seven days and on day 7 DMSO (Sigma Aldrich, St. Louis, MO, USA) was administered (300-500 μΐ i.p.). DMSO was used to préparé the cisplatin (CP) (Sigma Aldrich, St. Louis, MO, USA) solution used in this study, and the maximum volume of the injection set at 500 μΐ. Group 2 (CP+Vehicle, n=5-7): Rats were pretreated with vehicle (0.05% éthanol and 0.1% PEG-400 v/v) in drinking water for seven days and then on day 7 CP was administered (7mg/kg i.p.) followed by another five days treatment with vehicle. Group 3 (CP+EET-A, n=5-7): These rats are pretreated with the EET analog EET-A (lOmg/kg/day p.o.) for seven days in drinking water and then on day 7 administered CP as a single injection (7mg/kg i.p.) followed by another five days treatment with EET-A. Group 4 (CP+EET-B, n=5-7): Rats of this group are pretreated with another EET analog EET-B (lOmg/kg/day) for 7 days in drinking water and then on day 7 CP was administered as a single injection (7mg/kg i.p.) followed by another five days treatment with EET-B. Rats of groups 2, 3 and 4 had free access to vehicle, EET-A and -B in drinking water, respectively. One day before the rats were sacrificed, urine of each rat was collected over a 24-h period, and the volume was measured. Five days after CP or DMSO administration, rats were anesthetized for blood sample collection followed by euthanasia and tissue collection. Urine and plasma samples were kept frozen at -80°C until analyzed. The kidneys were removed, washed with physiological saline and stored at -80°C until used for RT-PCR analysis, thiobarbituric acid reactive substance (TBARS) measurement and caspase 3 activity assay. A part of the kidney also preserved in 10% buffered formalin for histological examination.
[00274] Biochemical analysis. The levels of blood urea nitrogen (BUN) (BioAssay Systems, Hayward, CA, USA) and sérum créatinine (Cayman Chemical Company, Ann Arbor, MI, USA) were measured spectrophotometrically using commercial kits. Urinary content of créatinine and protein were measured using commercial kits (Cayman Chemical Company, Ann Arbor, MI, USA), and the activity of urinary N-acetyl-b-glucosaminidase (NAG) in the urine was measured by a kit from Diazyme (Diazyme Laboratories, Poway, CA, USA). While urine content of kidney injury molecule-1 (KIM-1) was measured using ELISA (R&D Systems, Inc. Minneapolis, MN, USA).
[00275] Détermination of malondialdehyde in the kidney. Malondialdehyde (MDA) is a thiobarbituric acid reactive substance (TBARS) that is formed as an end-product of lipid peroxidation and serves as an important index of oxidative stress. To détermine the kidney MDA level, the rat kidney was homogenized with buffer containing 1.5% potassium chloride to obtain a 1:10 (w/v) whole kidney homogenate. Using a commercially available kit (Cayman Chemical Company, Ann Arbor, MI, USA), MDA was measured spectrophotometrically after reaction with thiobarbituric acid.
[00276] Détermination of Caspase 3 activity. Caspase 3 activity in the kidney homogenate was determined using a commercial fluorimetric assay kit (Sigma Aldrich, St. Louis, MO, USA). Kidney homogenate was prepared with a lysis Buffer (50 mM HEPES, pH 7.4, with 5 mM CHAPS and 5 mM DTT). Kidney homogenate was centrifuged at 10,000 g for 10 min and the resulting supernatant was used for the assay. The caspase 3 fluorimetric assay is based on the hydrolysis of the peptide substrate acetyl-Asp-Glu-ValAsp-7-amido-4-methylcoumarin (AcDEVD-AMC) by caspase 3, resulting in the release of the fluorescent 7-amino-4methylcoumarin (AMC) moiety. The caspase 3 activity is expressed as nmol of AMC/min/pL.
[00277] Real-Time PCR Analyses. Real-Time analysis was carried out to assess the expression of oxidative (gp91phox, N0X1, SOD1, SOD2, SOD3), inflammatory (TNF-a, IL-6, IL-Ιβ), apoptotic (Bax, Bak, Bcl-2) and endoplasmic réticulum stress (GRP78, caspase 12) related genes in the kidney. Total RNA was isolated from kidney homogenate using TRIzol LS reagents (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. The isolated RNA was treated with RNase-free DNase (Invitrogen, Carlsbad, CA,
USA) to remove traces of genomic DNA contamination. The mRNA samples were quantified by spectrophotometry at 260 nm and 1 pg of total RNA was reverse-transcribed to cDNA using iScript™ Select cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA).
[00278] The target gene expression was quantified by iScript One-Step RT-PCR Kit with SYBR green using MyiQ™ Single Color Real-Time PCR Détection System (Bio-Rad Laboratories, Hercules, CA, USA). Each amplified sample in ail wells was analyzed for homogeneity using dissociation curve analysis using iQ5 Optical System Software, Version 2.1(Bio-Rad Laboratories, Hercules, CA, USA). After dénaturation ai 95°C for 2 min, 40 cycles were performed at 95°C for 10 s and at 60°C for 30 s. Each sample was run in triplicate, and the comparative threshold cycle (Ct) method was used to quantify fold increase (2“ΔΔα) in the expression of the target genes compared to Controls. In analyzing the relative expression of the target genes, the Ct values were normalized to a housekeeping gene (pgkl). Statistical analyses were carried out for at least 5-7 experimental samples in each experimental group. Primers used in this study were designed based on several earlier reports. HAfter fixation of the kidneys with 10% buffered formalin, rénal tissues were sectioned and stained with periodic acid-Schiff (PAS) reagents for histological examination. The numbers of tubules that contain proteinaceous casts were determined at magnification of *200 to assess tubular damage using an image analyzing software NIS Eléments AR version 3.0 (Nikon instruments inc., Melville, NY, USA). The percentage area positive for cast was calculated from the mean of eight cortical and five medullary fields (x200) for each kidney sample. To minimize observer bias, the cast area calculation was performed in a blinded fashion without knowledge of the treatment group from which the tissues are originated.
[00279] In vitro anti-tumor activity of cisplatin in the presence and absence of EET analog. In this study, HEK293, U87MG, Hela cell-lines were obtained from the ATCC (Manassas, VA, USA) (HEK293, U87MG, Hela), and NCCIT was collected from Department of Pediatrics, UT Southwestern Medical Center at Dallas, TX, USA. Ail cell fines were maintained in DMEM or RPIM with 10% fêtai bovine sérum and penicillin/streptomycin purchased from Life Technologies (Grand Island, NY, USA). Cisplatin was purchased from either Sigma (St. Louis, MO, USA) or CalBiochem/EMD Biosciences (Billerica, MA ,USA). Cells were seeded in 96-well plates at 500 to 4,000 cells per well dépends on cell type. Twenty-four hours later, the cells were treated with cisplatin or vehicle and/or the EET analogue EET-A at various concentrations for 72 h. Cell viability was measured by alamar blue assay using resazurin (Sigma Aldrich) according to the manufacturer’s guidelines. Viability results were measured by fluorescence/absorbance in a 96-well plate reader from BMG Labtech (Cary, NC, USA) and the IC50 was calculated by GraphPad Prism5 software (GraphPad Software Inc, La Jolla, CA, USA).
[00280] Statistical analysis. Results are reported as mean ± S.E.M. Statistical significance between two measurements was determined by the two-tailed unpaired Student’s t test (and among groups it was determined by repeated measure one-way analysis of variance followed by Tukey’s post-hoc test) by using GraphPad Prism® Version 4.0 software (GraphPad Software Inc, La Jolla, CA, USA). Probability values of P <0.05 were considered significant where the critical value of P was two-sided.
[00281] Results. EET analog treatment atténuâtes rénal dysfunction and injury in cisplatin administered rats. To investigate the effects of EET analogs in cisplatin (CP)-induced rénal dysfunction, levels of urea (blood urea nitrogen or BUN) and créatinine were measured in the sérum of both EET analog-treated and -untreated rats after five days of the CP administration. As shown in the Figure 8, CP administration caused 3 and 9-fold increase in the sérum créatinine and BUN levels (Figures 7a and 7b), respectively (P<0.05). Treatment with EET analogs (EET-A and -B) resulted in 30-50% réductions in the elevated levels of sérum créatinine and BUN in rats administered with CP compared to those given vehicle (DMSO) (P<0.05). To détermine the effects of EET analogs in CP-induced rénal dysfunction, we further studied urinary excrétion of KIM-1, NAG and protein after five days of CP administration (Figures 7c and 7d). There were 5 and 10-fold increases in urinary excrétion of NAG and KIM-1 in the CP-administered rats compared to vehicle-administered Controls (P<0.05). Moreover, we also demonstrated that cisplatin-administi-ation caused marked proteinuria compare to vehicle administration (vehicle vs. cisplatin, 25.7±1 vs. 53±5.1 mg/d, P<0.05). Both EET analogs, EETA and EET-B resulted 30-50% réduction in the urinary excrétion of NAG and KIM-1 compared to CP-administered rats treated with vehicle (P<0.05) (Figures 7c-d).
[00282] We hâve also observed at least a 40% réduction of cisplatin-induced proteinuria by both EET analogs (Vehicle vs. EET-A and -B; 53±5 vs. 33±8 and 32±3 mg/d, P<0.05). In the présent study the CP-induced kidney dysfunction was further assessed using histological examination of the kidney. Administration of CP resulted in tubular injury as manifested by a vacuolation and desquamation of the rénal épithélial cells along with severe intra-tubular proteinaceous cast formation in both the cortical and medullary régions of the kidney compared to vehicle-administered rats. Both EET analogs protected the kidney in CP-administered rats with > 50% réduction of the tubular cast area in cortex and medulla compared to CPadministered rats treated with vehicle (P<0.05) (Figures 8a-b).
[00283] EET analog treatment atténuâtes cisplatin-induced rénal oxidative stress, inflammatory response and endoplasmic réticulum stress. Real-Time PCR analysis of the mRNA expressions of NADPH oxidase subunits NOX1 and gp91phox (Figure 9) demonstrated increased expression of these oxidative marker genes in cisplatin (CP) administered rats (P<0.05). There was 2-3-folds atténuation in the cisplatin-induced increase in the rénal expression of NOX1 and gp91phox mRNA were reduced by EET analogs A and B (P<0.05) (Figure 9a-b). CP-administration also resulted in a marked élévation in the kidney content of melondialdehyde (MDA), which is one of the important indicators of oxidative stress. Treatment with EET analogs caused 50% réduction of MDA level in the kidney of CP-administered rats (P<0.05) (Figure 9c). It was further observed that administration of CP resulted in 2-5-folds réductions in the mRNA expression of superoxide dismutase (SOD) 1 and SOD3 (P<0.05) while expression of SOD2 was unchanged. Treatment with EET analogs caused 2-3-folds increase m the expression of SOD1 in the CP- administered rats (P<0.05) while the expression of SOD3 remained unaltered across the experimental groups (Figures 9d-f).
[00284] To investigate the effect of EET analogs on the CP-induced inflammation that is 20 associated with rénal dysfunction, we studied the rénal expression of mRNAs that code for tumour necrosis factor-α (TNF- a), interleukin- 6 (IL-6) and interleukin-ΐβ. These variables demonstrated a 2-50-fold increase in their expression in the vehicle treated CP-admmistered rats compared to the rats administered vehicle (P <0.05) (Figures lOa-c). Treatment with both EET analogs (EET-A and B) resulted in 40-60% réductions in the rénal mRNA expressions of ail the inflammatory markers in CP-administered rats (ail PO.05).
[00285] We hâve also observed 4-fold increase in the mRNA expressions of ER stress markers GRP78/BÎP and caspase 12 in the vehicle treated CP-administered rats compared to vehicle-administered rats (P<0.05) (Figures 1 la-b). In CP-administered rats, treatment with both EET analogs (EET-A and B) caused 2-4-fold réduction in the elevated rénal expressions of 30 GRP78 and caspase 12 mRNAs compared to vehicle treatment (P<0.05) (Figures 1 la-b).
[00286] EET analog treatment atténuâtes cisplatin-induced rénal apoptosis. There was a 70% réduction in the rénal expression of Bcl-2 mRNA in the vehicle treated CP-administered rats compared to rats administered vehicle (P<0.05) (Figure 12a). EET analog treatment caused 2-10-fold increase in the expression of the anti-apoptotic Bcl-2 in the CP-administered rats compared to vehicle treated CP-administered rats (P<0.05) (Figure 12a). Moreover, CP administration resulted in 4-20-fold raise in the Bax/Bcl-2 and Bak/Bcl-2 ratios, and therefore indicated elevated apoptotic signalling in the CP-administered rats (Figures 12b-c) (P<0.05). EET analogs treatment caused 2-3-fold réduction in Bax/Bcl-2 and Bak/Bcl-2 ratios compared to
CP-administered rats treated with vehicle (P<0.05) (Figures I2c-d). The CP-induced elevated apoptotic signalling was further characterized with higher caspase 3 activity (Figure 12d) in CPadministered rats compared to the rats administered vehicle (P<0.05). Treatment with EET analogs attenuated such CP-induced caspase 3 activity by 50% compared to the CP-administered rats treated with vehicle ^<0.05) (Figure 12d). These results clearly demonstrated atténuation of CP-induced apoptotic signaling in the presence of EET analog treatment.
[00287] EET analog treatment dose not compromise the chemotherapeutic effect of cisplatin. We demonstrate that in three different cancer cell lines, Hela, NCCIT and U87 cisplatin markedly inliibit the cell growth with IC50 ranged from 1.1 — 9.24 μΜ (Figure Ija). In a similar approach with these cell lines, EET-A had no observable effects on cell number (Figure 13b). Moreover, concurrent application of EET-A and cisplatin did not influence the cisplatin’s chemotherapeutic effect neither on the normal kidney cells (data not shown) nor on the NCCIT cancer cell line (Figure 13c). It is demonstrated that when cisplatin and EET-A were used concurrently, the IC50 for cisplatin was 2.60, 2.55, and 2.44 pM with 0, 1, and 10 ng/ml EET in NCCIT cells.
[00288] Discussion. A critical limitation of cisplatin chemotherapy is the induction of tubulointestinal inflammation, rénal oxidative stress, ER stress and tubular cell apoptosis that lead to acute kidney injury. It is reported that 40% cancer patients who treated with cisplatin develops acute rénal injury. Unfortunately, efficient pharmacotherapies to attenuate this debilitating complication of a widely used chemotherapy like cisplatin are not available. In an attempt to contribute to this area, current study investigated the kidney protective effect of chronic treatment of epoxyeicosatrienoic acid (EET) analogs on cisplatin-induced nephrotoxicity.
[00289] There is strong evidence that EET analogs hâve ability to protect organ by mechanisms involving its anti-inflammatory, anti-apoptotic and anti-oxidative activities. With this background, in the présent study we hypothesized that with its strong organ protective ability, EET will protecf the kidney from cisplatin nephrotoxicity. In our attempt, we hâve synthesized two novel EET analogs and investigated their kidney protective effects in cisplatininduced nephrotoxicity using a clinically relevant approach with chronic administration of EET analogs in drinking water to the rat. We demonstrate that a single administration of cisplatin caused marked rénal injury évident from increased PCr, BUN, urinary excrétion of rénal tubular injury markers like NAG and KIM-1 along with marked proteinuria and tubular cast formation. Our results supports several earlier studies reported cisplatin-induced nephrotoxicity in preclinical animal models. Interestingly, we also demonstrate that the chronic treatment with EET analogs in drinking water markedly protected the kidney from cisplatin-induced nephrotoxic injury with réductions in ail rénal injury markers studied in this study. In relation to our approach in the présent study, a recent study demonstrated that acute administration of sEH inhibitor could reduce cisplatin-induced rénal dysfunction in mice. However, it is known that current sEH inhibitors are limited in effects as they undergo metabolism and incorporation into the membrane,36 thus indicates a limitation of this finding in clinical translational implication.
q e
Moreover, the study carried out by Parrish et al. did not provide evidence on the possible mechanism by which EET or sEH inhibitor reduces rénal dysfunction in cisplatin-induced nephrotoxicity.
[00290] Currently, we demonstrate marked over-expression of mRNAs for the major components of NADPH oxidase (NOX1 and gp91phox) in cisplatin-induced nephrotoxicty. Over-expression of these oxidative marker genes further accompanied by increased ROS génération évident from the elevated kidney lipid per-oxidation in the cisplatin-administered rat. We also demonstrate reduced rénal SOD1 and SOD3 expressions, and suggest that such réduction contributes to the oxidative stress in cisplatin administered rat. Similar observations are reported in earlier studies where cisplatin-induced nephropathy is accompanied by increased MDA level and elevated expression and activity of NADPH oxidase. Interestingly, our study also demonstrate that EET analogs markedly reduced the rénal oxidative stress by reducing the rénal lipid per-oxidation, marked réductions in the expression of the major NADPH oxidase subunits, and also by increased expression of SOD1. Indeed, in a recent study it is reported that EET up-regulates the expression and activity of SOD during toxic insult, thus enhance ROS scavenging and reduce oxidative stress. Similar to our fmdings, in another pathological model characterized with rénal injury, EET mediated réduction in oxidative stress and rénal injury has been reported. Apart from oxidative stress, we also demonstrate that cisplatin-induced nephrotoxicity is further accompanied by elevated rénal inflammatory response and supports earlier évidences on important rôle for inflammatory mechanisms in the pathogenesis of cisplatin-induced nephrotoxicity. Indeed, cisplatin induces increased rénal expression of a variety of inflammatory chemokines and cytokines, such as TNF-α and IL-1 β.
[00291] We further demonstrate that EET analog treatment reduced rénal expression of these inflammatory markers in cisplatin-induced nephrotoxicity. Our data support earlier reports of anti-inflammatory activity of EET that has been implicated in EET mediated organ protection in a number of pathologies characterized with organ injury. For instance, increased bioavailability of EET by sEH inhibition provides kidney protection in streptozotocin-induced diabètes. Moreover, over-expression of the EET producing enzyme CYP2J2 markedly protected kidney in a chronic rénal failure model of 5/6 nephrectomy. Thus, our data clearly indicate that along with marked réduction in oxidative stress, atténuation of cisplatin-induced rénal inflammatory responses is another mechanism by which EET analog protected kidney from cisplatin-induced nephrotoxicity.
[00292] We hâve further investigated EET analog’s effect on cisplatin-induced endoplasmic réticulum (ER) stress. There is evidence that ER is one of the sub-cellular targets of toxins and play important rôle in xenobiotic-induced nephrotoxicity. In the présent study we examined the rénal expression of caspase 12 and GRP78 (glucose-regulated protein 78) mRNAs to investigate the involvement of the ER stress in cisplatin-induced nephrotoxicity. GRP78 is considered one of the hallmarks of ER stress, while caspase 12 is an ER-specifïc caspase that is activated by ER stress and specifically participâtes in ER stress-induced apoptosis. We observe marked upregulation in the rénal expression of these ER stress markers that is attenuated by EET analog treatment. Our study supports earlier observations that cisplatin-induced nephrotoxicity is associated with ER stress. Most importantly, the présent study also provided an interesting and novel finding regarding the biological actions of EET, and demonstrates an important aspect on the therapeutic potential of this lipid mediator in treating cisplatin-induced nephrotoxicity.
[00293] Cisplatin and other drug-related nephrotoxicity is associated with apoptosis 10 that is caused by elevated oxidative stress, inflammation and ER stress. It is reported that during cisplatin-induced nephrotoxicity, the cellular stress caused by oxidative stress, inflammation and ER stress leads to a réduction of anti-apoptotic Bcl2 and activation of the pro-apoptotic Bcl2 family proteins like the Bcl-2 associated X protein (Bax) and Bcl-2 antagonist/killer protein (Bak) in the kidney. This enhanced pro-apoptotic signaling leads to the activation of caspase 3 followed by apoptosis of the rénal cells.. Here, we demonstrate that EET analog treatment protect the kidney from cisplatin-induced cell death by increasing the expression of antiapoptotic Bcl2 and reducing the pro-apoptotic Bak/Bcl2 and Bax/Bcl2 ratios along with a marked réduction in caspase 3 activity.
[00294] We also demonstrate an EET analog mediated atténuation in the rénal expression of caspase 12 that plays an essential rôle in ER stress mediated apoptosis. Indeed, it is earlier reported that EET atténuâtes several major apoptotic events including elevated Bcl2 protein mediated pro-apoptotic signaling and caspase 3 activity. These observations support our view on EET analog’s ability to reduce rénal cell death in cisplatin-induced nephrotoxicity through its effect on the Bcl2 proteins, ER stress spécifie caspase 12 and on the apoptosis executioner caspase, caspase 3.
[00295] We hâve clearly demonstrated that EET analog treatment provides protection from cisplatin-induced nephrotoxicity through multiple mechanisms, and strongly indicate a possible therapeutic promise. However, it is important that before the clinical use of new cytoprotective agents, not only protection from toxicity, but also the absence of an interférence of the agent with the anti-cancer activity of the cytotoxic agents used is demonstrated. To this end, in an in vitro approach we hâve investigated whether in vitro exposure of normal kidney cells (HEK293) or several human cancer cell- lines (Hela, NCCIT, U87) to various concentrations of an EET analog (EET-A) influence cell growth or the cytotoxic effect of cisplatin. Considering the comparable kidney protective effects of the two EET analogs used in this study, we hâve chosen one EET analog for this particular experiment. We demonstrated that in the presence and absence of EET analog (EET-A) cisplatin is equally potent in exerting its chemotherapeutic effect. Moreover, we hâve also investigated if EET-A influence the growth of any of the cancer lines used in this study, and clearly demonstrated that EET-A had no effect on the growth of any of these cancer cell lines.
[00296] In conclusion, we hâve provided strong evidence that the kidney protective effect of the above-identified EET analogs in drug-induced nephrotoxicitn, including cisplatin-induced nephrotoxicity. We hâve demonstrated that these EET analogs offered kidney protection by the inhibition of multiple signaling pathways that critically involve in the patho- physiology of cisplatin-induced nephrotoxicity. This study highlighted several important biological actions of novel EET analogs in terms of their anti-oxidative, anti-inflammatory, anti-ER stress and antiapoptotic activities. The results of the current study strengthen our view on the therapeutic promise of these novel EET analogs in treating cisplatin-induced nephrotoxicity without compromising cisplatin’s chemotherapeutic potential.
[00297] While this invention has been described in conjunction with the various exemplary embodiments outlined above, various alternatives, modifications, variations, improvements and/or substantial équivalents, whether known or that are or may be presently unforeseen, may become apparent to those having at least ordinary skill in the art. Accordingly, the exemplary embodiments according to this invention, as set forth above, are intended to be illustrative, not limiting. Various changes may be made without departing from the spirit and scope of the invention. Therefore, the invention is intended to embrace ail known or later-developed alternatives, modifications, variations, improvements, and/or substantial équivalents of these exemplary embodiments. Ail technical publications, patents and published patent applications cited herein are hereby incorporated by reference in their entirety for ail purposes.
References
1. American Heart Association. High blood pressure statistica. Available at: http://www.americanheart.org/presenter.jhtml?identifier=4621. Accessed November 2010.
2. Jacobson et al. Prostaglandins, and Membrane Ion Transport. New York: Raven Press,
1985:311-318.
3. Sakairi et al. Am J Physiol 1995;268:F931-939.
4. Campbell et al. Cire Res 1996;78:415-423.
5. Archer S et al. Circulation 2003;107:769-776.
6. Fisslthaler et al. Nature 1999;401:493-497.
7. King et al. Pharmacogenet Genomics 2005;15:7-13.
8. Capdevila et al. Kidney Int 2007;72:683-689.
9. ImigJD. Am J Physiol Rénal Physiol 2005;289:F496-503.
10. Imig et al. Hypertension 2005;46:975-981.
11. Imig et al. J Hypertens 2001;19:983-992.
12. Imig et al. Nat Rev Drug Discov 2009;8:794-805.
13. Sodhi et al. J Pharmacol Exp Ther 2009; 331:906-916.
14. Imig et al. U.S. Patent #7,550,617, Issued June 23, 2009
15. Imig et al. U.S. Patent #7,732,470, Issued June 8, 2010
16. Heizeretal. Stroke 1991;22:1389-1393.
17. Krotz et al. Arterioscler Thromb Vase Biol 2004;24:595-600.
18. Node et al. Science 1999;285:1276-1279.
19. Davis et al. Proc Natl Acad Sci USA 2002;99:2222-2227.
20. Fleming I. Prostaglandins Other Lipid Médiat 2007;82:60-67.
' 30 21. Yang et al. Arch. Biochem Biophys 2009;489:82-91.
22. Potente et al. J Biol Chem 2003;278:29619-29625.
23. Sun et al. Cire Res 2002;90:1020-1027.
24. Simpkins et al. Am J Pathol 2009;174:2086-2095.
25. Zhang et al. Stroke 2008;39:2073-2078.
26. Terashvili et al. J Pharmacol Exp Ther 2008;326:614-622.
27. Inceoglu et al. Life Sci 2006;79:2311 -2319.
28. Bongers et al. Pharmacoeconomics. 2012; 30(1):17-34.
29. Costantini et al. Scientific World Journal. 2011; 11:1981-94.
30. Levy et al. Curr Med Res Opin. 2011; 27(12):2253-9.
31. Wang et al. Nat Rev Drug Discov ;4(4):307-20.
32. Lameire et al. Acta Clin Belg. 2011; 66(5):337-45.
33. Miller et al. Toxins (Basel). 2010; 2(11):2490-518.
34. Yao et al. Am J Med Sci. 2007 Aug;334(2):l 15-24.
35. Lieberthal et al. Am J Physiol. 1996 Apr;270(4 Pt 2):F700-8.
36. Ma et al. Clin Exp Pharmacol Physiol. 2010; 37(4):460-5.
37. PablaN and Dong Z (2008) Kidney Int 73:994-1007.
38. Imig JD. Physiol Rev. 2012 Jan;92(l):101-30.
39. Imig JD. J Cardiovasc Pharmacol. 2010; 56(4):329-35.
40. Imig JD. Am J Physiol Rénal Physiol. 2005; 289(3):F496-503.
41. Pfister et al. Adv Pharmacol. 2010;60:27-59.
42. Gauthier et al. J Cardiovasc Pharmacol. 2007 Dec;50(6):601-8.
43. Olearczyk et al. Clin Sci (Lond). 2009; 116(1):61-70.
44. Elmarakby et al. Am J Physiol Regul Integr Comp Physiol. 2011; 301(5):R1307-17.
45. Imig JD, Hammock BD. Nat Rev Drug Discov. 2009 Oct;8(10):794-805.
46. Yang et al. Mol Pharmacol 60: 310-320, 2001.
47. Yang et al. Am J Physiol Heart Cire Physiol. 2007; 293(1):H142-51.
48. Morisseau C, Hammock BD (2005). Annu Rev Pharmacol Toxicol 45: 311-333.
49. Falck J Med Chem 2009, 52: 5069-5075.
50. Batchu et al. Br J Pharmacol. 2011; 162(4):897-907.
51. Simpkins et al. Am J Pathol. 2009; 174(6):2086-95.
52. Zhao et al. Am J Physiol Heart Cire Physiol. 2006; 290(6):H2187-95.
53. Jia Z et al. Kidney Int. 2011; 79(1):77-88.
54. Liu et al.. Eye (Lond). 2010; 24(1):137-44.
55. Xu et al. Nephrol Dial Transplant. 2010; 25(12):3859-67.
56. Akcali et al.World J Gastroenterol. 2004; 10(2):279-83.
57. Chabrashvili et al.Am J Physiol Regul Integr Comp Physiol. 2003; 285(1):R117-24.
58. Inagi R. Nephron Exp Nephrol. 2009; 112(l):el-9.
59. Mukhopadhyay et al. Free Radie Biol Med. 2012; 52(2):497-506.
60. Aleisa et al. Clin Exp Pharmacol Physiol. 2007; 34(12):1252-9.
61. Sahuet al. Food Chem Toxicol. 2011 Dec;49(12):3090-7.
62. Parrish et al. Cell Biol Toxicol. 2009; 25(3):217-25.
63. Spector et al. Prog Lipid Res. 2004; 43(1):55-90.
64. Suddek GM.. 2011 Oct 11. doi: 10.1111/j.1472-8206.2011.00996.x.
65. El-Beshbishy et al. Eur J Pharmacol. 2011; 668(1-2):278-84.
66. Liu et al. J Pharmacol Exp Ther. 2011; 339(2):451-63.
67. Ramesh G and Reeves WB (2002) J Clin Invest 110:835-842.
68. Yamate et al. Vet Pathol 39:322-333.
69. Faubel et al. J Pharmacol Exp Ther 322:8-15.
70. Zhang et al. (2007) Kidney Int 72:37—44.
71.Zhaoetal. Hum Gene Ther. 2012 Jan 19.
72. Cribb et al. Drug Metab Rev. 2005; 37(3):405-42.
73. Mandic et al. J Biol Chem. 2003; 278(11):9100-6.
74. Peyrou et al.Toxicol Sci. 2007 Sep;99(l):346-53. Epub 2007 Jun 12. PubMed PMID: 17567590.
75. Breckenridge et al. Oncogene. 2003; 22(53):8608-18.
76. Park et al. (2002) et al. J Am Soc Nephrol 13:858-865.
77. Wei et al. (2007) Kidney Int 72:53-62.
78. Lorz et al. J Am Soc Nephrol. 2004; 15(2):380-9.
Claims (15)
- What is claimed is:
- 2.The compound of claim 1, wherein the structure isM
- 3. The compound of claim 1, wherein the structure isWTN30 / o \ A ZK ,
- 4. A compound selected from the group consisting of
- 5. A composition comprising a compound of claims 1 or 4 and a pharmaceutically acceptable carrier.5. A method of reducing hypertension in a subject, comprising administering to a subject a therapeutically effective amount of a compound according to claims 1 or 4, wherein hypertension in said subject is reduced.
- 6. Use of a compound according to claims 1 or 4 for the manufacture of a médicament for treating hypertension in a subject.
- 7. A compound according to claims 1 or 4 for use in the treatment of hypertension in a subject.
- 8. A method of reducing nephrotoxicity in a subject, comprising administering to a subject a therapeutically effective amount of a compound according to claims 1 or 4, wherein nephrotoxicity in said subject is reduced.
- 9. The method of claim 8, wherein the nephrotoxicity is drug-induced.
- 10. The method of claim 9, wherein the nephrotoxicity is cisplatin-induced.
- 11. Use of a compound according to claims 1 or 4 for the manufacture of a médicament for treating drug-induced nephrotoxicity in a subject.
- 12. A compound according to claims 1 or 4 for use in the treatment of drug-induced nephrotoxicity in a subject.
- 13. A method of reducing cisplatin nephrotoxicity in a subject, comprising administering to a subject a therapeutically effective amount of a compound according to claims 1 or 4, wherein cisplatin nephrotoxicity in said subject is reduced.
- 14. Use of a compound according to claims 1 or 4 for the manufacture of a médicament for treating cisplatin nephrotoxicity in a subject.
- 15. A compound according to claims 1 or 4 for use in the treatment of cisplatin nephrotoxicity in a subject. j
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/472,410 | 2011-04-06 | ||
US61/608,361 | 2012-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19539A true OA19539A (en) | 2020-12-11 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012240256B2 (en) | Epoxyeicosatrienoic acid analogs and methods of making and using the same | |
ES2602615T3 (en) | Antibacterial agents | |
KR101496190B1 (en) | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | |
CZ277999B6 (en) | Amides of carboxylic acid and amides of sulfonic acid, process of their preparation and use | |
CA2949681A1 (en) | Macrocyclic broad spectrum antibiotics | |
EP2208721B1 (en) | Histone deacetylase inhibitor, composition and use thereof | |
CZ412898A3 (en) | Substituted cyclopentane compounds usable as neuroaminidase inhibitors | |
WO2009013293A1 (en) | Substituted cyclohexanecarboxamides useful as bace inhibitors | |
OA19539A (en) | Epoxyeicosatrienoic acid analogs and methods of making and using the same. | |
US10053490B2 (en) | Antimicrobial peptidomimetics | |
CA3115113A1 (en) | Novel compounds useful for treating cardiovascular diseases | |
NZ617402B2 (en) | Epoxyeicosatrienoic acid analogs and methods of making and using the same | |
US8420626B2 (en) | Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof | |
WO1997046520A1 (en) | 4-nitro-2-phenoxysulfonanilide derivatives |